| No. | Protein Name | Protein Sequence | Peptide Librar Design | Purity | Application | Condition/Topic |
| 1 | MoTif 001 M. tuberculosis (Ag85B) | MTDVSRKIRAWGRRLMIGTAAAVVLPGLVGLAGGAATAGAFSRPGLPVEYLQVPSPSMGRDIKVQ FQSGGNNSPAVYLLDGLRAQDDYNGWDINTPAFEWYYQSGLSIVMPVGGQSSFYSDWYSPACG KAGCQTYKWETFLTSELPQWLSANRAVKPTGSAAIGLSMAGSSAMILAAYHPQQFIYAGSLSALLD PSQGMGPSLIGLAMGDAGGYKAADMWGPSSDPAWERNDPTQQIPKLVANNTRLWVYCGNGT PNELGGANIPAEFLENFVRSSNLKFQDAYNAAGGHNAVFNFPPNGTHSWEYWGAQLNAMKGD LQSSLGAG | Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 2 | MoTif 002 M. tuberculosis (ESAT-6) | MTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQKWDATAT ELNNALQNLARTISEAGQAMASTEGNVTGMFA | Pool of 21 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 3 | MoTif 003 Pan-T. cruzi Select (Trans-Sialidasen) | see additional product documentation | Virus-specific pool of 72 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | T-cell immunity | Chagas disease, Fever, Infection, Sequence diversity |
| 4 | MoTif 004 M. tuberculosis (TB10.4) | MSQIMYNYPAMLGHAGDMAGYAGTLQSLGAEIAVEQAALQSAWQGDTGITYQAWQAQWNQ AMEDLVRAYHAMSSTHEANTMAMMARDTAEAAKWGG | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 5 | MoTif 005 M. tuberculosis (Antitoxin VapB47) | MRATVGLVEAIGIRELRQHASRYLARVEAGEELGVTNKGRLVARLIPVQAAERSREALIESGVLIPAR RPQNLLDVTAEPARGRKRTLSDVLNEMRDEQ | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 6 | MoTif 006 SARS-CoV-2 (Spike Fusion-Peptide) | KRSFIEDLLFNKVTLAD | Pool of 28 peptides derived from a peptide scan (truncational scan (peptide length 11 to 17aa)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 7 | MoTif 007 Collection EBV (2x1ug/peptide) | 14 different PepMixes, 2 aliquots of 14 peptide pools each containin 1µg per peptide /tube | Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Cancer, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 8 | MoTif 008 SARS-CoV-2 (VEMP) | MYSFVSEETGTLIVNSVLLFLAFVVFLLVTLAILTALRLCAYCCNIVNVSLVKPSFYVYSRVKNLNS SRVPDLLV | Pool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 9 | MoTif 009 HCoV-OC43 (Spike Glycoprotein) | MFLILLISLPTAFAVIGDLKCTSDNINDKDTGPPPISTDTVDVTNGLGTYYVLDRVYLNTTLFLNGYY PTSGSTYRNMALKGSVLLSRLWFKPPFLSDFINGIFAKVKNTKVIKDRVMYSEFPAITIGSTFVNTSY SVVVQPRTINSTQDGDNKLQGLLEVSVCQYNMCEYPQTICHPNLGNHRKELWHLDTGVVSCLYK RNFTYDVNADYLYFHFYQEGGTFYAYFTDTGVVTKFLFNVYLGMALSHYYVMPLTCNSKLTLEYWV TPLTSRQYLLAFNQDGIIFNAEDCMSDFMSEIKCKTQSIAPPTGVYELNGYTVQPIADVYRRKPNLP NCNIEAWLNDKSVPSPLNWERKTFSNCNFNMSSLMSFIQADSFTCNNIDAAKIYGMCFSSITIDK FAIPNGRKVDLQLGNLGYLQSFNYRIDTTATSCQLYYNLPAANVSVSRFNPSTWNKRFGFIEDSVFK PRPAGVLTNHDVVYAQHCFKAPKNFCPCKLNGSCVGSGPGKNNGIGTCPAGTNYLTCDNLCTPD PITFTGTYKCPQTKSLVGIGEHCSGLAVKSDYCGGNSCTCRPQAFLGWSADSCLQGDKCNIFANFIL HDVNSGLTCSTDLQKANTDIILGVCVNYDLYGILGQGIFVEVNATYYNSWQNLLYDSNGNLYGFR DYIINRTFMIRSCYSGRVSAAFHANSSEPALLFRNIKCNYVFNNSLTRQLQPINYFDSYLGCVVNAY NSTAISVQTCDLTVGSGYCVDYSKNRRSRGAITTGYRFTNFEPFTVNSVNDSLEPVGGLYEIQIPSEF TIGNMVEFIQTSSPKVTIDCAAFVCGDYAACKSQLVEYGSFCDNINAILTEVNELLDTTQLQVANSL MNGVTLSTKLKDGVNFNVDDINFSPVLGCLGSECSKASSRSAIEDLLFDKVKLSDVGFVEAYNNC TGGAEIRDLICVQSYKGIKVLPPLLSENQISGYTLAATSASLFPPWTAAAGVPFYLNVQYRINGLGV TMDVLSQNQKLIANAFNNALYAIQEGFDATNSALVKIQAVVNANAEALNNLLQQLSNRFGAISA SLQEILSRLDALEAEAQIDRLINGRLTALNAYVSQQLSDSTLVKFSAAQAMEKVNECVKSQSSRINF CGNGNHIISLVQNAPYGLYFIHFSYVPTKYVTARVSPGLCIAGDRGIAPKSGYFVNVNNTWMYTG SGYYYPEPITENNVVVMSTCAVNYTKAPYVMLNTSIPNLPDFKEELDQWFKNQTSVAPDLSLDYI NVTFLDLQVEMNRLQEAIKVLNQSYINLKDIGTYEYYVKWPWYVWLLICLAGVAMLVLLFFICCCT GCGTSCFKKCGGCCDDYTGYQELVIKTSHDD | Pool of 336 (168+168) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 10 | MoTif 010 SARS-CoV-2 (Nsp4) | KIVNNWLKQLIKVTLVFLFVAAIFYLITPVHVMSKHTDFSSEIIGYKAIDGGVTRDIASTDTCFANKHA DFDTWFSQRGGSYTNDKACPLIAAVITREVGFVVPGLPGTILRTTNGDFLHFLPRVFSAVGNICYTPS KLIEYTDFATSACVLAAECTIFKDASGKPVPYCYDTNVLEGSVAYESLRPDTRYVLMDGSIIQFPNTYL EGSVRVVTTFDSEYCRHGTCERSEAGVCVSTSGRWVLNNDYYRSLPGVFCGVDAVNLLTNMFTPL IQPIGALDISASIVAGGIVAIVVTCLAYYFMRFRRAFGEYSHVVAFNTLLFLMSFTVLCLTPVYSFLPGV YSVIYLYLTFYLTNDVSFLAHIQWMVMFTPLVPFWITIAYIICISTKHFYWFFSNYLKRRVVFNGVSFS TFEEAALCTFLLNKEMYLKLRSDVLLPLTQYNRYLALYNKYKYFSGAMDTTSYREAACCHLAKALN DFSNSGSDVLYQPPQTSITSAVLQ | Pool of 123 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 11 | MoTif 011SARS-CoV-2 (Nsp9) | NNELSPVALRQMSCAAGTTQTACTDDNALAYYNTTKGGRFVLALLSDLQDLKWARFPKSDGTG TIYTELEPPCRFVTDTPKGPKVKYLYFIKGLNNLNRGMVLGSLAATVRLQ | Pool of 26 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 12 | MoTif 012SARS-CoV-2 (Nsp12) | SADAQSFLNRVCGVSAARLTPCGTGTSTDVVYRAFDIYNDKVAGFAKFLKTNCCRFQEKDEDDNLI DSYFVVKRHTFSNYQHEETIYNLLKDCPAVAKHDFFKFRIDGDMVPHISRQRLTKYTMADLVYALRH FDEGNCDTLKEILVTYNCCDDDYFNKKDWYDFVENPDILRVYANLGERVRQALLKTVQFCDAMRN AGIVGVLTLDNQDLNGNWYDFGDFIQTTPGSGVPVVDSYYSLLMPILTLTRALTAESHVDTDLTKPYI KWDLLKYDFTEERLKLFDRYFKYWDQTYHPNCVNCLDDRCILHCANFNVLFSTVFPPTSFGPLVRKI FVDGVPFVVSTGYHFRELGVVHNQDVNLHSSRLSFKELLVYAADPAMHAASGNLLLDKRTTCFSVA ALTNNVAFQTVKPGNFNKDFYDFAVSKGFFKEGSSVELKHFFFAQDGNAAISDYDYYRYNLPTMCD IRQLLFVVEVVDKYFDCYDGGCINANQVIVNNLDKSAGFPFNKWGKARLYYDSMSYEDQDALFAY TKRNVIPTITQMNLKYAISAKNRARTVAGVSICSTMTNRQFHQKLLKSIAATRGATVVIGTSKFYGGW HNMLKTVYSDVENPHLMGWDYPKCDRAMPNMLRIMASLVLARKHTTCCSLSHRFYRLANECAQ VLSEMVMCGGSLYVKPGGTSSGDATTAYANSVFNICQAVTANVNALLSTDGNKIADKYVRNLQHR LYECLYRNRDVDTDFVNEFYAYLRKHFSMMILSDDAVVCFNSTYASQGLVASIKNFKSVLYYQNNVF MSEAKCWTETDLTKGPHEFCSQHTMLVKQGDDYVYLPYPDPSRILGAGCFVDDIVKTDGTLMIERF VSLAIDAYPLTKHPNQEYADVFHLYLQYIRKLHDELTGHMLDMYSVMLTNDNTSRYWEPEFYEAM YTPHTVLQ | Pool of 231 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 13 | MoTif 013 SARS-CoV-2 (ORF10) | MGYINVFAFPFTIYSLLLCRMNSRNYIAQVDVVNFNLT | Pool of 7 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 14 | MoTif 014 SARS-CoV-2 (VME1) | MADSNGTITVEELKKLLEQWNLVIGFLFLTWICLLQFAYANRNRFLYIIKLIFLWLLWPVTLACFVLA AVYRINWITGGIAIAMACLVGLMWLSYFIASFRLFARTRSMWSFNPETNILLNVPLHGTILTRPLLES ELVIGAVILRGHLRIAGHHLGRCDIKDLPKEITVATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYK LNTDHSSSSDNIALLVQ | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 15 | MoTif 015 SARS-CoV-2 (C+NSP11) | see additional product documentation | Pool of 16 peptides derived from a peptide scan (16mers + 1 x 13mer) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 16 | MoTif 016 SARS-CoV-2 (NS6) | MFHLVDFQVTIAEILLIIMRTFKVSIWNLDYIINLIIKNLSKSLTENKYSQLDEEQPMEID | Pool of 13 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 17 | MoTif 017 SARS-CoV-2 (NS7B) | MIELSLIDFYLCFLAFLLFLVLIMLIIFWFSLELQDHNETCHA | Pool of 8 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 18 | MoTif 018 SARS-CoV-2 (Nsp5) | SGFRKMAFPSGKVEGCMVQVTCGTTTLNGLWLDDVVYCPRHVICTSEDMLNPNYEDLLIRKSNH NFLVQAGNVQLRVIGHSMQNCVLKLKVDTANPKTPKYKFVRIQPGQTFSVLACYNGSPSGVYQCA MRPNFTIKGSFLNGSCGSVGFNIDYDCVSFCYMHHMELPTGVHAGTDLEGNFYGPFVDRQTAQA AGTDTTITVNVLAWLYAAVINGDRWFLNRFTTTLNDFNLVAMKYNYEPLTQDHVDILGPLSAQTGI AVLDMCASLKELLQNGMNGRTILGSALLEDEFTPFDVVRQCSGVTFQ | Pool of 74 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 19 | MoTif 019 SARS-CoV-2 (Nsp6) | SAVKRTIKGTHHWLLLTILTSLLVLVQSTQWSLFFFLYENAFLPFAMGIIAMSAFAMMFVKHKHAFL CLFLLPSLATVAYFNMVYMPASWVMRIMTWLDMVDTSLSGFKLKDCVMYASAVVLLILMTARTV YDDGARRVWTLMNVLTLVYKVYYGNALDQAISMWALIISVTSNYSGVVTTVMFLARGIVFMCVE YCPIFFITGNTLQCIMLVYCFLGYFCTCYFGLFCLLNRYFRLTLGVYDYLVSTQEFRYMNSQGLLPPKN SIDAFKLNIKLLGVGGKPCIKVATVQ | Pool of 70 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 20 | MoTif 020 SARS-CoV-2 (Nsp8) | AIASEFSSLPSYAAFATAQEAYEQAVANGDSEVVLKKLKKSLNVAKSEFDRDAAMQRKLEKMADQ AMTQMYKQARSEDKRAKVTSAMQTMLFTMLRKLDNDALNNIINNARDGCVPLNIIPLTTAAKLM VVIPDYNTYKNTCDGTTFTYASALWEIQQVVDADSKIVQLSEISMDNSPNLAWPLIVTALRANSAV KLQ | Pool of 47 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 21 | MoTif 021 SARS-CoV-2 (Nsp10) | AGNATEVPANSTVLSFCAFAVDAAKAYKDYLASGGQPITNCVKMLCTHTGTGQAITVTPEANMD QESFGGASCCLYCRCHIDHPNPKGFCDLKGKYVQIPTTCANDPVGFTLKNTVCTVCGMWKGYGC SCDQLREPMLQ | Pool of 32 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 22 | MoTif 022 HCoV-HKU1 (Spike Glycoprotein) | MLLIIFILPTTLAVIGDFNCTNFAINDLNTTVPRISEYVVDVSYGLGTYYILDRVYLNTTILFTGYFPK SGANFRDLSLKGTTYLSTLWYQKPFLSDFNNGIFSRVKNTKLYVNKTLYSEFSTIVIGSVFINNSYTIV VQPHNGVLEITACQYTMCEYPHTICKSKGSSRNESWHFDKSEPLCLFKKNFTYNVSTDWLYFHFY QERGTFYAYYADSGMPTTFLFSLYLGTLLSHYYVLPLTCNAISSNTDNETLQYWVTPLSKRQYLLKF DNRGVITNAVDCSSSFFSEIQCKTKSLLPNTGVYDLSGFTVKPVATVHRRIPDLPDCDIDKWLNNF NVPSPLNWERKIFSNCNFNLSTLLRLVHTDSFSCNNFDESKIYGSCFKSIVLDKFAIPNSRRSDLQL GSSGFLQSSNYKIDTTSSSCQLYYSLPAINVTINNYNPSSWNRRYGFNNFNLSSHSVVYSRYCFSV NNTFCPCAKPSFASSCKSHKPPSASCPIGTNYRSCESTTVLDHTDWCRCSCLPDPITAYDPRSCSQ KKSLVGVGEHCAGFGVDEEKCGVLDGSYNVSCLCSTDAFLGWSYDTCVSNNRCNIFSNFILNGIN SGTTCSNDLLQPNTEVFTDVCVDYDLYGITGQGIFKEVSAVYYNSWQNLLYDSNGNIIGFKDFVT NKTYNIFPCYAGRVSAAFHQNASSLALLYRNLKCSYVLNNISLTTQPYFDSYLGCVFNADNLTDYS VSSCALRMGSGFCVDYNSPSSSSSRRKRRSISASYRFVTFEPFNVSFVNDSIESVGGLYEIKIPTNFT IVGQEEFIQTNSPKVTIDCSLFVCSNYAACHDLLSEYGTFCDNINSILDEVNGLLDTTQLHVADTLM QGVTLSSNLNTNLHFDVDNINFKSLVGCLGPHCGSSSRSFFEDLLFDKVKLSDVGFVEAYNNCTG GSEIRDLLCVQSFNGIKVLPPILSESQISGYTTAATVAAMFPPWSAAAGIPFSLNVQYRINGLGVTM DVLNKNQKLIATAFNNALLSIQNGFSATNSALAKIQSVVNSNAQALNSLLQQLFNKFGAISSSLQ EILSRLDALEAQVQIDRLINGRLTALNAYVSQQLSDISLVKFGAALAMEKVNECVKSQSPRINFCGN GNHILSLVQNAPYGLLFMHFSYKPISFKTVLVSPGLCISGDVGIAPKQGYFIKHNDHWMFTGSSYY YPEPISDKNVVFMNTCSVNFTKAPLVYLNHSVPKLSDFESELSHWFKNQTSIAPNLTLNLHTINATF LDLYYEMNLIQESIKSLNNSYINLKDIGTYEMYVKWPWYVWLLISFSFIIFLVLLFFICCCTGCGSACFS KCHNCCDEYGGHHDFVIKTSHDD | Pool of 337 (169+168) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 23 | MoTif 023 Collection EBV (25ug/peptide) | 14 different PepMixes,1 aliquots of 14 peptide pools each containin 15µg per peptide /tube | Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 24 | MoTif 024 Collection HCMV (25ug/peptide) | 19 different PepMixes,1 aliquot of 19 peptide pools in 20 vials each containin 25µg per peptide /tube | Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections |
| 25 | MoTif 025 Collection HCMV (2x1ug/peptide) | 19 different PepMixes,2 aliquots of 19 peptide pools each containin 1µg per peptide /tube | Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Control, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections |
| 26 | MoTif 026 SARS-CoV-2 (S-RBD BA.2.75) | RVQPTESIVRFPNITNLCPFHEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVS PTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVS GNYNYLYRLFRKSKLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLQSYGFRPTYGVGHQPYRV VVLSFELLHAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 27 | MoTif 027 SARS-CoV-2 (Nsp13) | AVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQL YLGGMSYYCKSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANT CTERLKLFAAETLKATEETFKLSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKN SKVQIGEYTFEKGDYGDAVVYRGTTTYKLNVGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYP TLNISDEFSSNVANYQKVGMQKYSTLQGPPGTGKSHFAIGLALYYPSARIVYTACSHAAVDALC EKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIVVFDEISMATNYDL SVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCPAEIV DTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAWRKAVFIS PYNSQNAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKVGILCIMSD RDLYDKLQFTSLEIPRRNVATLQ | Pool of 148 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 28 | MoTif 028 SARS-CoV-2 (Nsp14) | AENVTGLFKDCSKVITGLHPTQAPTHLSVDTKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNY QVNGYPNMFITREEAIRHVRAWIGFDVEGCHATREAVGTNLPLQLGFSTGVNLVAVPTGYVDTP NNTDFSRVSAKPPPGDQFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKNLSDRVVFVLWAHGFE LTSMKYFVKIGPERTCCLCDRRATCFSTASDTYACWHHSIGFDYVYNPFMIDVQQWGFTGNLQS NHDLYCQVHGNAHVASCDAIMTRCLAVHECFVKRVDWTIEYPIIGDELKINAACRKVQHMVVK AALLADKFPVLHDIGNPKAIKCVPQADVEWKFYDAQPCSDKAYKIEELFYSYATHSDKFTDGVCL FWNCNVDRYPANSIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPAFDKSAFVNLKQLPFFYY SDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANEYRLYLDAYNMMISAGFSLWVY KQFDTYNLWNTFTRLQ | Pool of 129 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 29 | MoTif 029 SARS-CoV-2 (ORF9B) | MDPKISEMHPALRLVDPQIQLAVTRMENAVGRDQNNVGPKVYPIILRLGSPLSLNMARKTLNSL EDKAFQLTPIAVQMTKLATTEELPDEFVVVTVK | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 30 | MoTif 030 SARS-CoV-2 (NS7A) | MKIILFLALITLATCELYHYQECVRGTTVLLKEPCSSGTYEGNSPFHPLADNKFALTCFSTQFAFACP DGVKHVYQLRARSVSPKLFIRQEEVQELYSPIFLIVAAIVFITLCFTLKRKTE | Pool of 28 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 31 | MoTif 031 SARS-CoV-2 (Nsp1) | MESLVPGFNEKTHVQLSLPVLQVRDVLVRGFGDSVEEVLSEARQHLKDGTCGLVEVEKGVLPQLE QPYVFIKRSDARTAPHGHVMVELVAELEGIQYGRSGETLGVLVPHVGEIPVAYRKVLLRKNGNKGA GGHSYGADLKSFDLGDELGTDPYEDFQENWNTKHSSGVTRELMRELNGG | Pool of 43 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 32 | MoTif 032 SARS-CoV-2 (Nsp2) | AYTRYVDNNFCGPDGYPLECIKDLLARAGKASCTLSEQLDFIDTKRGVYCCREHEHEIAWYTERSE KSYELQTPFEIKLAKKFDTFNGECPNFVFPLNSIIKTIQPRVEKKKLDGFMGRIRSVYPVASPNECNQ MCLSTLMKCDHCGETSWQTGDFVKATCEFCGTENLTKEGATTCGYLPQNAVVKIYCPACHNSEVG PEHSLAEYHNESGLKTILRKGGRTIAFGGCVFSYVGCHNKCAYWVPRASANIGCNHTGVVGEGSE GLNDNLLEILQKEKVNINIVGDFKLNEEIAIILASFSASTSAFVETVKGLDYKAFKQIVESCGNFKVTK GKAKKGAWNIGEQKSILSPLYAFASEAARVVRSIFSRTLETAQNSVRVLQKAAITILDGISQYSLRLID AMMFTSDLATNNLVVMAYITGGVVQLTSQWLTNIFGTVYEKLKPVLDWLEEKFKEGVEFLRDGW EIVKFISTCACEIVGGQIVTCAKEIKESVQTFFKLVNKFLALCADSIIIGGAKLKALNLGETFVTHSKGLY RKCVKSREETGLLMPLKAPKEIIFLEGETLPTEVLTEEVVLKTGDLQPLEQPTSEAVEAPLVGTPVCING LMLLEIKDTEKYCALAPNMMVTNNTFTLKGG | Pool of 157 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 33 | MoTif 033 SARS-CoV-2 (Nsp15) | SLENVAFNVVNKGHFDGQQGEVPVSIINNTVYTKVDGVDVELFENKTTLPVNVAFELWAKRNIKPVPE VKILNNLGVDIAANTVIWDYKRDAPAHISTIGVCSMTDIAKKPTETICAPLTVFFDGRVDGQVDLFRNAR NGVLITEGSVKGLQPSVGPKQASLNGVTLIGEAVKTQFNYYKKVDGVVQQLPETYFTQSRNLQEFKPRSQ MEIDFLELAMDEFIERYKLEGYAFEHIVYGDFSHSQLGGLHLLIGLAKRFKESPFELEDFIPMDSTVKNYFIT DAQTGSSKCVCSVIDLLLDDFVEIIKSQDLSVVSKVVKVTIDYTEISFMLWCKDGHVETFYPKLQ | Pool of 84 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 34 | MoTif 034 SARS-CoV-2 (AP3A) | MDLFMRIFTIGTVTLKQGEIKDATPSDFVRATATIPIQASLPFGWLIVGVALLAVFQSASKIITLKKRWQLA LSKGVHFVCNLLLLFVTVYSHLLLVAAGLEAPFLYLYALVYFLQSINFVRIIMRLWLCWKCRSKNPLLYDAN YFLCWHTNCYDYCIPYNSVTSSIVITSGDGTTSPISEHDYQIGGYTEKWESGVKDCVVLHSYFTSDYYQLY STQLSTDTGVEHVTFFIYNKIVDEPEEHVQIHTIDGSSGVVNPVMEPIYDEPTTTTSVPL | Pool of 66 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 35 | MoTif 035 SARS-CoV-2 (NS8) | MKFLVFLGIITTVAAFHQECSLQSCTQHQPYVVDDPCPIHFYSKWYIRVGARKSAPLIELCVDEAGSKSPI QYIDIGNYTVSCLPFTINCQEPKLGSLVVRCSFYEDFLEYHDVRVVLDFI | Pool of 28 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 36 | MoTif 036 SARS-CoV-2 (Nsp3) | APTKVTFGDDTVIEVQGYKSVNITFELDERIDKVLNEKCSAYTVELGTEVNEFACVVADAVIKTLQPVSEL LTPLGIDLDEWSMATYYLFDESGEFKLASHMYCSFYPPDEDEEEGDCEEEEFEPSTQYEYGTEDDYQGKP LEFGATSAALQPEEEQEEDWLDDDSQQTVGQQDGSEDNQTTTIQTIVEVQPQLEMELTPVVQTIEVNS FSGYLKLTDNVYIKNADIVEEAKKVKPTVVVNAANVYLKHGGGVAGALNKATNNAMQVESDDYIATN GPLKVGGSCVLSGHNLAKHCLHVVGPNVNKGEDIQLLKSAYENFNQHEVLLAPLLSAGIFGADPIHSL RVCVDTVRTNVYLAVFDKNLYDKLVSSFLEMKSEKQVEQKIAEIPKEEVKPFITESKPSVEQRKQDDKKIK ACVEEVTTTLEETKFLTENLLLYIDINGNLHPDSATLVSDIDITFLKKDAPYIVGDVVQEGVLTAVVIPTKKA GGTTEMLAKALRKVPTDNYITTYPGQGLNGYTVEEAKTVLKKCKSAFYILPSIISNEKQEILGTVSWNLRE MLAHAEETRKLMPVCVETKAIVSTIQRKYKGIKIQEGVVDYGARFYFYTSKTTVASLINTLNDLNETLVTM PLGYVTHGLNLEEAARYMRSLKVPATVSVSSPDAVTAYNGYLTSSSKTPEEHFIETISLAGSYKDWSYSGQ STQLGIEFLKRGDKSVYYTSNPTTFHLDGEVITFDNLKTLLSLREVRTIKVFTTVDNINLHTQVVDMSMTY GQQFGPTYLDGADVTKIKPHNSHEGKTFYVLPNDDTLRVEAFEYYHTTDPSFLGRYMSALNHTKKWKY PQVNGLTSIKWADNNCYLATALLTLQQIELKFNPPALQDAYYRARAGEAANFCALILAYCNKTVGELGDV RETMSYLFQHANLDSCKRVLNVVCKTCGQQQTTLKGVEAVMYMGTLSYEQFKKGVQIPCTCGKQATKY LVQQESPFVMMSAPPAQYELKHGTFTCASEYTGNYQCGHYKHITSKETLYCIDGALLTKSSEYKGPITDVF YKENSYTTTIKPVTYKLDGVVCTEIDPKLDNYYKKDNSYFTEQPIDLVPNQPYPNASFDNFKFVCDNIKFA DDLNQLTGYKKPASRELKVTFFPDLNGDVVAIDYKHYTPSFKKGAKLLHKPIVWHVNNATNKATYKPNT WCIRCLWSTKPVETSNSFDVLKSEDAQGMDNLACEDLKPVSEEVVENPTIQKDVLECNVKTTEVVGDIIL KPANNSLKITEEVGHTDLMAAYVDNSSLTIKKPNELSRVLGLKTLATHGLAAVNSVPWDTIANYAKPFLN KVVSTTTNIVTRCLNRVCTNYMPYFFTLLLQLCTFTRSTNSRIKASMPTTIAKNTVKSVGKFCLEASFNYLK SPNFSKLINIIIWFLLLSVCLGSLIYSTAALGVLMSNLGMPSYCTGYREGYLNSTNVTIATYCTGSIPCSVCLS GLDSLDTYPSLETIQITISSFKWDLTAFGLVAEWFLAYILFTRFFYVLGLAAIMQLFFSYFAVHFISNSWLMW LIINLVQMAPISAMVRMYIFFASFYYVWKSYVHVVDGCNSSTCMMCYKRNRATRVECTTIVNGVRRSFY VYANGGKGFCKLHNWNCVNCDTFCAGSTFISDEVARDLSLQFKRPINPTDQSSYIVDSVTVKNGSIHLYF DKAGQKTYERHSLSHFVNLDNLRANNTKGSLPINVIVFDGKSKCEESSAKSASVYYSQLMCQPILLLDQA LVSDVGDSAEVAVKMFDAYVNTFSSTFNVPMEKLKTLVATAEAELAKNVSLDNVLSTFISAARQGFVDSD VETKDVVECLKLSHQSDIEVTGDSCNNYMLTYNKVENMTPRDLGACIDCSARHINAQVAKSHNIALIWN VKDFMSLSEQLRKQIRSAAKKNNLPFKLTCATTRQVVNVVTTKIALKGG | Pool of 484 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 37 | MoTif 037 HCoV-229E (Spike Glycoprotein) | MFVLLVAYALLHIAGCQTTNGLNTSYSVCNGCVGYSENVFAVESGGYIPSDFAFNNWFLLTNTSSVVDGV VRSFQPLLLNCLWSVSGLRFTTGFVYFNGTGRGDCKGFSSDVLSDVIRYNLNFEENLRRGTILFKTSYGVVV FYCTNNTLVSGDAHIPFGTVLGNFYCFVNTTIGNETTSAFVGALPKTVREFVISRTGHFYINGYRYFTLGNV EAVNFNVTTAETTDFCTVALASYADVLVNVSQTSIANIIYCNSVINRLRCDQLSFDVPDGFYSTSPIQSVELP VSIVSLPVYHKHTFIVLYVDFKPQSGGGKCFNCYPAGVNITLANFNETKGPLCVDTSHFTTKYVAVYANVGR WSASINTGNCPFSFGKVNNFVKFGSVCFSLKDIPGGCAMPIVANWAYSKYYTIGSLYVSWSDGDGITGVP QPVEGVSSFMNVTLDKCTKYNIYDVSGVGVIRVSNDTFLNGITYTSTSGNLLGFKDVTKGTIYSITPCNPPD QLVVYQQAVVGAMLSENFTSYGFSNVVELPKFFYASNGTYNCTDAVLTYSSFGVCADGSIIAVQPRNVSYD SVSAIVTANLSIPSNWTTSVQVEYLQITSTPIVVDCSTYVCNGNVRCVELLKQYTSACKTIEDALRNSARLES ADVSEMLTFDKKAFTLANVSSFGDYNLSSVIPSLPTSGSRVAGRSAIEDILFSKLVTSGLGTVDADYKKCTKG LSIADLACAQYYNGIMVLPGVADAERMAMYTGSLIGGIALGGLTSAVSIPFSLAIQARLNYVALQTDVLQEN QKILAASFNKAMTNIVDAFTGVNDAITQTSQALQTVATALNKIQDVVNQQGNSLNHLTSQLRQNFQAISS SIQAIYDRLDTIQADQQVDRLITGRLAALNVFVSHTLTKYTEVRASRQLAQQKVNECVKSQSKRYGFCGNG THIFSIVNAAPEGLVFLHTVLLPTQYKDVEAWSGLCVDGTNGYVLRQPNLALYKEGNYYRITSRIMFEPRIPT MADFVQIENCNVTFVNISRSELQTIVPEYIDVNKTLQELSYKLPNYTVPDLVVEQYNQTILNLTSEISTLENKS AELNYTVQKLQTLIDNINSTLVDLKWLNRVETYIKWPWWVWLCISVVLIFVVSMLLLCCCSTGCCGFFSCFA SSIRGCCESTKLPYYDVEKIHIQ | Pool of 291 (146+145) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 38 | MoTif 038 SARS-CoV-2 (S-RBD B.1.617.2 / Delta) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDL CFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSN LKPFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTN LVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 39 | MoTif 039 SARS-CoV-2 (S-RBD B.1.1.529 / BA.1 / Omicron) | RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDL CFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNL KPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLV KNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 40 | MoTif 040 SARS-CoV-2 (Spike B.1.1.529 / BA.1 / Omicron) | MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTN GTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNN KSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIIVREPEDLPQG FSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCA LDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADY SVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWN SNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYSFRPTYGVGHQPYR VVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQ TLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGA EYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILP VSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGF NFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGLTVLPPLLTDEMIAQYT SALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASAL GKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAE IRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGK AHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFK NHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVM VTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 41 | MoTif 041 SARS-CoV-2 (S-RBD B.1.1.529 / BA.2 / Omicron) | RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDL CFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYLYRLFRKSN LKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTN LVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 42 | MoTif 042 SARS-CoV-2 (Spike B.1.1.529 / BA.4 & BA.5 / Omicron) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTNGT KRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHK NNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLP QGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAV DCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNC VADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGC VIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYG VGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTT DAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQ TRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTN FTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYK TPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPL LTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQ DSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYV TQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTA PAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFK EELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA GLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 43 | MoTif 043 SARS-CoV-2 (S-RBD B.1.617.2 / Delta) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLC FTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYRLFRKSNLK PFERDISTEIYQAGSKPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVK NKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 44 | MoTif 044SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNG TKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKN NKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLPQG FSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCAL DPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSV LYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSN KLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVV VLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEI LDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYV NNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSM TKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQI LPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLA GTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQD VVNHNAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGV FVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDL GDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSC CSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 45 | MoTif 045 SARS-CoV-2 (Spike B.1.1.529 / BA.2 / Omicron) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGT KRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYYHKNN KSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPINLGRDLPQGFS ALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDP LSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYN FAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDS KVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLRSYGFRPTYGVGHQPYRVVVLSFE LLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPC SFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYEC DIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDC TMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPS KRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTF GAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQAL NTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLG QSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQ RNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQ KEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCK FDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 46 | MoTif 046 SARS-CoV-2 (Nsp13) | AVGACVLCNSQTSLRCGACIRRPFLCCKCCYDHVISTSHKLVLSVNPYVCNAPGCDVTDVTQLYLGGMSYYC KSHKPPISFPLCANGQVFGLYKNTCVGSDNVTDFNAIATCDWTNAGDYILANTCTERLKLFAAETLKATEETFK LSYGIATVREVLSDRELHLSWEVGKPRPPLNRNYVFTGYRVTKNSKVQIGEYTFEKGDYGDAVVYRGTTTYKLN VGDYFVLTSHTVMPLSAPTLVPQEHYVRITGLYPTLNISDEFSSNVANYQKVGMQKYSTLQGPPGTGKSHFAIG LALYYPSARIVYTACSHAAVDALCEKALKYLPIDKCSRIIPARARVECFDKFKVNSTLEQYVFCTVNALPETTADIV VFDEISMATNYDLSVVNARLRAKHYVYIGDPAQLPAPRTLLTKGTLEPEYFNSVCRLMKTIGPDMFLGTCRRCP AEIVDTVSALVYDNKLKAHKDKSAQCFKMFYKGVITHDVSSAINRPQIGVVREFLTRNPAWRKAVFISPYNSQ NAVASKILGLPTQTVDSSQGSEYDYVIFTQTTETAHSCNVNRFNVAITRAKVGILCIMSDRDLYDKLQFTSLEIPR RNVATLQ | Pool of 148 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 47 | MoTif 047 SARS-CoV-2 (Nsp2) | AYTRYVDNNFCGPDGYPLECIKDLLARAGKASCTLSEQLDFIDTKRGVYCCREHEHEIAWYTERSEKSYELQT PFEIKLAKKFDTFNGECPNFVFPLNSIIKTIQPRVEKKKLDGFMGRIRSVYPVASPNECNQMCLSTLMKCDHCG ETSWQTGDFVKATCEFCGTENLTKEGATTCGYLPQNAVVKIYCPACHNSEVGPEHSLAEYHNESGLKTILRKGG RTIAFGGCVFSYVGCHNKCAYWVPRASANIGCNHTGVVGEGSEGLNDNLLEILQKEKVNINIVGDFKLNEEIAI ILASFSASTSAFVETVKGLDYKAFKQIVESCGNFKVTKGKAKKGAWNIGEQKSILSPLYAFASEAARVVRSIFSRT LETAQNSVRVLQKAAITILDGISQYSLRLIDAMMFTSDLATNNLVVMAYITGGVVQLTSQWLTNIFGTVYEKLK PVLDWLEEKFKEGVEFLRDGWEIVKFISTCACEIVGGQIVTCAKEIKESVQTFFKLVNKFLALCADSIIIGGAKLKA LNLGETFVTHSKGLYRKCVKSREETGLLMPLKAPKEIIFLEGETLPTEVLTEEVVLKTGDLQPLEQPTSEAVEAPLVG TPVCINGLMLLEIKDTEKYCALAPNMMVTNNTFTLKGG | Pool of 157 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 48 | MoTif 048 SARS-CoV-2 (Nsp14) | AENVTGLFKDCSKVITGLHPTQAPTHLSVDTKFKTEGLCVDIPGIPKDMTYRRLISMMGFKMNYQVNGYPN MFITREEAIRHVRAWIGFDVEGCHATREAVGTNLPLQLGFSTGVNLVAVPTGYVDTPNNTDFSRVSAKPPPGD QFKHLIPLMYKGLPWNVVRIKIVQMLSDTLKNLSDRVVFVLWAHGFELTSMKYFVKIGPERTCCLCDRRATCFS TASDTYACWHHSIGFDYVYNPFMIDVQQWGFTGNLQSNHDLYCQVHGNAHVASCDAIMTRCLAVHECFVK RVDWTIEYPIIGDELKINAACRKVQHMVVKAALLADKFPVLHDIGNPKAIKCVPQADVEWKFYDAQPCSDKAYKIEELFYSYATHSDKFTDGVCLFWNCNVDRYPANSIVCRFDTRVLSNLNLPGCDGGSLYVNKHAFHTPAFDKSAFVNLKQLPFFYYSDSPCESHGKQVVSDIDYVPLKSATCITRCNLGGAVCRHHANEYRLYLDAYNMMISAGFSLWVYKQFDTYNLWNTFTRLQ | Pool of 129 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 49 | MoTif 049 HCoV-229E (Spike Glycoprotein) | MFVLLVAYALLHIAGCQTTNGLNTSYSVCNGCVGYSENVFAVESGGYIPSDFAFNNWFLLTNTSSVVDGVVRS FQPLLLNCLWSVSGLRFTTGFVYFNGTGRGDCKGFSSDVLSDVIRYNLNFEENLRRGTILFKTSYGVVVFYCTNN TLVSGDAHIPFGTVLGNFYCFVNTTIGNETTSAFVGALPKTVREFVISRTGHFYINGYRYFTLGNVEAVNFNVTTAETTDFCTVALASYADVLVNVSQTSIANIIYCNSVINRLRCDQLSFDVPDGFYSTSPIQSVELPVSIVSLPVYHKHTFIVLYVDFKPQSGGGKCFNCYPAGVNITLANFNETKGPLCVDTSHFTTKYVAVYANVGRWSASINTGNCPFSFGKVNNFVKFGSVCFSLKDIPGGCAMPIVANWAYSKYYTIGSLYVSWSDGDGITGVPQPVEGVSSFMNVTLDKCTKYNIYDVSGVGVIRVSNDTFLNGITYTSTSGNLLGFKDVTKGTIYSITPCNPPDQLVVYQQAVVGAMLSENFTSYGFSNVVELPKFFYASNGTYNCTDAVLTYSSFGVCADGSIIAVQPRNVSYDSVSAIVTANLSIPSNWTTSVQVEYLQITSTPIVVDCSTYVCNGNVRCVELLKQYTSACKTIEDALRNSARLESADVSEMLTFDKKAFTLANVSSFGDYNLSSVIPSLPTSGSRVAGRSAIEDILFSKLVTSGLGTVDADYKKCTKGLSIADLACAQYYNGIMVLPGVADAERMAMYTGSLIGGIALGGLTSAVSIPFSLAIQARLNYVALQTDVLQENQKILAASFNKAMTNIVDAFTGVNDAITQTSQALQTVATALNKIQDVVNQQGNSLNHLTSQLRQNFQAISSSIQAIYDRLDTIQADQQVDRLITGRLAALNVFVSHTLTKYTEVRASRQLAQQKVNECVKSQSKRYGFCGNGTHIFSIVNAAPEGLVFLHTVLLPTQYKDVEAWSGLCVDGTNGYVLRQPNLALYKEGNYYRITSRIMFEPRIPTMADFVQIENCNVTFVNISRSELQTIVPEYIDVNKTLQELSYKLPNYTVPDLVVEQYNQTILNLTSEISTLENKSAELNYTVQKLQTLIDNINSTLVDLKWLNRVETYIKWPWWVWLCISVVLIFVVSMLLLCCCSTGCCGFFSCFASSIRGCCESTKLPYYDVEKIHIQ | Pool of 291 (146+145) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 50 | MoTif 050 SARS-CoV-2 (S-RBD B.1.351 / Beta) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLND LCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRK SNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKK STNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 51 | MoTif 051 SARS-CoV-2 (S-RBD B.1.1.529 / BA.4 & BA.5 / Omicron) | RVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLND LCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRK SNLKPFERDISTEIYQAGNKPCNGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 52 | MoTif 052 Collection EBV (25ug/peptide) | 14 different PepMixes,1 aliquots of 14 peptide pools each containing 15µg per peptide /tube | Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 53 | MoTif 053 Collection HCMV (25ug/peptide) | 19 different PepMixes,1 aliquot of 19 peptide pools in 20 vials each containing 25µg per peptide /tube | Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections |
| 54 | MoTif 054 Collection HCMV (2x1ug/peptide) | 19 different PepMixes,2 aliquots of 19 peptide pools each containing 1µg per peptide /tube | Collection of 19 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Control, Cytomegalovirus disease, Infectious mononucleosis, Opportunistic infections |
| 55 | MoTif 055 Arabidopsis (WRKY47) | MEEHIQDRREIAFLHSGEFLHGDSDSKDHQPNESPVERHHESSIKEVDFFAAKSQPFDLGHVRTTTIVG SSGFNDGLGLVNSCHGTSSNDGDDKTKTQISRLKLELERLHEENHKLKHLLDEVSESYNDLQRRVLLAR QTQVEGLHHKQHEDVPQAGSSQALENRRPKDMNHETPATTLKRRSPDDVDGRDMHRGSPKTPRID QNKSTNHEEQQNPHDQLPYRKARVSVRARSDATTVNDGCQWRKYGQKMAKGNPCPRAYYRCTMA VGCPVRKQVQRCAEDTTILTTTYEGNHNHPLPPSATAMAATTSAAAAMLLSGSSSSNLHQTLSSPSAT SSSSFYHNFPYTSTIATLSASAPFPTITLDLTNPPRPLQPPPQFLSQYGPAAFLPNANQIRSMNNNNQQ LLIPNLFGPQAPPREMVDSVRAAIAMDPNFTAALAAAISNIIGGGNNDNNNNTDINDNKVDAKSGG SSNGDSPQLPQSCTTFSTN | Pool of 120 peptides derived from a peptide scan through Transcription factors/activators (Swiss-Prot ID: Q9ZSI7) of . | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 56 | MoTif 056 Collection SARS-CoV-2 Wuhan Structural Proteins | 8 different SARS-CoV-2 PepMixes: SARS-CoV-2 (Spike Glycoprotein) SARS-CoV- 2 (S-RBD) SARS-CoV-2 (NCAP) SARS-CoV-2 (VEMP) SARS-CoV-2 (VME1) SARS- CoV-2 (AP3A) SARS-CoV-2 (ORF9B) SARS-CoV-2 (Y14) | Collection of 8 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19 |
| 57 | MoTif 057 HCoV-NL63 (NCAP) | MASVNWADDRAARKKFPPPSFYMPLLVSSDKAPYRVIPRNLVPIGKGNKDEQIGYWNVQERWRMR RGQRVDLPPKVHFYYLGTGPHKDLKFRQRSDGVVWVAKEGAKTVNTSLGNRKRNQKPLEPKFSIALP PELSVVEFEDRSNNSSRASSRSSTRNNSRDSSRSTSRQQSRTRSDSNQSSSDLVAAVTLALKNLGFDN QSKSPSSSGTSTPKKPNKPLSQPRADKPSQLKKPRWKRVPTREENVIQCFGPRDFNHNMGDSDLVQ NGVDAKGFPQLAELIPNQAALFFDSEVSTDEVGDNVQITYTYKMLVAKDNKNLPKFIEQISAFTKPSSI KEMQSQSSHVAQNTVLNASIPESKPLADDDSAIIEIVNEVLH | Pool of 92 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 58 | MoTif 058 Collection SARS-CoV-2 Wuhan Non-Structural Proteins | 20 different SARS-CoV-2 PepMixes: SARS-CoV-2 (NSP1) SARS-CoV-2 (NSP2) SARS-CoV-2 (NSP3)SARS-CoV-2 (NSP4) SARS-CoV-2 (NSP5) SARS-CoV-2 (NSP6) SARS-CoV-2 (NSP7) SARS-CoV-2(NSP8) SARS-CoV-2 (NSP9) SARS-CoV-2 (NSP10) SARS-CoV-2 (C+NSP11) SARS-CoV-2 (NSP12) SARS-CoV-2 (NSP13) SARS-CoV-2 (NSP14) SARS-CoV-2 (NSP15) SARS-CoV-2 (NSP16) SARS-CoV-2 (NS6) SARS-CoV-2 (NS7A) SARS-CoV-2 (NS7B) SARS-CoV-2 (NS8) | Collection of 20 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19 |
| 59 | MoTif 059 Pan-Psoriasis Select | see additional product documentation | Virus-specific pool of 79 peptides (defined HLA class I & II-restricted T-cell epitopes) from selected proteins of Human for T cell assays (e.g. ELISPOT). | 70%-90% | T-cell immunity | Autoimmune disease |
| 60 | MoTif 060 Pan-Hepatitis C Virus Select | see additional product documentation | Virus-specific pool of 150 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | / | Hepatitis, Infection |
| 61 | MoTif 061 SARS-CoV (Spike Glycoprotein) | MFIFLLFLTLTSGSDLDRCTTFDDVQAPNYTQHTSSMRGVYYPDEIFRSDTLYLTQDLFLPFYSNVTGF HTINHTFGNPVIPFKDGIYFAATEKSNVVRGWVFGSTMNNKSQSVIIINNSTNVVIRACNFELCDNP FFAVSKPMGTQTHTMIFDNAFNCTFEYISDAFSLDVSEKSGNFKHLREFVFKNKDGFLYVYKGYQPID VVRDLPSGFNTLKPIFKLPLGINITNFRAILTAFSPAQDIWGTSAAAYFVGYLKPTTFMLKYDENGTITD AVDCSQNPLAELKCSVKSFEIDKGIYQTSNFRVVPSGDVVRFPNITNLCPFGEVFNATKFPSVYAWER KKISNCVADYSVLYNSTFFSTFKCYGVSATKLNDLCFSNVYADSFVVKGDDVRQIAPGQTGVIADYNY KLPDDFMGCVLAWNTRNIDATSTGNYNYKYRYLRHGKLRPFERDISNVPFSPDGKPCTPPALNCYW PLNDYGFYTTTGIGYQPYRVVVLSFELLNAPATVCGPKLSTDLIKNQCVNFNFNGLTGTGVLTPSSKRF QPFQQFGRDVSDFTDSVRDPKTSEILDISPCSFGGVSVITPGTNASSEVAVLYQDVNCTDVSTAIHAD QLTPAWRIYSTGNNVFQTQAGCLIGAEHVDTSYECDIPIGAGICASYHTVSLLRSTSQKSIVAYTMSLG ADSSIAYSNNTIAIPTNFSISITTEVMPVSMAKTSVDCNMYICGDSTECANLLLQYGSFCTQLNRALSG IAAEQDRNTREVFAQVKQMYKTPTLKYFGGFNFSQILPDPLKPTKRSFIEDLLFNKVTLADAGFMKQY GECLGDINARDLICAQKFNGLTVLPPLLTDDMIAAYTAALVSGTATAGWTFGAGAALQIPFAMQMAY RFNGIGVTQNVLYENQKQIANQFNKAISQIQESLTTTSTALGKLQDVVNQNAQALNTLVKQLSSNFG AISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVD FCGKGYHLMSFPQAAPHGVVFLHVTYVPSQERNFTTAPAICHEGKAYFPREGVFVFNGTSWFITQRN FFSPQIITTDNTFVSGNCDVVIGIINNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVV NIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYVWLGFIAGLIAIVMVTILLCCMTSCCSCLKG ACSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 311 (156+155) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 62 | MoTif 062 SARS-CoV-2 (Spike Fusion-Peptide) | KRSFIEDLLFNKVTLAD | Pool of 28 peptides derived from a peptide scan (truncational scan (peptide length 11 to 17aa)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 63 | MoTif 063 Pan-Yellow Fever Virus Select | see additional product documentation | Virus-specific pool of 150 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | / | Infection, Yellow Fever |
| 64 | MoTif 064 Collection EBV (2x1ug/peptide) | Collection of 14 peptide pools (overlapping peptide scans, 15mers with 11 aa overlap) | 14 different PepMixes, 2 aliquots of 14 peptide pools each containing 1µg per peptide /tube | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Cancer, Hodgkin's lymphoma, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 65 | MoTif 065 SARS-CoV-2 (NCPMUT) | MSDNGPQNQRNALRITFGGPSDSTGSN (MUT_NCAP_SARS2_0013P/L) + QASSRSSSRSRNISR NSTPGSSRGTSP (MUT_NCAP_SARS2_0193S/I) + QASSRSSSRSRNSLRNSTPGSSRGTSP (MUT_ NCAP_SARS2_0194S/L) + RSSSRSRNSSRNLTPGSSRGTSPARMA (MUT_NCAP_SARS2_0197S/L) + RSRNSSRNSTPGSSKGTSPARMAGNGG (MUT_NCAP_SARS2_0203R/K) + SSRNSTPGSSRRTSP ARMAGNGG (MUT_NCAP_SARS2_0204G/R) | Pool of 23 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 66 | MoTif 066 HCoV-HKU1 (NCAP) | MSYTPGHYAGSRSSSGNRSGILKKTSWADQSERNYQTFNRGRKTQPKFTVSTQPQGNTIPHYSWFSG ITQFQKGRDFKFSDGQGVPIAFGVPPSEAKGYWYRHSRRSFKTADGQQKQLLPRWYFYYLGTGPYANA SYGESLEGVFWVANHQADTSTPSDVSSRDPTTQEAIPTRFPPGTILPQGYYVEGSGRSASNSRPGSRSQ SRGPNNRSLSRSNSNFRHSDSIVKPDMADEIANLVLAKLGKDSKPQQVTKQNAKEIRHKILTKPRQKRT PNKHCNVQQCFGKRGPSQNFGNAEMLKLGTNDPQFPILAELAPTPGAFFFGSKLDLVKRDSEADSPV KDVFELHYSGSIRFDSTLPGFETIMKVLEENLNAYVNSNQNTDSDSLSSKPQRKRGVKQLPEQFDSLNL SAGTQHISNDFTPEDHSLLATLDDPYVEDSVA | Pool of 108 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 67 | MoTif 067 HCoV-NL63 (Spike Glycoprotein) | MKLFLILLVLPLASCFFTCNSNANLSMLQLGVPDNSSTIVTGLLPTHWFCANQSTSVYSANGFFYIDVG NHRSAFALHTGYYDANQYYIYVTNEIGLNASVTLKICKFSRNTTFDFLSNASSSFDCIVNLLFTEQLGAP LGITISGETVRLHLYNVTRTFYVPAAYKLTKLSVKCYFNYSCVFSVVNATVTVNVTTHNGRVVNYTVCD DCNGYTDNIFSVQQDGRIPNGFPFNNWFLLTNGSTLVDGVSRLYQPLRLTCLWPVPGLKSSTGFVYFN ATGSDVNCNGYQHNSVVDVMRYNLNFSANSLDNLKSGVIVFKTLQYDVLFYCSNSSSGVLDTTIPFG PSSQPYYCFINSTINTTHVSTFVGILPPTVREIVVARTGQFYINGFKYFDLGFIEAVNFNVTTASATDFWT VAFATFVDVLVNVSATNIQNLLYCDSPFEKLQCEHLQFGLQDGFYSANFLDDNVLPETYVALPIYYQHT DINFTATASFGGSCYVCKPHQVNISLNGNTSVCVRTSHFSIRYIYNRVKSGSPGDSSWHIYLKSGTCPFS FSKLNNFQKFKTICFSTVEVPGSCNFPLEATWHYTSYTIVGALYVTWSEGNSITGVPYPVSGIREFSNLVL NNCTKYNIYDYVGTGIIRSSNQSLAGGITYVSNSGNLLGFKNVSTGNIFIVTPCNQPDQVAVYQQSIIGA MTAVNESRYGLQNLLQLPNFYYVSNGGNNCTTAVMTYSNFGICADGSLIPVRPRNSSDNGISAIITANL SIPSNWTTSVQVEYLQITSTPIVVDCATYVCNGNPRCKNLLKQYTSACKTIEDALRLSAHLETNDVSSML TFDSNAFSLANVTSFGDYNLSSVLPQRNIRSSRIAGRSALEDLLFSKVVTSGLGTVDVDYKSCTKGLSIAD LACAQYYNGIMVLPGVADAERMAMYTGSLIGGMVLGGLTSAAAIPFSLALQARLNYVALQTDVLQENQ KILAASFNKAINNIVASFSSVNDAITQTAEAIHTVTIALNKIQDVVNQQGSALNHLTSQLRHNFQAISNSI QAIYDRLDSIQADQQVDRLITGRLAALNAFVSQVLNKYTEVRGSRRLAQQKINECVKSQSNRYGFCGN GTHIFSIVNSAPDGLLFLHTVLLPTDYKNVKAWSGICVDGIYGYVLRQPNLVLYSDNGVFRVTSRVMFQP RLPVLSDFVQIYNCNVTFVNISRVELHTVIPDYVDVNKTLQEFAQNLPKYVKPNFDLTPFNLTYLNLSSELK QLEAKTASLFQTTVELQGLIDQINSTYVDLKLLNRFENYIKWPWWVWLIISVVFVVLLSLLVFCCLSTGCCG CCNCLTSSMRGCCDCGSTKLPYYEFEKVHVQ | Pool of 337 (169+168) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 68 | MoTif 068 Influenza B (M1) Ultra | see additional product documentation | Pool of 67 peptides derived from a peptide scan (15mers) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Sequence diversity |
| 69 | MoTif 069 SARS-CoV-2 (Spike BF.7) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGTN GTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDV YYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPI NLGRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYN ENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATTFASVY AWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIA DYNYKLPDDFTGCVIAWNSNKLDSKVGGNYNYRYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGV NCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTE SNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVA IHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQS IIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQ LKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGF IKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQM AYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKF GAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRV DFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQ RNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINAS VVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLK GCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 70 | MoTif 070 Pan-Human Rhinovirus Select | see additional product documentation | Virus-specific pool of 169 peptides (defined HLA class I & II-restricted T-cell epitopes) from selected proteins of for T cell assays (e.g. ELISPOT). | 70%-90% | T-cell immunity | Common cold, Infection, Respiratory infection |
| 71 | MoTif 071 SARS-CoV-2 (Spike BQ.1.1) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAISGT NGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFL DVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSK HTPINLGRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTF LLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNAT TFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPG QTGNIADYNYKLPDDFTGCVIAWNSNKLDSTVGGNYNYRYRLFRKSKLKPFERDISTEIYQAGNKPC NGVAGVNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGL TGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQG VNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSH RRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECS NLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIED LLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTF GAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNH NAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANL AATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFP REGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKN HTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIV MVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 72 | MoTif 072 Human (TERT) | MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPP AAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGS GAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCER AWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSD RGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSS GDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQC PYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLR RLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLR EEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVR QHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLG ASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVV QKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCH HAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRT LVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIR ASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQ VWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLL GSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD | Pool of 281 peptides derived from a peptide scan through Telomerase reverse transcriptase (Swiss-Prot ID: O14746) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Breast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer |
| 73 | MoTif 073 Human (TYMS) | MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLR DEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQ WRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVV NSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRP FPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV | Pool of 76 peptides derived from a peptide scan through Thymidylate synthase (Swiss-Prot ID: P04818) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 74 | MoTif 074 VZV (gE) | MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHTDEDKLDTNSVYEPYYHSDHAESSWVNR GESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGI HVIPTLNGDDRHKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETW SFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTS TLFDELELDPPEIEPGVLKVLRTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRG AEFHMWNYHSHVFSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCL SHMNSGCTFTSPHLAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGL YVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGL AAVVLLCLVIFLICTAKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSY TVYIDKTR | Pool of 153 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Chicken Pox, Herpes zoster, Infection, Shingles |
| 75 | MoTif 075 Human (PAP) | MRAAPLLLARAASLSLGFLFLLFFWLDRSVLAKELKFVTLVFRHGDRSPIDTFPTDPIKESSWPQGFGQL TQLGMEQHYELGEYIRKRYRKFLNESYKHEQVYIRSTDVDRTLMSAMTNLAALFPPEGVSIWNPILLW QPIPVHTVPLSEDQLLYLPFRNCPRFQELESETLKSEEFQKRLHPYKDFIATLGKLSGLHGQDLFGIWSKV YDPLYCESVHNFTLPSWATEDTMTKLRELSELSLLSLYGIHKQKEKSRLQGGVLVNEILNHMKRATQIPSY KKLIMYSAHDTTVSGLQMALDVYNGLLPPYASCHLTELYFEKGEYFVEMYYRNETQHEPYPLMLPGCSP SCPLERFAELVGPVIPQDWSTECMTTNSHQGTEDSTD | Pool of 94 peptides derived from a peptide scan through Prostatic acid phosphatase (PAP) (Swiss-Prot ID: P15309) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Phosphatase, Prostate cancer |
| 76 | MoTif 076 Human (AFP) | MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALT AIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPE PVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRE SSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEK IMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASF VHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGE YYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVN PGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQI TEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV | Pool of 150 peptides derived from a peptide scan through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 77 | MoTif 077 Dengue 1 (E) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan through Envelope Protein of Dengue Virus - type 1 (DENV1). | 70%-90% | T-cell immunity | Dengue fever, Infection, Sequence diversity |
| 78 | MoTif 078 HIV-1 (GAG) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) | 70%-90% | T-cell immunity | AIDS (HIV), HIV, Infection, Sequence diversity |
| 79 | MoTif 079 HIV-1 (POL) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) | 70%-90% | T-cell immunity | AIDS (HIV), HIV, Infection, Sequence diversity |
| 80 | MoTif 080 HPIV-3 (Matrix Protein) | MSITNSAIYTFPESSFSENGHIEPLPLKVNEQRKAVPHIRVAKIGNPPKHGSRYLDVFLLGFFEMERIKDKYGSVNDLDSDPGYKVCGSGSLPIGLAKYTGNDQELLQAATKLDIEVRRTVKAKEMIVYTVQNIKPELYPWSSRLRKGMLFDANKVALAPQCLPLDRSIKFRVIFVNCTAIGSITLFKIPKSMASLSLPSTISINLQVHIKTGVQTDSKGIVQILDEKGEKSLNFMVHLGLIKRKVGRMYSVEYCKQKIEKMRLIFSLGLVGGISLHVNATGSISKTLASQLVFKREICYPLMDLNPHLNLVIWASSVEITRVDAIFQPSLPGEFRYYPNIIAKGVGKIKQWN | Pool of 86 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Bronchitis, Infection, Respiratory infection |
| 81 | MoTif 081 Human (TERT) | MPRAPRCRAVRSLLRSHYREVLPLATFVRRLGPQGWRLVQRGDPAAFRALVAQCLVCVPWDARPPPAAPSFRQVSCLKELVARVLQRLCERGAKNVLAFGFALLDGARGGPPEAFTTSVRSYLPNTVTDALRGSGAWGLLLRRVGDDVLVHLLARCALFVLVAPSCAYQVCGPPLYQLGAATQARPPPHASGPRRRLGCERAWNHSVREAGVPLGLPAPGARRRGGSASRSLPLPKRPRRGAAPEPERTPVGQGSWAHPGRTRGPSDRGFCVVSPARPAEEATSLEGALSGTRHSHPSVGRQHHAGPPSTSRPPRPWDTPCPPVYAETKHFLYSSGDKEQLRPSFLLSSLRPSLTGARRLVETIFLGSRPWMPGTPRRLPRLPQRYWQMRPLFLELLGNHAQCPYGVLLKTHCPLRAAVTPAAGVCAREKPQGSVAAPEEEDTDPRRLVQLLRQHSSPWQVYGFVRACLRRLVPPGLWGSRHNERRFLRNTKKFISLGKHAKLSLQELTWKMSVRDCAWLRRSPGVGCVPAAEHRLREEILAKFLHWLMSVYVVELLRSFFYVTETTFQKNRLFFYRKSVWSKLQSIGIRQHLKRVQLRELSEAEVRQHREARPALLTSRLRFIPKPDGLRPIVNMDYVVGARTFRREKRAERLTSRVKALFSVLNYERARRPGLLGASVLGLDDIHRAWRTFVLRVRAQDPPPELYFVKVDVTGAYDTIPQDRLTEVIASIIKPQNTYCVRRYAVVQKAAHGHVRKAFKSHVSTLTDLQPYMRQFVAHLQETSPLRDAVVIEQSSSLNEASSGLFDVFLRFMCHHAVRIRGKSYVQCQGIPQGSILSTLLCSLCYGDMENKLFAGIRRDGLLLRLVDDFLLVTPHLTHAKTFLRTLVRGVPEYGCVVNLRKTVVNFPVEDEALGGTAFVQMPAHGLFPWCGLLLDTRTLEVQSDYSSYARTSIRASLTFNRGFKAGRNMRRKLFGVLRLKCHSLFLDLQVNSLQTVCTNIYKILLLQAYRFHACVLQLPFHQQVWKNPTFFLRVISDTASLCYSILKAKNAGMSLGAKGAAGPLPSEAVQWLCHQAFLLKLTRHRVTYVPLLGSLRTAQTQLSRKLPGTTLTALEAAANPALPSDFKTILD | Pool of 281 peptides derived from a peptide scan through Telomerase reverse transcriptase (Swiss-Prot ID: O14746) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Breast cancer, Burkitt's lymphoma, Cancer, Gastric cancer, Malignant genital cancers, Melanoma, Prostate cancer |
| 82 | MoTif 082 Human (TYMS) | MPVAGSELPRRPLPPAAQERDAEPRPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV | Pool of 76 peptides derived from a peptide scan through Thymidylate synthase (Swiss-Prot ID: P04818) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 83 | MoTif 083 Human (AFP) | MKWVESIFLIFLLNFTESRTLHRNEYGIASILDSYQCTAEISLADLATIFFAQFVQEATYKEVSKMVKDALTAIEKPTGDEQSSGCLENQLPAFLEELCHEKEILEKYGHSDCCSQSEEGRHNCFLAHKKPTPASIPLFQVPEPVTSCEAYEEDRETFMNKFIYEIARRHPFLYAPTILLWAARYDKIIPSCCKAENAVECFQTKAATVTKELRESSLLNQHACAVMKNFGTRTFQAITVTKLSQKFTKVNFTEIQKLVLDVAHVHEHCCRGDVLDCLQDGEKIMSYICSQQDTLSNKITECCKLTTLERGQCIIHAENDEKPEGLSPNLNRFLGDRDFNQFSSGEKNIFLASFVHEYSRRHPQLAVSVILRVAKGYQELLEKCFQTENPLECQDKGEEELQKYIQESQALAKRSCGLFQKLGEYYLQNAFLVAYTKKAPQLTSSELMAITRKMAATAATCCQLSEDKLLACGEGAADIIIGHLCIRHEMTPVNPGVGQCCTSSYANRRPCFSSLVVDETYVPPAFSDDKFIFHKDLCQAQGVALQTMKQEFLINLVKQKPQITEEQLEAVIADFSGLLEKCCQGQEQEVCFAEEGQKLISKTRAALGV | Pool of 150 peptides derived from a peptide scan through Alpha-fetoprotein (Swiss-Prot ID: P02771) of Human. | 70%-90% | Cancer | Cancer biomarker research, T-cell immunity |
| 84 | MoTif 084 Human (HMMR) | MSFPKAPLKRFNDPSGCAPSPGAYDVKTLEVLKGPVSFQKSQRFKQQKESKQNLNVDKDTTLPASARKVKSSESKESQKNDKDLKILEKEIRVLLQERGAQDRRIQDLETELEKMEARLNAALREKTSLSANNATLEKQLIELTRTNELLKSKFSENGNQKNLRILSLELMKLRNKRETKMRGMMAKQEGMEMKLQVTQRSLEESQGKIAQLEGKLVSIEKEKIDEKSETEKLLEYIEEISCASDQVEKYKLDIAQLEENLKEKNDEILSLKQSLEENIVILSKQVEDLNVKCQLLEKEKEDHVNRNREHNENLNAEMQNLKQKFILEQQEREKLQQKELQIDSLLQQEKELSSSLHQKLCSFQEEMVKEKNLFEEELKQTLDELDKLQQKEEQAERLVKQLEEEAKSRAEELKLLEEKLKGKEAELEKSSAAHTQATLLLQEKYDSMVQSLEDVTAQFESYKALTASEIEDLKLENSSLQEKAAKAGKNAEDVQHQILATESSNQEYVRMLLDLQTKSALKETEIKEITVSFLQKITDLQNQLKQQEEDFRKQLEDEEGRKAEKENTTAELTEEINKWRLLYEELYNKTKPFQLQLDAFEVEKQALLNEHGAAQEQLNKIRDSYAKLLGHQNLKQKIKHVVKLKDENSQLKSEVSKLRCQLAKKKQSETKLQEELNKVLGIKHFDPSKAFHHESKENFALKTPLKEGNTNCYRAPMECQESWK | Pool of 179 peptides derived from a peptide scan through Hyaluronan mediated motility receptor (Swiss-Prot ID: O75330) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Breast cancer, Cancer, Cell motility |
| 85 | MoTif 085 Human (BRAF) | MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLDALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQRCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQRDRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGGSTTGLSATPPASLPGSLTNVKALQKSPGPQRERKSSSSSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHRSASEPSLNRAGFQTEDFSLYACASPKTPIQAGGYGAFPVH | Pool of 189 peptides derived from a peptide scan (15mers with 11 aa overlap) through Serine/threonine-protein kinase B-raf (Swiss-Prot ID: P15056) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 86 | MoTif 086 Dengue 1 (E) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan through Envelope Protein of Dengue Virus - type 1 (DENV1). | 70%-90% | T-cell immunity | Dengue fever, Infection, Sequence diversity |
| 87 | MoTif 087 HIV-1 (GAG) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) through Gag polyprotein (gag) of Human Immunodeficiency Virus (HIV). | 70%-90% | T-cell immunity | AIDS (HIV), HIV, Infection, Sequence diversity |
| 88 | MoTif 088 HIV-1 (POL) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) through Pol polyprotein (POL) of Human Immunodeficiency Virus (HIV). | 70%-90% | T-cell immunity | AIDS (HIV), HIV, Infection, Sequence diversity |
| 89 | MoTif 089 HPIV-3 (Matrix Protein) | MSITNSAIYTFPESSFSENGHIEPLPLKVNEQRKAVPHIRVAKIGNPPKHGSRYLDVFLLGFFEMERIKDKYGSVNDLDSDPGYKVCGSGSLPIGLAKYTGNDQELLQAATKLDIEVRRTVKAKEMIVYTVQNIKPELYPWSSRLRKGMLFDANKVALAPQCLPLDRSIKFRVIFVNCTAIGSITLFKIPKSMASLSLPSTISINLQVHIKTGVQTDSKGIVQILDEKGEKSLNFMVHLGLIKRKVGRMYSVEYCKQKIEKMRLIFSLGLVGGISLHVNATGSISKTLASQLVFKREICYPLMDLNPHLNLVIWASSVEITRVDAIFQPSLPGEFRYYPNIIAKGVGKIKQWN | Pool of 86 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Bronchitis, Infection, Respiratory infection |
| 90 | MoTif 090 Human (WT1/WT33) | MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL | Pool of 110 peptides derived from a peptide scan through Wilms tumor protein (Swiss-Prot ID: P19544) of Human. | 70%-90% | T-cell Immunity, Cancer biomarker research | Cancer, Wilms tumor 1 |
| 91 | MoTif 091 SARS-CoV-2 (Y14) | MLQSCYNFLKEQHCQKASTQKGAEAAVKPLLVPHHVVATVQEIQLQAAVGELLLLEWLAMAVMLLLLCCCLTD | Pool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 92 | MoTif 092 Influenza A (HA/H1N1/Wisconsin/2019) | MKAILVVMLYTFTTANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTARSWSYIVETSNSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAACPHAGAKSFYKNLIWLVKKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIADQQSLYQNADAYVFVGTSRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVAPRYAFTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTSLPFQNVHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLDSTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza |
| 93 | MoTif 093 Human (NY-ESO-2) | MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPRGGAPRGPHGGAASAQDGRCPCGARRPDSRLLELHITMPFSSPMEAELVRRILSRDAAPLPRPGAVLKDFTVSGNLLFMSVRDQDREGAGRMRVVGWGLGSASPEGQKARDLRTPKHKVSEQRPGTPGPPPPEGAQGDGCRGVAFNVMFSAPHI | Pool of 50 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Malignant genital cancers |
| 94 | MoTif 094 Human (Prame/OIP4) | MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN | Pool of 125 peptides derived from a peptide scan through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (Swiss-Prot ID: P78395) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 95 | MoTif 095 Human (Matrilysin, MMP7) | MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLKEMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK | Pool of 64 peptides derived from a peptide scan through Matrilysin (Swiss-Prot ID: P09237) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 96 | MoTif 096 HSV2 (E3 ICP0) | MEPRPGTSSRADPGPERPPRQTPGTQPAAPHAWGMLNDMQWLASSDSEEETEVGISDDDLHRDSTSEAGSTDTEMFEAGLMDAATPPARPPAERQGSPTPADAQGSCGGGPVGEEEAEAGGGGDVCAVCTDEIAPPLRCQSFPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDPRTRVEAEAAVRAGTAVDFIWTGNPRTAPRSLSLGGHTVRALSPTPPWPGTDDEDDDLADVDYVPPAPRRAPRRGGGGAGATRGTSQPAATRPAPPGAPRSSSSGGAPLRAGVGSGSGGGPAVAAVVPRVASLPPAAGGGRAQARRVGEDAAAAEGRTPPARQPRAAQEPPIVISDSPPPSPRRPAGPGPLSFVSSSSAQVSSGPGGGGLPQSSGRAARPRAAVAPRVRSPPRAAAAPVVSASADAAGPAPPAVPVDAHRAPRSRMTQAQTDTQAQSLGRAGATDARGSGGPGAEGGPGVPRGTNTPGAAPHAAEGAAARPRKRRGSDSGPAASSSASSSAAPRSPLAPQGVGAKRAAPRRAPDSDSGDRGHGPLAPASAGAAPPSASPSSQAAVAAASSSSASSSSASSSSASSSSASSSSASSSSASSSSASSSAGGAGGSVASASGAGERRETSLGPRAAAPRGPRKCARKTRHAEGGPEPGARDPAPGLTRYLPIAGVSSVVALAPYVNKTVTGDCLPVLDMETGHIGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHARNCVRPPDYPTPPASEWNSLWMTPVGNMLFDQGTLVGALDFHGLRSRHPWSREQGAPAPAGDAPAGHGE | Pool of 204 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 97 | MoTif 097Human (RGS5) | MCKGLAALPHSCLERAKEIKIKLGILLQKPDSVGDLVIPYNEKPEKPAKTQKTSLDEALQWRDSLDKLLQNNYGLASFKSFLKSEFSEENLEFWIACEDYKKIKSPAKMAEKAKQIYEEFIQTEAPKEVNIDHFTKDITMKNLVEPSLSSFDMAQKRIHALMEKDSLPRFVRSEFYQELIK | Pool of 43 peptides derived from a peptide scan through Regulator of G-protein signaling 5 (Swiss-Prot ID: O15539) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 98 | MoTif 098 Measles virus (Hemagglutinin glycoprotein) | MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRLHRAAIYTAEIHKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKLISDKIKFLNPDREYDFRDLTWCINPPERIKLDYDQYCADVAAEELMNALVNSTLLETRTTNQFLAVSKGNCSGPTTIRGQFSNMSLSLLDLYLGRGYNVSSIVTMTSQGMYGGTYLVEKPNLSSKRSELSQLSMYRVFEVGVIRNPGLGAPVFHMTNYLEQPVSNDLSNCMVALGELKLAALCHGEDSITIPYQGSGKGVSFQLVKLGVWKSPTDMQSWVPLSTDDPVIDRLYLSSHRGVIADNQAKWAVPTTRTDDKLRMETCFQQACKGKIQALCENPEWAPLKDNRIPSYGVLSVDLSLTVELKIKIASGFGPLITHGSGMDLYKSNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPYLFTVPIKEAGEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYFYPFRLPIKGVPIELQVECFTWDQKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDGTNRR | Pool of 152 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Measles |
| 99 | MoTif 099 Influenza A (HA/H1N1/Wisconsin/2019) | MKAILVVMLYTFTTANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTARSWSYIVETSNSDNGTCYPGDFINYEELREQLSSVSSFERFEIFPKTSSWPNHDSDNGVTAACPHAGAKSFYKNLIWLVKKGKSYPKINQTYINDKGKEVLVLWGIHHPPTIADQQSLYQNADAYVFVGTSRYSKKFKPEIATRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVAPRYAFTMERDAGSGIIISDTPVHDCNTTCQTPEGAINTSLPFQNVHPITIGKCPKYVKSTKLRLATGLRNVPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDKITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRNQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREKIDGVKLDSTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza |
| 100 | MoTif 100 Human (WT1/WT33) | MGSDVRDLNALLPAVPSLGGGGGCALPVSGAAQWAPVLDFAPPGASAYGSLGGPAPPPAPPPPPPPPPHSFIKQEPSWGGAEPHEEQCLSAFTVHFSGQFTGTAGACRYGPFGPPPPSQASSGQARMFPNAPYLPSCLESQPAIRNQGYSTVTFDGTPSYGHTPSHHAAQFPNHSFKHEDPMGQQGSLGEQQYSVPPPVYGCHTPTDSCTGSQALLLRTPYSSDNLYQMTSQLECMTWNQMNLGATLKGVAAGSSSSVKWTEGQSNHSTGYESDNHTTPILCGAQYRIHTHGVFRGIQDVRRVPGVAPTLVRSASETSEKRPFMCAYPGCNKRYFKLSHLQMHSRKHTGEKPYQCDFKDCERRFSRSDQLKRHQRRHTGVKPFQCKTCQRKFSRSDHLKTHTRTHTGKTSEKPFSCRWPSCQKKFARSDELVRHHNMHQRNMTKLQLAL | Pool of 110 peptides derived from a peptide scan through Wilms tumor protein (Swiss-Prot ID: P19544) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Wilms tumor 1 |
| 101 | MoTif 101 SARS-CoV-2 (Y14) | MLQSCYNFLKEQHCQKASTQKGAEAAVKPLLVPHHVVATVQEIQLQAAVGELLLLEWLAMAVMLLLLCCCLTD | Pool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 102 | MoTif 102 Human (Prame/OIP4) | MERRRLWGSIQSRYISMSVWTSPRRLVELAGQSLLKDEALAIAALELLPRELFPPLFMAAFDGRHSQTLKAMVQAWPFTCLPLGVLMKGQHLHLETFKAVLDGLDVLLAQEVRPRRWKLQVLDLRKNSHQDFWTVWSGNRASLYSFPEPEAAQPMTKKRKVDGLSTEAEQPFIPVEVLVDLFLKEGACDELFSYLIEKVKRKKNVLRLCCKKLKIFAMPMQDIKMILKMVQLDSIEDLEVTCTWKLPTLAKFSPYLGQMINLRRLLLSHIHASSYISPEKEEQYIAQFTSQFLSLQCLQALYVDSLFFLRGRLDQLLRHVMNPLETLSITNCRLSEGDVMHLSQSPSVSQLSVLSLSGVMLTDVSPEPLQALLERASATLQDLVFDECGITDDQLLALLPSLSHCSQLTTLSFYGNSISISALQSLLQHLIGLSNLTHVLYPVPLESYEDIHGTLHLERLAYLHARLRELLCELGRPSMVWLSANPCPHCGDRTFYDPEPILCPCFMPN | Pool of 125 peptides derived from a peptide scan through Melanoma antigen preferentially expressed in tumors (PRAME/OIP4) (Swiss-Prot ID: P78395) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 103 | MoTif 103 Human (Matrilysin, MMP7) | MRLTVLCAVCLLPGSLALPLPQEAGGMSELQWEQAQDYLKRFYLYDSETKNANSLEAKLKEMQKFFGLPITGMLNSRVIEIMQKPRCGVPDVAEYSLFPNSPKWTSKVVTYRIVSYTRDLPHITVDRLVSKALNMWGKEIPLHFRKVVWGTADIMIGFARGAHGDSYPFDGPGNTLAHAFAPGTGLGGDAHFDEDERWTDGSSLGINFLYAATHELGHSLGMGHSSDPNAVMYPTYGNGDPQNFKLSQDDIKGIQKLYGKRSNSRKK | Pool of 64 peptides derived from a peptide scan through Matrilysin (Swiss-Prot ID: P09237) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 104 | MoTif 104 Human (NY-ESO-2) | MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPRGGAPRGPHGGAASAQDGRCPCGARRPDSRLLELHITMPFSSPMEAELVRRILSRDAAPLPRPGAVLKDFTVSGNLLFMSVRDQDREGAGRMRVVGWGLGSASPEGQKARDLRTPKHKVSEQRPGTPGPPPPEGAQGDGCRGVAFNVMFSAPHI | Pool of 50 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Malignant genital cancers |
| 105 | MoTif 105 HSV2 (E3 ICP0) | MEPRPGTSSRADPGPERPPRQTPGTQPAAPHAWGMLNDMQWLASSDSEEETEVGISDDDLHRDSTSEAGSTDTEMFEAGLMDAATPPARPPAERQGSPTPADAQGSCGGGPVGEEEAEAGGGGDVCAVCTDEIAPPLRCQSFPCLHPFCIPCMKTWIPLRNTCPLCNTPVAYLIVGVTASGSFSTIPIVNDPRTRVEAEAAVRAGTAVDFIWTGNPRTAPRSLSLGGHTVRALSPTPPWPGTDDEDDDLADVDYVPPAPRRAPRRGGGGAGATRGTSQPAATRPAPPGAPRSSSSGGAPLRAGVGSGSGGGPAVAAVVPRVASLPPAAGGGRAQARRVGEDAAAAEGRTPPARQPRAAQEPPIVISDSPPPSPRRPAGPGPLSFVSSSSAQVSSGPGGGGLPQSSGRAARPRAAVAPRVRSPPRAAAAPVVSASADAAGPAPPAVPVDAHRAPRSRMTQAQTDTQAQSLGRAGATDARGSGGPGAEGGPGVPRGTNTPGAAPHAAEGAAARPRKRRGSDSGPAASSSASSSAAPRSPLAPQGVGAKRAAPRRAPDSDSGDRGHGPLAPASAGAAPPSASPSSQAAVAAASSSSASSSSASSSSASSSSASSSSASSSSASSSSASSSAGGAGGSVASASGAGERRETSLGPRAAAPRGPRKCARKTRHAEGGPEPGARDPAPGLTRYLPIAGVSSVVALAPYVNKTVTGDCLPVLDMETGH IGAYVVLVDQTGNVADLLRAAAPAWSRRTLLPEHARNCVRPPDYPTPPASEWNSLWMTPVGNMLFDQGTLVGALDFHGLRSRHPWSREQGAPAPAGDAPAGHGE | Pool of 204 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 106 | MoTif 106 Human (Actin) | MCDEDETTALVCDNGSGLVKAGFAGDDAPRAVFPSIVGRPRHQGVMVGMGQKDSYVGDEAQSKRGILTLKYPIEHGIITNWDDMEKIWHHTFYNELRVAPEEHPTLLTEAPLNPKANREKMTQIMFETFNVPAMYVAIQAVLSLYASGRTTGIVLDSGDGVTHNVPIYEGYALPHAIMRLDLAGRDLTDYLMKILTERGYSFVTTAEREIVRDIKEKLCYVALDFENEMATAASSSSLEKSYELPDGQVITIGNERFRCPETLFQPSFIGMESAGIHETTYNSIMKCDIDIRKDLYANNVMSGGTTMYPGIADRMQKEITALAPSTMKIKIIAPPERKYSVWIGGSILASLSTFQQMWITKQEYDEAGPSIVHRKCF | Control Pool of 92 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control |
| 107 | MoTif 107 Human (MOG) | GQFRVIGPRHPIRALVGDEVELPCRISPGKNATGMEVGWYRPPFSRVVHLYRNGKDQDGDQAPEYRGRTELLKDAIGEGKVTLRIRNVRFSDEGGFTCFFRDHSYQEEAAMELKVEDPFYWVSPG | Control Pool of 29 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control |
| 108 | MoTif 108 Human (CEA) | MESPSAPPHRWCIPWQRLLLTASLLTFWNPPTTAKLTIESTPFNVAEGKEVLLLVHNLPQHLFGYSWYKGERVDGNRQIIGYVIGTQQATPGPAYSGREIIYPNASLLIQNIIQNDTGFYTLHVIKSDLVNEEATGQFRVYPELPKPSISSNNSKPVEDKDAVAFTCEPETQDATYLWWVNNQSLPVSPRLQLSNGNRTLTLFNVTRNDTASYKCETQNPVSARRSDSVILNVLYGPDAPTISPLNTSYRSGENLNLSCHAASNPPAQYSWFVNGTFQQSTQELFIPNITVNNSGSYTCQAHNSDTGLNRTTVTTITVYAEPPKPFITSNNSNPVEDEDAVALTCEPEIQNTTYLWWVNNQSLPVSPRLQLSNDNRTLTLLSVTRNDVGPYECGIQNKLSVDHSDPVILNVLYGPDDPTISPSYTYYRPGVNLSLSCHAASNPPAQYSWLIDGNIQQHTQELFISNITEKNSGLYTCQANNSASGHSRTTVKTITVSAELPKPSISSNNSKPVEDKDAVAFTCEPEAQNTTYLWWVNGQSLPVSPRLQLSNGNRTLTLFNVTRNDARAYVCGIQNSVSANRSDPVTLDVLYGPDTPIISPPDSSYLSGANLNLSCHSASNPSPQYSWRINGIPQQHTQVLFIAKITPNNNGTYACFVSNLATGRNNSIVKSITVSASGTSPGLSAGATVGIMIGVLVGVALI | Pool of 173 peptides derived from a peptide scan through Carcinoembryonic antigen-related cell adhesion molecule 5 (Swiss-Prot ID: P06731) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Epithelium |
| 109 | MoTif 109 Human (PSMA) | MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA | Pool of 185 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Alzheimer's disease, Breast cancer, Cancer, Epithelium, Gastric cancer, Malignant genital cancers, Melanoma, Neurodegeneration, Prostate cancer |
| 110 | MoTif 110 Human (PSMA) | MWNLLHETDSAVATARRPRWLCAGALVLAGGFFLLGFLFGWFIKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA | Pool of 185 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Alzheimer's disease, Breast cancer, Cancer, Epithelium, Gastric cancer, Malignant genital cancers, Melanoma, Neurodegeneration, Prostate cancer |
| 111 | MoTif 111 Mouse (Tyrosinase) | MFLAVLYCLLWSFQISDGHFPRACASSKNLLAKECCPPWMGDGSPCGQLSGRGSCQDILLSSAPSGPQFPFKGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFGGPNCTEKRVLIRRNIFDLSVSEKNKFFSYLTLAKHTISSVYVIPTGTYGQMNNGSTPMFNDINIYDLFVWMHYYVSRDTLLGGSEIWRDIDFAHEAPGFLPWHRLFLLLWEQEIRELTGDENFTVPYWDWRDAENCDICTDEYLGGRHPENPNLLSPASFFSSWQIICSRSEEYNSHQVLCDGTPEGPLLRNPGNHDKAKTPRLPSSADVEFCLSLTQYESGSMDRTANFSFRNTLEGFASPLTGIADPSQSSMHNALHIFMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLLEVYPEANAPIGHNRDSYMVPFIPLYRNGDFFITSKDLGYDYSYLQESDPGFYRNYIEPYLEQASRIWPW | Pool of 117 peptides derived from a peptide scan through Tyrosinase (Swiss-Prot ID: P11344, region: 1-447) of Mouse. | 70%-90% | Cancer biomarker research, T-cell immunity | Albinism, Cancer, Melanoma |
| 112 | MoTif 112 Human (Tyrosinase) | MLLAVLYCLLWSFQTSAGHFPRACVSSKNLMEKECCPPWSGDRSPCGQLSGRGSCQNILLSNAPLGPQFPFTGVDDRESWPSVFYNRTCQCSGNFMGFNCGNCKFGFWGPNCTERRLLVRRNIFDLSAPEKDKFFAYLTLAKHTISSDYVIPIGTYGQMKNGSTPMFNDINIYDLFVWMHYYVSMDALLGGSEIWRDIDFAHEAPAFLPWHRLFLLRWEQEIQKLTGDENFTIPYWDWRDAEKCDICTDEYMGGQHPTNPNLLSPASFFSSWQIVCSRLEEYNSHQSLCNGTPEGPLRRNPGNHDKSRTPRLPSSADVEFCLSLTQYESGSMDKAANFSFRNTLEGFASPLTGIADASQSSMHNALHIYMNGTMSQVQGSANDPIFLLHHAFVDSIFEQWLRRHRPLQEVYPEANAPIGHNRESYMVPFIPLYRNGDFFISSKDLGYDYSYLQDSDPDSFQDYIKSYLEQASRIWSWLLGAAMVGAVLTALLAGLVSLLCRHKRKQLPEEKQPLLMEKEDYHSLYQSHL | Pool of 130 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Albinism, Cancer, Melanoma |
| 113 | MoTif 113 Mouse (Survivin) | MGAPALPQIWQLYLKNYRIATFKNWPFLEDCACTPERMAEAGFIHCPTENEPDLAQCFFCFKELEGWEPDDNPIEEHRKHSPGCAFLTVKKQMEELTVSEFLKLDRQRAKNKIAKETNNKQKEFEETAKTTRQSIEQLAA | Pool of 33 peptides derived from a peptide scan through Baculoviral IAP repeat-containing protein 5 (Survivin) (Swiss-Prot ID: O70201) of Mouse. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 114 | MoTif 114 Human (TPTE) | MNESPDPTDLAGVIIELGPNDSPQTSEFKGATEEAPAKESPHTSEFKGAARVSPISESVLARLSKFEVEDAENVASYDSKIKKIVHSIVSSFAFGLFGVFLVLLDVTLILADLIFTDSKLYIPLEYRSISLAIALFFLMDVLLRVFVERRQQYFSDLFNILDTAIIVILLLVDVVYIFFDIKLLRNIPRWTHLLRLLRLIILLRIFHLFHQKRQLEKLIRRRVSENKRRYTRDGFDLDLTYVTERIIAMSFPSSGRQSFYRNPIKEVVRFLDKKHRNHYRVYNLCSERAYDPKHFHNRVVRIMIDDHNVPTLHQMVVFTKEVNEWMAQDLENIVAIHCKGGTDRTGTMVCAFLIASEICSTAKESLYYFGERRTDKTHSEKFQGVKTPSQKRYVAYFAQVKHLYNWNLPPRRILFIKHFIIYSIPRYVRDLKIQIEMEKKVVFSTISLGKCSVLDNITTDKILIDVFDGLPLYDDVKVQFFYSNLPTYYDNCSFYFWLHTSFIENNRLYLPKNELDNLHKQKARRIYPSDFAVEILFGEKMTSSDVVAGSD | Pool of 135 peptides derived from a peptide scan through Putative tyrosine-protein phosphatase TPTE (Swiss-Prot ID: P56180) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 115 | MoTif 115 Human (Brachyury) | MSSPGTESAGKSLQYRVDHLLSAVENELQAGSEKGDPTERELRVGLEESELWLRFKELTNEMIVTKNGRRMFPVLKVNVSGLDPNAMYSFLLDFVAADNHRWKYVNGEWVPGGKPEPQAPSCVYIHPDSPNFGAHWMKAPVSFSKVKLTNKLNGGGQIMLNSLHKYEPRIHIVRVGGPQRMITSHCFPETQFIAVTAYQNEEITALKIKYNPFAKAFLDAKERSDHKEMMEEPGDSQQPGYSQWGWLLPGTSTLCPPANPHPQFGGALSLPSTHSCDRYPTLRSHRSSPYPSPYAHRNNSPTYSDNSPACLSMLQSHDNWSSLGMPAHPSMLPVSHNASPPTSSSQYPSLWSVSNGAVTPGSQAAAVSNGLGAQFFRGSPAHYTPLTHPVSAPSSSGSPLYEGAAAATDIVDSQYDAAAQGRLIASWTPVSPPSM | Pool of 106 peptides derived from a peptide scan through Transcription factors/activators (Swiss-Prot ID: O15178) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Brachyury Mutation, Cancer |
| 116 | MoTif 116 HBV (Capsid Protein) Ultra | see additional product documentation | Pool of 155 peptides derived from a peptide scan (selected 15mers) through Capsid protein of Hepatitis B Virus (HBV). | 70%-90% | T-cell immunity | Hepatitis, Infection, Sequence diversity |
| 117 | MoTif 117 Measles virus (Hemagglutinin glycoprotein) | MSPQRDRINAFYKDNPHPKGSRIVINREHLMIDRPYVLLAVLFVMFLSLIGLLAIAGIRLHRAAIYTAEIHKSLSTNLDVTNSIEHQVKDVLTPLFKIIGDEVGLRTPQRFTDLVKLISDKIKFLNPDREYDFRDLTWCINPPERIKLDYDQYCADVAAEELMNALVNSTLLETRTTNQFLAVSKGNCSGPTTIRGQFSNMSLSLLDLYLGRGYNVSSIVTMTSQGMYGGTYLVEKPNLSSKRSELSQLSMYRVFEVGVIRNPGLGAPVFHMTNYLEQPVSNDLSNCMVALGELKLAALCHGEDSITIPYQGSGKGVSFQLVKLGVWKSPTDMQSWVPLSTDDPVIDRLYLSSHRGVIADNQAKWAVPTTRTDDKLRMETCFQQACKGKIQALCENPEWAPLKDNRIPSYGVLSVDLSLTVELKIKIASGFGPLITHGSGMDLYKSNHNNVYWLTIPPMKNLALGVINTLEWIPRFKVSPYLFTVPIKEAGEDCHAPTYLPAEVDGDVKLSSNLVILPGQDLQYVLATYDTSRVEHAVVYYVYSPSRSFSYFYPFRLPIKGVPIELQVECFTWDQKLWCRHFCVLADSESGGHITHSGMVGMGVSCTVTREDGTNRR | Pool of 152 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Measles |
| 118 | MoTif 118 VZV (IE62)_2 subpools | MDTPPMQRSTPQRAGSPDTLELMDLLDAAAAAAEHRARVVTSSQPDDLLFGENGVMVGREHEIVSIPSVSGLQPEPRTEDVGEELTQDDYVCEDGQDLMGSPVIPLAEVFHTRFSEAGAREPTGADRSLETVSLGTKLARSPKPPMNDGETGRGTTPPFPQAFSPVSPASPVGDAAGNDQREDQRSIPRQTTRGNSPGLPSVVHRDRQTQSISGKKPGDEQAGHAHASGDGVVLQKTQRPAQGKSPKKKTLKVKVPLPARKPGGPVPGPVEQLYHVLSDSVPAKGAKADLPFETDDTRPRKHDARGITPRVPGRSSGGKPRAFLALPGRSHAPDPIEDDSPVEKKPKSREFVSSSSSSSSWGSSSEDEDDEPRRVSVGSETTGSRSGREHAPSPSNSDDSDSNDGGSTKQNIQPGYRSISGPDPRIRKTKRLAGEPGRQRQKSFSLPRSRTPIIPPVSGPLMMPDGSPWPGSAPLPSNRVRFGPSGETREGHWEDEAVRAARARYEASTEPVPLYVPELGDPARQYRALINLIYCPDRDPIAWLQNPKLTGVNSALNQFYQKLLPPGRAGTAVTGSVASPVPHVGEAMATGEALWALPHAAAAVAMSRRYDRAQKHFILQSLRRAFASMAYPEATGSSPAARISRGHPSPTTPATQTPDPQPSAAARSLSVCPPDDRLRTPRKRKSQPVESRSLLDKIRETPVADARVADDHVVSKAKRRVSEPVTITSGPVVDPPAVITMPLDGPAPNGGFRRIPRGALHTPVPSDQARKAYCTPETIARLVDDPLFPTAWRPALSFDPGALAEIAARRPGGGDRRFGPPSGVEALRRRCAWMRQIPDPEDVRLLIIYDPLPGEDINGPLESTLATDPGPSWSPSRGGLSVVLAALSNRLCLPSTHAWAGNWTGPPDVSALNARGVLLLSTRDLAFAGAVEYLGSRLASARRRLLVLDAVALERWPRDGPALSQYHVYVRAPARPDAQAVVRWPDSAVTEGLARAVFASSRTFGPASFARIETAFANLYPGEQPLCLCRGGNVAYTVCTRAGPKTRVPLSPREYRQYVLPGFDGCKDLARQSRGLGLGAADFVDEAAHSHRAANRWGLGAALRPVFLPEGRRPGAAGPEAGDVPTWARVFCRHALLEPDPAAEPLVLPPVAGRSVALYASADEARNALPPIPRVMWPPGFGAAETVLEGSDGTRFVFGHHGGSERPAETQAGRQRRTADDREHALEPDDWEVGCEDAWDSEEGGGDDGDAPGSSFGVSIVSVAPGVLRDRRVGLRPAVKVELLSSSSSSEDEDDVWGGRGGRSPPQSRG | Pool of 325 (163 + 162) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Chicken Pox, Herpes zoster, Infection, Shingles |
| 119 | MoTif 119 Human (P53) | MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPRVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD | Pool of 96 peptides derived from a peptide scan through Cellular tumor antigen p53 (Swiss-Prot ID: P04637) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 120 | MoTif 120 Vaccinia virus (MVA018L) | MGIQHEFDIIINGDIALRNLQLHKGDNYGCKLKIISNDYKKLKFRFIIRPDWSEIDEVKGLTVFANNYAVKVNKVDDTFYYVIYEAVIHLYNKKTEILIYSDDENELFKHYYPYISLNMISKKYKVKEENYSSPYIEHPLIPYRDYESMD | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 121 | MoTif 121 Vaccinia virus (MVA121L) | MMPIKSIVTLDQLEDSEYLFRIVSTVLPHLCLDYKVCDQLKTTFVHPFDILLNNSLGSVTKQDELQAAISKLGINYLIDTTSRELKLFNVTLNAGNIDIINTPINISSETNPIINTHSFYDLPPFTQHLLNIRLTDTEYRARFIGGYIKPDGSDSMDVLAEKKYPDLNFDNTYLFNILYKDVINAPIKEFKAKIVNGVLSRQDFDNLIGVRQYITAQDRPRFDNAYNIADAARHYGVNLNTLPLPNVDLTTMPTYKHLIMFEQYFIYTYDRVDIYYNGNKMLLDDEIMNFCISMRYQSLIPRLVEFFPDIPVNNNIVLHTRDPQNAAVNVTVALPNVQFVDIGRNHKFFINFFNLLAKEQRSTAIKVTKSMFWDGMDYEEYKSKNLQDMMFINSTCYVFGLYNHNNTTYCSILSDIISAEKTPIRVCLLPRVVGGKTVTNLISETLKSISSMTIREFPRKDKSIMHIGLSETGFMRFFQLLRLMADKPHETAIKEVVMAYVGIKLGDKGSPYYIRKESYQDFIYLLFASMGFKVTTRRSIMGSNNISIISIRPRVTKQYIVTTLMKTSCSKNEAEKLITSAFDLLNFMVSVSDFRDYQSYRQYRNYCPRYFYAGSPEGEETIICDSEPISILDRIDTRGIFSAYTINEMMDTDIFSPENKAFKNNLSRFIESGNITGEDIFCAMPYNILDRIITNAGTCTVSIGDMLDNITTQSDCNMTNEITDMINASLKNTISKDNNMLVSQALDSVANRSKQTIGDLRQSSCKMALLFKNLATSIYTIERIFNAKVGDDVKASMLEKYKVFTDISMSLYKDLIAMENLKAMLYIIRRSGCRIDDAQITTDDLVKSYSLIRPKILSMINYYNEMSRGYFEHMKKNLNMTDGDSVSFDDE | Pool of 220 (110 + 110 (in 2 vials)) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 122 | MoTif 122 Vaccinia virus (MVA074R) | MGIKNLKSLLLENKSLTILDDNLYKVYNGIFVDTMSIYIAVANCVRNLEELTTVFIKYVNGWVKKGGHVTLFIDRGSIKIKQDVRDKRRKYSKLTKDRKMLELEKCTSEIQNVTGFMEEEIKAEMQLKIDKLTFQIYLSDSDNIKISLNEILTHFNNNENVTLFYCDERDAEFVMCLEAKTHFSTTGEWPLIISTDQDTMLFASTDNHPKMIKNLTQLFKFVPSAEDNYLAKLTALVNGCDFFPGLYGASITPTNLNKIQLFSDFTIDNIVTSLAIKNYYRKTNSTVDVRNIVTFINDYANLDDVYSYVPPCQCTVQEFIFSALDEKWNNFKSSYLETVPLPCQLMYALEPRKEIDVSEVKTLSSYIDFENTKSDIDVIKSISSIFGYSNENCNTIVFGIYKDNLLLSINSSFYFNDSLLITNTKSDNIINIGY | Pool of 106 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 123 | MoTif 123 Human Adenovirus 26 (Hexon Protein) | MATPSMMPQWAYMHIAGQDASEYLSPGLVQFARATDTYFSLGNKFRNPTVAPTHDVTTDRSQRLTLRFVPVDREDTTYSYKARFTLAVGDNRVLDMASTYFDIRGVLDRGPSFKPYSGTAYNSLAPKGAPNPSQWETKEKQGTTGGVQQEKDVTKTFGVAATGGINITNQGLLLGTDETAENGKKDIYADKTFQPEPQVGEENWQENEAFYGGRALKKDTKMKPCYGSFARPTNEKGGQAKFKPVNEGEQPKDLDIDFAYFDVPGGSPPAGGSGEEYKADIILYTENVNLETPDTHVVYKPGTSDNSSEINLVQQSMPNRPNYIGFRDNFVGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSLGDRTRYFSMWNSAVDSYDPDVRIIENHGVEDELPNYCFPLNGTGTNSTYQGVKITNGNDGAEESEWEKDDAISRQNQICKGNVYAMEINLQANLWKSFLYSNVALYLPDSYKYTPANVKLPANTNTYEYMNGRVVAPSLVDAYIHIGARWSLDPMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKNLLLLPGSYTYEWNFRKDVNMILQSSLGNDLRVDGASVRFDSVNLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLYPIPAKATNVPISIPSRNWAAFRGWSFTRLKTKETPSLGSGFDPYFVYSGSIPYLDGTFYLNHTFKKVSIMFDSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLSHYNIGYQGFHVPEGYKDRMYSFFRNFQPMSRQVVDEINYKDYKAVTLPFQHNNSGFTGYLAPTMRQGQPYPANFPYPLIGQTAVPSVTQKKFLCDRVMWRIPFSSNFMSMGALTDLGQNMLYANSAHALDMTFEVDPMDEPTLLYLLFEVFDVVRVHQPHRGVIEAVYLRTPFSAGNATT | Pool of 236 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection |
| 124 | MoTif 124 Human Adenovirus 5 (Hexon Protein) | MATPSMMPQWSYMHISGQDASEYLSPGLVQFARATETYFSLNNKFRNPTVAPTHDVTTDRSQRLTLRFIPVDREDTAYSYKARFTLAVGDNRVLDMASTYFDIRGVLDRGPTFKPYSGTAYNALAPKGAPNPCEWDEAATALEINLEEEDDDNEDEVDEQAEQQKTHVFGQAPYSGINITKEGIQIGVEGQTPKYADKTFQPEPQIGESQWYETEINHAAGRVLKKTTPMKPCYGSYAKPTNENGGQGILVKQQNGKLESQVEMQFFSTTEATAGNGDNLTPKVVLYSEDVDIETPDTHISYMPTIKEGNSRELMGQQSMPNRPNYIAFRDNFIGLMYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSIGDRTRYFSMWNQAVDSYDPDVRIIENHGTEDELPNYCFPLGGVINTETLTKVKPKTGQENGWEKDATEFSDKNEIRVGNNFAMEINLNANLWRNFLYSNIALYLPDKLKYSPSNVKISDNPNTYDYMNKRVVAPGLVDCYINLGARWSLDYMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKNLLLLPGSYTYEWNFRKDVNMVLQSSLGNDLRVDGASIKFDSICLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLYPIPANATNVPISIPSRNWAAFRGWAFTRLKTKETPSLGSGYDPYYTYSGSIPYLDGTFYLNHTFKKVAITFDSSVSWPGNDRLLTPNEFEIKRSVDGEGYNVAQCNMTKDWFLVQMLANYNIGYQGFYIPESYKDRMYSFFRNFQPMSRQVVDDTKYKDYQQVGILHQHNNSGFVGYLAPTMREGQAYPANFPYPLIGKTAVDSITQKKFLCDRTLWRIPFSSNFMSMGALTDLGQNLLYANSAHALDMTFEVDPMDEPTLLYVLFEVFDVVRVHRPHRGVIETVYLRTPFSAGNATT | Pool of 236 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection, Respiratory infection |
| 125 | MoTif 125 HPV 18 (E7) | MHGPKATLQDIVLHLEPQNEIPVDLLCHEQLSDSEEENDEIDGVNHQHLPARRAEPQRHTMLCMCCKCEARIKLVVESSADDLRAFQQLFLNTLSFVCPWCASQQ | Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 126 | MoTif 126 HPV35 (E6) | MFQDPAERPYKLHDLCNEVEESIHEICLNCVYCKQELQRSEVYDFACYDLCIVYREGQPYGVCMKCLKFYSKISEYRWYRYSVYGETLEKQCNKQLCHLLIRCITCQKPLCPVEKQRHLEEKKRFHNIGGRWTGRCMSCWKPTRRETEV | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 127 | MoTif 127 HPV58 (E7) | MRGNNPTLREYILDLHPEPTDLFCYEQLCDSSDEDEIGLDGPDGQAQPATANYYIVTCCYTCGTTVRLCINSTTTDVRTLQQLLMGTCTIVCPSCAQQ | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 128 | MoTif 128 HPV16 (E4) | MADPAAATKYPLLKLLGSTWPTTPPRPIPKPSPWAPKKHRRLSSDQDQSQTPETPATPLSCCTETQWTVLQSSLHLTAHTKDGLTVIVTLHP | Pool of 21 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 129 | MoTif 129 HPV18 (E5) | MLSLIFLFCFCVCMYVCCHVPLLPSVCMCAYAWVLVFVYIVVITSPATAFTVYVFCFLLPMLLLHIHAILSLQ | Pool of 16 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 130 | MoTif 130 HPV 06 (E7) | MHGRHVTLKDIVLDLQPPDPVGLHCYEQLVDSSEDEVDEVDGQDSQPLKQHYQIVTCCCGCDSNVRLVVQCTETDIREVQQLLLGTLNIVCPICAPKT | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 131 | MoTif 131 HPV 31 (E6) | MFKNPAERPRKLHELSSALEIPYDELRLNCVYCKGQLTETEVLDFAFTDLTIVYRDDTPHGVCTKCLRFYSKVSEFRWYRYSVYGTTLEKLTNKGICDLLIRCITCQRPLCPEEKQRHLDKKKRFHNIGGRWTGRCIACWRRPRTETQV | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 132 | MoTif 132 HPV33 (E7) | MRGHKPTLKEYVLDLYPEPTDLYCYEQLSDSSDEDEGLDRPDGQAQPATADYYIVTCCHTCNTTVRLCVNSTASDLRTIQQLLMGTVNIVCPTCAQQ | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 133 | MoTif 133 HCoV-OC43 (NCAP) | MSFTPGKQSSSRASSGNRSGNGILKWADQSDQVRNVQTRGRRAQPKQTATSQQPSGGNVVPYYSWFSGITQFQKGKEFEFVEGQGPPIAPGVPATEAKGYWYRHNRGSFKTADGNQRQLLPRWYFYYLGTGPHAKDQYGTDIDGVYWVASNQADVNTPADIVDRDPSSDEAIPTRFPPGTVLPQGYYIEGSGRSAPNSRSTSRTSSRASSAGSRSRANSGNRTPTSGVTPDMADQIASLVLAKLGKDATKPQQVTKHTAKEVRQKILNKPRQKRSPNKQCTVQQCFGKRGPNQNFGGGEMLKLGTSDPQFPILAELAPTAGAFFFGSRLELAKVQNLSGNPDEPQKDVYELRYNGAIRFDSTLSGFETIMKVLNENLNAYQQQDGMMNMSPKPQRQRGHKNGQGENDNISVAVPKSRVQQNKSRELTAEDISLLKKMDEPYTEDTSEI | Pool of 110 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 134 | MoTif 134 Influenza A (HA /California (H1N1)) | MKAILVVLLYTFATANADTLCIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDKHNGKLCKLRGVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETPSSDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPNHDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSKSYINDKGKEVLVLWGIHHPSTSADQQSLYQNADAYVFVGSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDKITFEATGNLVVPRYAFAMERNAGSGIIISDTPVHDCNTTCQTPKGAINTSLPFQNIHPITIGKCPKYVKSTKLRLATGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADLKSTQNAIDEITNKVNSVIEKMNTQFTAVGKEFNHLEKRIENLNKKVDDGFLDIWTYNAELLVLLENERTLDYHDSNVKNLYEKVRSQLKNNAKEIGNGCFEFYHKCDNTCMESVKNGTYDYPKYSEEAKLNREEIDGVKLESTRIYQILAIYSTVASSLVLVVSLGAISFWMCSNGSLQCRICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 135 | MoTif 135 Influenza A (Neuroamidase /California (H1N1) | MNPNQKIITIGSVCMTIGMANLILQIGNIISIWISHSIQLGNQNQIETCNQSVITYENNTWVNQTYVNISNTNFAAGQSVVSVKLAGNSSLCPVSGWAIYSKDNSVRIGSKGDVFVIREPFISCSPLECRTFFLTQGALLNDKHSNGTIKDRSPYRTLMSCPIGEVPSPYNSRFESVAWSASACHDGINWLTIGISGPDNGAVAVLKYNGIITDTIKSWRNNILRTQESECACVNGSCFTVMTDGPSNGQASYKIFRIEKGKIVKSVEMNAPNYHYEECSCYPDSSEITCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGIFGDNPRPNDKTGSCGPVSSNGANGVKGFSFKYGNGVWIGRTKSISSRNGFEMIWDPNGWTGTDNNFSIKQDIVGINEWSGYSGSFVQHPELTGLDCIRPCFWVELIRGRPKENTIWTSGSSISFCGVNSDTVGWSWPDGAELPFTIDK | Pool of 115 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 136 | MoTif 136 Influenza A (HA/Indonesia (H5N1)) | MEKIVLLLAIVSLVKSDQICIGYHANNSTEQVDTIMEKNVTVTHAQDILEKTHNGKLCDLDGVKPLILRDCSVAGWLLGNPMCDEFINVPEWSYIVEKANPTNDLCYPGSFNDYEELKHLLSRINHFEKIQIIPKSSWSDHEASSGVSSACPYLGSPSFFRNVVWLIKKNSTYPTIKKSYNNTNQEDLLVLWGIHHPNDAAEQTRLYQNPTTYISIGTSTLNQRLVPKIATRSKVNGQSGRMEFFWTILKPNDAINFESNGNFIAPEYAYKIVKKGDSAIMKSELEYGNCNTKCQTPMGAINSSMPFHNIHPLTIGECPKYVKSNRLVLATGLRNSPQRESRRKKRGLFGAIAGFIEGGWQGMVDGWYGYHHSNEQGSGYAADKESTQKAIDGVTNKVNSIIDKMNTQFEAVGREFNNLERRIENLNKKMEDGFLDVWTYNAELLVLMENERTLDFHDSNVKNLYDKVRLQLRDNAKELGNGCFEFYHKCDNECMESIRNGTYNYPQYSEEARLKREEISGVKLESIGTYQILSIYSTVASSLALAIMIAGLSLWMCSNGSLQCRICI | Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 137 | MoTif 137 Human (Tyrosinase-related protein 2) | MSPLWWGFLLSCLGCKILPGAQGQFPRVCMTVDSLVNKECCPRLGAESANVCGSQQGRGQCTEVRADTRPWSGPYILRNQDDRELWPRKFFHRTCKCTGNFAGYNCGDCKFGWTGPNCERKKPPVIRQNIHSLSPQEREQFLGALDLAKKRVHPDYVITTQHWLGLLGPNGTQPQFANCSVYDFFVWLHYYSVRDTLLGPGRPYRAIDFSHQGPAFVTWHRYHLLCLERDLQRLIGNESFALPYWNFATGRNECDVCTDQLFGAARPDDPTLISRNSRFSSWETVCDSLDDYNHLVTLCNGTYEGLLRRNQMGRNSMKLPTLKDIRDCLSLQKFDNPPFFQNSTFSFRNALEGFDKADGTLDSQVMSLHNLVHSFLNGTNALPHSAANDPIFVVLHSFTDAIFDEWMKRFNPPADAWPQELAPIGHNRMYNMVPFFPPVTNEELFLTSDQLGYSYAIDLPVSVEETPGWPTTLLVVMGTLVALVGLFVLLAFLQYRRLRKGYTPLMETHLSSKRYTEEA | Pool of 127 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 138 | MoTif 138 HIV-1 (Con B gag motif) | See Sequences under Product Documentation | Pool of 123 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | AIDS (HIV), HIV, Infection |
| 139 | MoTif 139 Zaire Ebola (GP/Kikwit-95) | MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVGLNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRGFPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHPLREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKRSNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTAVSNRAKNISGQSPARTSSDPGTNTTTEDHKIMASENSSAMVQVHSQGREAAVSHLTTLATISTSPQPPTTKPGPDNSTHNTPVYKLDISEATQVEQHHRRTDNDSTASDTPPATTAAGPLKAENTNTSKGTDLLDPATTTSPQNHSETAGNNNTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRARREAIVNAQPKCNPNLHYWTTQDEGAAIGLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLLQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGIGVTGVIIAVIALFCICKFVF | Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Ebola, Ebola fever, Infection |
| 140 | MoTif 140 Human (Tyrosinase-related protein 1) | MSAPKLLSLGCIFFPLLLFQQARAQFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSSGRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGAACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFENISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQEPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLGTLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVEGYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNADISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPSREFSVPEIIAIAVVGALLLVALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEEYEKLQNPNQSVV | Pool of 132 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 141 | MoTif 141 SARS-CoV-2 (S-RBD BF.7) | / | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 142 | MoTif 142 Human (PLAC1) | MKVFKFIGLMILLTSAFSAGSGQSPMTVLCSIDWFMVTVHPFMLNNDVCVHFHELHLGLGCPPNHVQPHAYQFTYRVTECGIRAKAVSQDMVIYSTEIHYSSKGTPSKFVIPVSCAAPQKSPWLTKPCSMRVASKSRATAQKDEKCYEVFSLSQSSQRPNCDCPPCVFSEEEHTQVPCHQAGAQEAQPLQPSHFLDISEDWSLHTDDMIGSM | Pool of 51 peptides derived from a peptide scan through Placenta-specific protein 1 (Swiss-Prot ID: Q9HBJ0) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 143 | MoTif 143 EBV (BRLF1) | MRPKKDGLEDFLRLTPEIKKQLGSLVSDYCNVLNKEFTAGSVEITLRSYKICKAFINEAKAHGREWGGLMATLNICNFWAILRNNRVRRRAENAGNDACSIACPIVMRYVLDHLIVVTDRFFIQAPSNRVMIPATIGTAMYKLLKHSRVRAYTYSKVLGVDRAAIMASGKQVVEHLNRMEKEGLLSSKFKAFCKWVFTYPVLEEMFQTMVSSKTGHLTDDVKDVRALIKTLPRASYSSHAGQRSYVSGVLPACLLSTKSKAVETPILVSGADRMDEELMGNDGGASHTEARYSESGQFHAFTDELESLPSPTMPLKPGAQSADCGDSSSSSSDSGNSDTEQSEREEARAEAPRLRAPKSRRTSRPNRGQTPCPSNAAEPEQPWIAAVHQESDERPIFPHPSKPTFLPPVKRKKGLRDSREGMFLPKPEAGSAISDVFEGREVCQPKRIRPFHPPGSPWANRPLPASLAPTPTGPVHEPVGSLTPAPVPQPLDPAPAVTPEASHLLEDPDEETSQAVKALREMADTVIPQKEEAAICGQMDLSHPPPRGHLDELTTTLESMTEDLNLDSPLTPELNEILDTFLNDECLLHAMHISTGLSIFDTSLF | Pool of 149 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 144 | MoTif 144 EBV (EBNA1) | MSDEGPGTGPGNGLGEKGDTSGPEGSGGSGPQRRGGDNHGRGRGRGRGRGGGRPGAPGGSGSGPRHRDGVRRPQKRPSCIGCKGTHGGTGAGAGAGGAGAGGAGAGGGAGAGGGAGGAGGAGGAGAGGGAGAGGGAGGAGGAGAGGGAGAGGGAGGAGAGGGAGGAGGAGAGGGAGAGGGAGGAGAGGGAGGAGGAGAGGGAGAGGAGGAGGAGAGGAGAGGGAGGAGGAGAGGAGAGGAGAGGAGAGGAGGAGAGGAGGAGAGGAGGAGAGGGAGGAGAGGGAGGAGAGGAGGAGAGGAGGAGAGGAGGAGAGGGAGAGGAGAGGGGRGRGGSGGRGRGGSGGRGRGGSGGRRGRGRERARGGSRERARGRGRGRGEKRPRSPSSQSSSSGSPPRRPPPGRRPFFHPVGEADYFEYHQEGGPDGEPDVPPGAIEQGPADDPGEGPSTGPRGQGDGGRRKKGGWFGKHRGQGGSNPKFENIAEGLRALLARSHVERTTDEGTWVAGVFVYGGSKTSLYNLRRGTALAIPQCRLTPLSRLPFGMAPGPGPQPGPLRESIVCYFMVFLQTHIFAEVLKDAIKDLVMTKPAPTCNIRVTVCSFDDGVDLPPWFPPMVEGAAAEGDDGDDGDEGGDGDEGEEGQE | Pool of 158 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 145 | MoTif 145 EBV (EBNA2) | MPTFYLALHGGQTYHLIVDTDSLGNPSLSVIPSNPYQEQLSDTPLIPLTIFVGENTGVPPPLPPPPPPPPPPPPPPPPPPPPPPPPPPSPPPPPPPPPPPQRRDAWTQEPSPLDRDPLGYDVGHGPLASAMRMLWMANYIVRQSRGDRGLILPQGPQTAPQARLVQPHVPPLRPTAPTILSPLSQPRLTPPQPLMMPPRPTPPTPLPPATLTVPPRPTRPTTLPPTPLLTVLQRPTELQPTPSPPRMHLPVLHVPDQSMHPLTHQSTPNDPDSPEPRSPTVFYNIPPMPLPPSQLPPPAAPAQPPPGVINDQQLHHLPSGPPWWPPICDPPQPSKTQGQSRGQSRGRGRGRGRGRGKGKSRDKQRKPGGPWRPEPNTSSPSMPELSPVLGLHQGQGAGDSPTPGPSNAAPVCRNSHTATPNVSPIHEPESHNSPEAPILFPDDWYPPSIDPADLDESWDYIFETTESPSSDEDYVEGPSKRPRPSIQ | Pool of 119 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 146 | MoTif 146 HCMVA (IE-1) | MESSAKRKMDPDNPDEGPSSKVPRPETPVTKATTFLQTMLRKEVNSQLSLGDPLFPELAEESLKTFEQVTEDCNENPEKDVLAELVKQIKVRVDMVRHRIKEHMLKKYTQTEEKFTGAFNMMGGCLQNALDILDKVHEPFEEMKCIGLTMQSMYENYIVPEDKREMWMACIKELHDVSKGAANKLGGALQAKARAKKDELRRKMMYMCYRNIEFFTKNSAFPKTTNGCSQAMAALQNLPQCSPDEIMAYAQKIFKILDEERDKVLTHIDHIFMDILTTCVETMCNEYKVTSDACMMTMYGGISLLSEFCRVLCCYVLEETSVMLAKRPLITKPEVISVMKRRIEEICMKVFAQYILGADPLRVCSPSVDDLRAIAEESDEEEAIVAYTLATAGVSSSDSLVSPPESPVPATIPLSSVIVAENSDQEESEQSDEEEEEGAQEEREDTVSVKSEPVSEIEEVAPEEEEDGAEEPTASGGKSTHPMVTRSKADQ | Pool of 120 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 147 | MoTif 147 HCMVA (UL82) | MSQASSSPGEGPSSEAAAISEAEAASGSFGRLHCQVLRLITNVEGGSLEAGRLRLLDLRTNIEVSRPSVLCCFQENKSPHDTVDLTDLNIKGRCVVGEQDRLLVDLNNFGPRRLTPGSENNTVSVLAFALPLDRVPVSGLHLFQSQRRGGEENRPRMEARAIIRRTAHHWAVRLTVTPNWRRRTDSSLEAGQIFVSQFAFRAGAIPLTLVDALEQLACSDPNTYIHKTETDERGQWIMLFLHHDSPHPPTSVFLHFSVYTHRAEVVARHNPYPHLRRLPDNGFQLLIPKSFTLTRIHPEYIVQIQNAFETNQTHDTIFFPENIPGVSIEAGPLPDRVRITLRVTLTGDQAVHLEHRQPLGRIHFFRRGFWTLTPGKPDKIKRPQVQLRAGLFPRSNVMRGAVSEFLPQSPGLPPTEEEEEEEEEDDEDDLSSTPTPTPLSEAMFAGFEEASGDEDSDTQAGLSPALILTGQRRRSGNNGALTLVIPSWHVFASLDDLVPLTVSVQHAALRPTSYLRSDMDGDVRTAADISSTLRSVPAPRPSPISTASTSSTPRSRPRI | Pool of 137 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 148 | MoTif 148 HCMVA (UL99) | MGAELCKRICCEFGTTPGEPLKDALGRQVSLRSYDNIPPTSSSDEGEDDDDGEDDDNEERQQKLRLCGSGCGGNDSSSGSHREATHDGSKKNAVRSTFREDKAPKPSKQSKKKKKPSKHHHHQQSSIMQETDDLDEEDTSIYLSPPPVPPVQVVAKRLPRPDTPRTPRQKKISQRPPTPGTKKPAASLPF | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 149 | MoTif 149 EBV (BARF1) | MARFIAQLLLLASCVAAGQAVTAFLGERVTLTSYWRRVSLGPEIEVSWFKLGPGEEQVLIGRMHHDVIFIEWPFRGFFDIHRSANTFFLVVTAANISHDGNYLCRMKLGETEVTKQEHLSVVKPLTLSVHSERSQFPDFSVLTVTCTVNAFPHPHVQWLMPEGVEPAPTAANGGVMKEKDGSLSVAVDLSLPKPWHLPVTCVGKNDKEEAHGVYVSGYLSQ | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 150 | MoTif 150 Human (MAGEA3) | MPLEQRSQHCKPEEGLEARGEALGLVGAQAPATEEQEAASSSSTLVEVTLGEVPAAESPDPPQSPQGASSLPTTMNYPLWSQSYEDSSNQEEEGPSTFPDLESEFQAALSRKVAELVHFLLLKYRAREPVTKAEMLGSVVGNWQYFFPVIFSKASSSLQLVFGIELMEVDPIGHLYIFATCLGLSYDGLLGDNQIMPKAGLLIIVLAIIAREGDCAPEEKIWEELSVLEVFEGREDSILGDPKKLLTQHFVQENYLEYRQVPGSDPACYEFLWGPRALVETSYVKVLHHMVKISGGPHISYPPLHEWVLREGEE | Pool of 76 peptides derived from a peptide scan through Melanoma-associated antigen (MAGE) (Swiss-Prot ID: P43357) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 151 | MoTif 151 Human (MAGEA10) | MPRAPKRQRCMPEEDLQSQSETQGLEGAQAPLAVEEDASSSTSTSSSFPSSFPSSSSSSSSSCYPLIPSTPEEVSADDETPNPPQSAQIACSSPSVVASLPLDQSDEGSSSQKEESPSTLQVLPDSESLPRSEIDEKVTDLVQFLLFKYQMKEPITKAEILESVIRNYEDHFPLLFSEASECMLLVFGIDVKEVDPTGHSFVLVTSLGLTYDGMLSDVQSMPKTGILILILSIVFIEGYCTPEEVIWEALNMMGLYDGMEHLIYGEPRKLLTQDWVQENYLEYRQVPGSDPARYEFLWGPRAHAEIRKMSLLKFLAKVNGSDPRSFPLWYEEALKDEEERAQDRIATTDDTTAMASASSSATGSFSYPE | Pool of 90 peptides derived from a peptide scan through Melanoma-associated antigen 10 (Swiss-Prot ID: P43363) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma, Prostate cancer |
| 152 | MoTif 152 Human (MAGEA9) | MSLEQRSPHCKPDEDLEAQGEDLGLMGAQEPTGEEEETTSSSDSKEEEVSAAGSSSPPQSPQGGASSSISVYYTLWSQFDEGSSSQEEEEPSSSVDPAQLEFMFQEALKLKVAELVHFLLHKYRVKEPVTKAEMLESVIKNYKRYFPVIFGKASEFMQVIFGTDVKEVDPAGHSYILVTALGLSCDSMLGDGHSMPKAALLIIVLGVILTKDNCAPEEVIWEALSVMGVYVGKEHMFYGEPRKLLTQDWVQENYLEYRQVPGSDPAHYEFLWGSKAHAETSYEKVINYLVMLNAREPICYPSLYEEVLGEEQEGV | Pool of 76 peptides derived from a peptide scan through Melanoma-associated antigen (MAGE) (Swiss-Prot ID: P43362) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 153 | MoTif 153 Human (ACTL8) | MAARTVIIDHGSGFLKAGTAGWNEPQMVFPNIVNYLPCKENPGPSYARRRVSLGIDICHPDTFSYPIERGRILNWEGVQYLWSFVLENHRREQEVPPVIITETPLREPADRKKMLEILFELLHVPSVLLADQLQMSLYASGLLTGVVVDSGYGLTRVQPFHQGRPLPASGKTLEFAGQDLSAYLLKSLFKEDCDRRCLFQLETVAVTQMNKCYVPQNLGEALDFRERQQSALDESNTYQLPDGSRVELTPMQRVAPEMFFSPQVFEQPGPSIPRAIVESVESCEISLRPLLVSHVMACGGNTLYPGFTKRLFRELMGDHVSSTKATVWEGSNRNFSVWLGASVVAHLSTYQSEWMSREEYGEHMRM | Pool of 89 peptides derived from a peptide scan through Actin-like protein 8 (Swiss-Prot ID: Q9H568) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Epithelium |
| 154 | MoTif 154 Human (MAGEC2) | MPPVPGVPFRNVDNDSPTSVELEDWVDAQHPTDEEEEEASSASSTLYLVFSPSSFSTSSSLILGGPEEEEVPSGVIPNLTESIPSSPPQGPPQGPSQSPLSSCCSSFSWSSFSEESSSQKGEDTGTCQGLPDSESSFTYTLDEKVAELVEFLLLKYEAEEPVTEAEMLMIVIKYKDYFPVILKRAREFMELLFGLALIEVGPDHFCVFANTVGLTDEGSDDEGMPENSLLIIILSVIFIKGNCASEEVIWEVLNAVGVYAGREHFVYGEPRELLTKVWVQGHYLEYREVPHSSPPYYEFLWGPRAHSESIKKKVLEFLAKLNNTVPSSFPSWYKDALKDVEERVQATIDTADDATVMASESLSVMSSNVSFSE | Pool of 91 peptides derived from a peptide scan (Peptide Scan (15mers with 11aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 155 | MoTif 155 HCoV-229E (NCAP) | MATVKWADASEPQRGRQGRIPYSLYSPLLVDSEQPWKVIPRNLVPINKKDKNKLIGYWNVQKRFRTRKGKRVDLSPKLHFYYLGTGPHKDAKFRERVEGVVWVAVDGAKTEPTGYGVRRKNSEPEIPHFNQKLPNGVTVVEEPDSRAPSRSQSRSQSRGRGESKPQSRNPSSDRNHNSQDDIMKAVAAALKSLGFDKPQEKDKKSAKTGTPKPSRNQSPASSQTSAKSLARSQSSETKEQKHEMQKPRWKRQPNDDVTSNVTQCFGPRDLDHNFGSAGVVANGVKAKGYPQFAELVPSTAAMLFDSHIVSKESGNTVVLTFTTRVTVPKDHPHLGKFLEELNAFTREMQQHPLLNPSALEFNPSQTSPATAEPVRDEVSIETDIIDEVN | Pool of 95 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Common cold, Covid-19, Infection, Respiratory infection |
| 156 | MoTif 156 Influenza A (MP2 /California (H1N1)) | MSLLTEVETPTRSEWECRCSDSSDPLVIAANIIGILHLILWITDRLFFKCIYRRFKYGLKRGPSTEGVPESMREEYQQEQQSAVDVDDGHFVNIELE | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 157 | MoTif 157 EBV (EBNA-LP) | MGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPRGDRSEGPGPTRPGPPGIGPEGPLGQLLRRHRSPSPTRGGQEPRRVRRRVLVQQEEEVVSGSPSGPLRPRPRPPARSLREWLLRIRDHFEPPTVTTQRQSVYIEEEEDED | Pool of 124 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 158 | MoTif 158 ZIKV (E) Ultra | Envelope protein E based on the following polyprotein sequences: AMC33116.1 (Martinique); AMC13913. (Guatemala); AMC13912.1 (Guatemala); AMC13911.1 (Puerto Rico); AMB37295.1 (Haiti); AMA12087.1 (Brazil); AMA12086.1 (Brazil); AMA12085.1 (Brazil); AMA12084.1 (Brazil); ALX35659.1 (Suriname); AHL37808.1 (Canada); AHZ13508.1 (French Polynesia); AFD30972.1 (Cambodia); ACD75819.1 (Micronesia); ALU33341.1 (Brazil) Country of sample origin is given in parentheses if available. All sequences are completely covered. | Pool of 146 peptides derived from a peptide scan (15mers) through Envelope protein of ZIKA virus (ZIKV). | 70%-90% | T-cell immunity | Infection, Microcephaly, Sequence diversity, ZIKA fever, Zika virus disease |
| 159 | MoTif 159 HBV (LEP) Ultra | see additional product documentation | Pool of 121 peptides derived from a peptide scan (selected 15mers) through Large envelope protein of Hepatitis B Virus (HBV). | 70%-90% | T-cell immunity | Hepatitis, Infection, Sequence diversity |
| 160 | MoTif 160 HRSVA (Matrix Protein) | METYVNKLHEGSTYTAAVQYNVLEKDDDPASLTIWVPMFQSSMPADLLIKELANVNILVKQISTPKGPSLRVMINSRSAVLA QMPSKFTICANVSLDERSKLAYDVTTPCEIKACSLTCLKSKNMLTTVKDLTMKTLNPTHDIIALCEFENIVTSKKVIIPTYLRSISV RNKDLNTLENITTTEFKNAITNAKIIPYSGLLLVITVTDNKGAFKYIKPQSQFIVDLGAYLEKESIYYVTTNWKHTATRFAIKPMED | Pool of 62 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection |
| 161 | MoTif 161 Human (FJX1) | MGRRMRGAAATAGLWLLALGSLLALWGGLLPPRTELPASRPPEDRLPRRPARSGGPAPAPRFPLPPPLAWDARGGSLKTFR ALLTLAAGADGPPRQSRSEPRWHVSARQPRPEESAAVHGGVFWSRGLEEQVPPGFSEAQAAAWLEAARGARMVALERGG CGRSSNRLARFADGTRACVRYGINPEQIQGEALSYYLARLLGLQRHVPPLALARVEARGAQWAQVQEELRAAHWTEGSVVS LTRWLPNLTDVVVPAPWRSEDGRLRPLRDAGGELANLSQAELVDLVQWTDLILFDYLTANFDRLVSNLFSLQWDPRVMQRA TSNLHRGPGGALVFLDNEAGLVHGYRVAGMWDKYNEPLLQSVCVFRERTARRVLELHRGQDAAARLLRLYRRHEPRFPELAA LADPHAQLLQRRLDFLAKHILHCKAKYGRRSGT | Pool of 107 peptides derived from a peptide scan through Four-jointed box protein 1 (Swiss-Prot ID: Q86VR8) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Freeze-dried in glass vial |
| 162 | MoTif 162 SARS-CoV-2 (Spike P.1 / Gamma) | MFVFLVLLPLVSSQCVNFTNRTQLPSAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNYPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLSEFVFKNIDGYFKIYSKHTPINLVRDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGTIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTNSPRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAAIKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASFVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Peptide scan through the entire Spike glycoprotein of SARS-CoV-2 P.1, (Severe Acute Respiratory Syndrome-related coronavirus 2, Lineage P.1, Brazil) covering the following mutations: L0018F, T0020N, P0026S, D0138Y, R0190S, K0417T, E0484K, N0501Y, D0614G, H0655Y, T1027I, V1176F. | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 163 | MoTif 163 SARS-CoV-2 (Spike BA.2.75.2) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSS VLHSTQDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPVLPFN DGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKV CEFQFCNDPFLDVYYHENNKSRMESELRVYSSANNCTFEYV SQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPVNLG RDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSS WTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSET KCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFHEVFN ATTFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPT KLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPD DFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSKLKPFERDIS TEIYQAGNKPCNGVAGSNCYFPLQSYGFRPTYGVGHQPYRV VVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVL TESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGV SVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVY STGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTK SHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVT TEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRA LTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPS KPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQK FNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPF AMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSS TASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDILSR LDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATK MSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPA QEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEP QIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFK NHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLINLQ ELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLK GCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 164 | MoTif 164 CyCMV (TP-UL83) | MALSQRYRLDYVSELGPIAGKVIQSVFDEAREPVKPHETKIVKT GLRVQVHRPSIIFLTQFARNLKPDPRYEHNTLQIKHTTFEDQEL KDVYLHVHNPTDKPITPADEPMSFFLYALPLRHLVLADLTLHPG GTYNPELPTYDAAVQAFAQGYHTRFNAYHLQWTQRYNRWM PHGVHHTASFYVNTSPMPLWSINVANELVCSLRNTHVRKVQL VDKVKGLVRIFLESFQEETPDDKVFVHLAWEQSNGVITMNRNP KPFLTPQQRNGYTILNPKRLHLKPREHANVMIDTYFESDKYIGFI CPKSVPGCSISCNPIMPTQCIFIEIRSLHDSVYIEAFQAIASLHFFD RSLFFTYKKTDHSIFKDQYRVTTSFEYHQGKGVPIVQDSSEDDD SSSSESEDMDVFEVASTTPHAGTSSSSSASKKREKLYKPLVQRKR FTEDDGARKSSSDDDNDDFFPTLFWGVWQFGVRASELTPMIA SVCGDQLPHQEFSWEGDDDLRIFSGLSGSWHMYQTPKRRHYS PSEQLPSTSGESVSKRPCE | Pool of 133 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Infectious mononucleosis |
| 165 | MoTif 165 Human (Cyclin-B1) | MALRVTRNSKINAENKAKINMAGAKRVPTAPAATSKPGLRPRT ALGDIGNKVSEQLQAKMPMKKEAKPSATGKVIDKKLPKPLEKV PMLVPVPVSEPVPEPEPEPEPEPVKEEKLSPEPILVDTASPSPMET SGCAPAEEDLCQAFSDVILAVNDVDAEDGADPNLCSEYVKDIY AYLRQLEEEQAVRPKYLLGREVTGNMRAILIDWLVQVQMKFRL LQETMYMTVSIIDRFMQNNCVPKKMLQLVGVTAMFIASKYEE MYPPEIGDFAFVTDNTYTKHQIRQMEMKILRALNFGLGRPLPL HFLRRASKIGEVDVEQHTLAKYLMELTMLDYDMVHFPPSQIAA GAFCLALKILDNGEWTPTLQHYLSYTEESLLPVMQHLAKNVVM VNQGLTKHMTVKNKYATSKHAKISTLPQLNS ALVQDLAKAVAKV | Pool of 106 peptides derived from a peptide scan through G2/mitotic-specific cyclin-B1 (Swiss-Prot ID: P14635) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 166 | MoTif 166 Human (NKX3-1) | MLRVPEPRPGEAKAEGAAPPTPSKPLTSFLIQDILRDGAQRQGG RTSSQRQRDPEPEPEPEPEGGRSRAGAQNDQLSTGPRAAPEEA ETLAETEPERHLGSYLLDSENTSGALPRLPQTPKQPQKRSRAAFS HTQVIELERKFSHQKYLSAPERAHLAKNLKLTETQVKIWFQNRR YKTKRKQLSSELGDLEKHSSLPALKEEAFSRASLVSVYNSYPYYPY LYCVGSWSPAFW | Pool of 56 peptides derived from a peptide scan through Homeobox protein Nkx-3.1 (Swiss-Prot ID: Q99801) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Prostate cancer |
| 167 | MoTif 167 Human (PD-L1) | MRIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPV EKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARL LKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKV NAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQ VLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEEN HTAELVIPELPLAHPPNERTHLVILGAILLCLGVALTFIFRLRKGRM MDVKKCGIQDTNSKKQSDTHLEET | Pool of 70 peptides derived from a peptide scan through Programmed cell death 1 ligand (Swiss-Prot ID: Q9NZQ7) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Immune checkpoint |
| 168 | MoTif 168 Human (ErbB2_ICD) | LVVVLGVVFGILIKRRQQKIRKYTMRRLLQETELVEPLTPSGAMPN QAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKV LRENTSPKANKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQL MPYGCLLDHVRENRGRLGSQDLLNWCMQIAKGMSYLEDVRLV HRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIK WMALESILRRRFTHQSDVWSYGVTVWELMTFGAKPYDGIPAREI PDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRFRELVSEFS RMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAE EYLVPQQGFFCPDPAPGAGGMVHHRHRSSSTRSGGGDLTLGLEP SEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPSPLQ RYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREG PLPAARPAGATLERPKTLSPGKNGVVKDVFAFGGAVENPEYLTPQ GGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAE NPEYLGLDVPV | Pool of 146 peptides derived from a peptide scan through ErbB-2 receptor tyrosin-protein kinase (Swiss-Prot ID: P04626, region: 663-1255) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Breast cancer, Cancer, Gastric cancer, Glioma, Malignant genital cancers |
| 169 | MoTif 169 HIV-1 (NEF) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) through Nef protein (NEF) of Human Immunodeficiency Virus (HIV). | 70%-90% | AIDS (HIV), HIV, Infection, Sequence diversity | T-cell immunity |
| 170 | MoTif 170 HAdV-5 (penton protein) | MRRAAMYEEGPPPSYESVVSAAPVAAALGSPFDAPLDPPFVP PRYLRPTGGRNSIRYSELAPLFDTTRVYLVDNKSTDVASLNYQN DHSNFLTTVIQNNDYSPGEASTQTINLDDRSHWGGDLKTILHT NMPNVNEFMFTNKFKARVMVSRLPTKDNQVELKYEWVEFTL PEGNYSETMTIDLMNNAIVEHYLKVGRQNGVLESDIGVKFDTR NFRLGFDPVTGLVMPGVYTNEAFHPDIILLPGCGVDFTHSRLSN LLGIRKRQPFQEGFRITYDDLEGGNIPALLDVDAYQASLKDDTE QGGGGAGGSNSSGSGAEENSNAAAAAMQPVEDMNDHAIR GDTFATRAEEKRAEAEAAAEAAAPAAQPEVEKPQKKPVIKPLTE DSKKRSYNLISNDSTFTQYRSWYLAYNYGDPQTGIRSWTLLCTP DVTCGSEQVYWSLPDMMQDPVTFRSTRQISNFPVVGAELLPV HSKSFYNDQAVYSQLIRQFTSLTHVFNRFPENQILARPPAPTITT VSENVPALTDHGTLPLRNSIGGVQRVTITDARRRTCPYVYKALG IVSPRVLSSRTF | Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection, Respiratory infection |
| 171 | MoTif 171 HCMVA (UL151) | MVFVSGTALGTGFHRAEGSFCGCEGRSFFRTLGTGLGDGGCA GRRWXRXVAGTGITLGTGTRGPGLRDGGDGGVCGEDGGLLR RGRGLAGPAVAGVCGDGGLLQRRGLRGQECAXPGGFAGGH GTGGGGDSTNHTHTQLTSAVALSEPPLFFINVLIPPAYTRNAAC SYAHTLSLHSDMLLRLCTAAADTSGHRHLPPHMAHVLRRPAS YVVCSQHGAFFPARHLHRTPSAAFAVASTREQYATACAVAAAT WPPRLPHLFRTPNLWLPTTDVQGSRTRRPIPPILQRPRPPSQTS WKPTQTQHSIDARPRCCATSSSPATPNAALPTEPHPRGLP | Pool of 82 peptides derived from a peptide scan (15mers with 11 aa overlap - X = synthesized as A) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 172 | MoTif 172 HSV2 (gD) | MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRF RGKNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAV LERACRSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMG DNCAIPITVMEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSED NLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRARASCKY ALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYS LKIAGWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALL EDPAGTVSSQIPPNWHIPSIQDVAPHHAPAAPSNPGLIIGALA GSTLAVLVIGGIAFWVRRRAQMAPKRLRLPHIRDDDAPPSHQ PLFY | Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 173 | MoTif 173 Influenza A (NP (H3N2)) | MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQ MCTELKLSDYEGRLIQNSLTIERMVLSAFDERRNRYLEEHPSAG KDPKKTGGPIYKRVDGRWMRELVLYDKEEIRRIWRQANNGDD ATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQ GSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGE NGRKTRSAYERMCNILKGKFQTAAQRAMMDQVRESRNPGN AEIEDLIFSARSALILRGSVAHKSCLPACVYGPAVSSGYNFEKEGY SLVGIDPFKLLQNSQVYSLIRPNENPAHKSQLVWMACHSAAFE DLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMESSTLELRS RYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFEKSTV MAAFTGNTEGRTSDMRAEIIRMMEGAKPEEVSFRGRGVFELSD EKATNPIVPSFDMSNEGSYFFGDNAEEYDN | Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 174 | MoTif 174 HPV 18 (L1) | MCLYTRVLILHYHLLPLYGPLYHPRPLPLHSILVYMVHIIICGHYIIL FLRNVNVFPIFLQMALWRPSDNTVYLPPPSVARVVNTDDYVTP TSIFYHAGSSRLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFR VQLPDPNKFGLPDTSIYNPETQRLVWACAGVEIGRGQPLGVGL SGHPFYNKLDDTESSHAATSNVSEDVRDNVSVDYKQTQLCILG CAPAIGEHWAKGTACKSRPLSQGDCPPLELKNTVLEDGDMVDT GYGAMDFSTLQDTKCEVPLDICQSICKYPDYLQMSADPYGDSM FFCLRREQLFARHFWNRAGTMGDTVPQSLYIKGTGMPASPGSC VYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNGVCWHNQLFV TVVDTTPSTNLTICASTQSPVPGQYDATKFKQYSRHVEEYDLQFI FQLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRF VQSVAITCQKDAAPAENKDPYDKLKFWNVDLKEKFSLDLDQYP LGRKFLVQAGLRRKPTIGPRKRSAPSATTSSKPAKRVRVRARK | Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 175 | MoTif 175 HPV 06 (E6) | MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYS YAYKQLKVLFRGGYPYAACACCLEFHGKINQYRHFDYAGYATTV EEETKQDILDVLIRCYLCHKPLCEVEKVKHILTKARFIKLNCTWKG RCLHCWTTCMEDMLP | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 176 | MoTif 176 HPV 18 (E6) | MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEF AFKDLFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKL TNTGLYNLLIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQ CHSCCNRARQERLQRRRETQV | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 177 | MoTif 177 HPV 11 (E6) | MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAY AYKNLKVVWRDNFPFAACACCLELQGKINQYRHFNYAAYAPTV EEETNEDILKVLIRCYLCHKPLCEIEKLKHILGKARFIKLNNQWKGR CLHCWTTCMEDLLP | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E6 (Swiss-Prot ID: P04019) of Human Papillomavirus (HPV). | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 178 | MoTif 178 HCMVA (UL151) | MVFVSGTALGTGFHRAEGSFCGCEGRSFFRTLGTGLGDGGCAGR RWXRXVAGTGITLGTGTRGPGLRDGGDGGVCGEDGGLLRRGRG LAGPAVAGVCGDGGLLQRRGLRGQECAXPGGFAGGHGTGGGG DSTNHTHTQLTSAVALSEPPLFFINVLIPPAYTRNAACSYAHTLSL HSDMLLRLCTAAADTSGHRHLPPHMAHVLRRPASYVVCSQHG AFFPARHLHRTPSAAFAVASTREQYATACAVAAATWPPRLPHLFR TPNLWLPTTDVQGSRTRRPIPPILQRPRPPSQTSWKPTQTQHSID ARPRCCATSSSPATPNAALPTEPHPRGLP | Pool of 82 peptides derived from a peptide scan (15mers with 11 aa overlap - X = synthesized as A) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 179 | MoTif 179 BKV (capsid protein VP2) | MGAALALLGDLVASVSEAAAATGFSVAEIAAGEAAAAIEVQIASLA TVEGITSTSEAIAAIGLTPQTYAVIAGAPGAIAGFAALIQTVSGISSLA QVGYRFFSDWDHKVSTVGLYQQSGMALELFNPDEYYDILFPGVN TFVNNIQYLDPRHWGPSLFATISQALWHVIRDDIPSITSQELQRRT ERFFRDSLARFLEETTWTIVNAPINFYNYIQQYYSDLSPIRPSMVRQ VAEREGTRVHFGHTYSIDDADSIEEVTQRMDLRNQQSVHSGEFIE KTIAPGGANQRTAPQWMLPLLLGLYGTVTPALEAYEDGPNQKKRR VSRGSSQKAKGTRASAKTTNKRRSRSSRS | Pool of 85 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Merkel cell carcinoma, Nephritis, interstitial |
| 180 | MoTif 180 Influenza B (HA/H0N0/Austria/2021) | MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIP LTTTPTKSHFANLKGTETRGKLCPKCLNCTDLDVALGRPKCTGKIPS ARVSILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEHVRLSTHNV INTEDAPGGPYEIGTSGSCLNITNGKGFFATMAWAVPKNKTATNPL TIEVPYICTEEEDQITVWGFHSDDETQMARLYGDSKPQKFTSSANG VTTHYVSQIGGFPNQTEDGGLPQSGRIVVDYMVQKSGKTGTITYQ RGILLPQKVWCASGKSKVIKGSLPLIGEADCLHEKYGGLNKSKPYYT GEHAKAIGNCPIWVKTPLKLANGTKYRPPAKLLKERGFFGAIAGFLE GGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAINKITKNLNSL SELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLS NEGIINSEDEHLLALERKLKKMLGPSAVEIGNGCFETKHKCNQTCLD RIAAGTFDAGEFSLPTFDSLNITAASLNDDGLDNHTILLYYSTAASSL AVTLMIAIFVVYMVSRDNVSCSICL | Pool of 143 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 181 | MoTif 181 HSV2 (gD) | MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRG KNLPVLDQLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLERAC RSVLLHAPSEAPQIVRGASDEARKHTYNLTIAWYRMGDNCAIPITV MEYTECPYNKSLGVCPIRTQPRWSYYDSFSAVSEDNLGFLMHAPA FETAGTYLRLVKINDWTEITQFILEHRARASCKYALPLRIPPAACLTSK AYQQGVTVDSIGMLPRFIPENQRTVALYSLKIAGWHGPKPPYTSTL LPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPPNWHIPSI QDVAPHHAPAAPSNPGLIIGALAGSTLAVLVIGGIAFWVRRRAQM APKRLRLPHIRDDDAPPSHQPLFY | Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 182 | MoTif 182 SARS-CoV-2 (Spike HK.3) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLH STHDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFAS TEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFL DVYQKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKEGN FKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGFSALEPLVDLPIGI NITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKY NENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTES IVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNF APFFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTG NIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYNYLYRFLRKSK LKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGH QPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTG VLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVS VITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGS NVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRAR SVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMT KTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKN TQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFN KVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEM IAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQ NVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQ ALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSL QTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYH LMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPRE GVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNT VYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAI VMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLH YT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 183 | MoTif 183 SARS-CoV-2 (Spike JG.3) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHS THDLFLPFFSNVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFASTE KSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVY QKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKEGNFKNL REFVFKNIDGYFKIYSKHTPINLERDLPQGFSALEPLVDLPIGINITRFQ TLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTIT DAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNL CPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGV SPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDF TGCVIAWNSNKLDSKPSGNYNYLYRFLRKSKLKPFERDISTEIYQAGN KPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIA DTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCT EVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIP IGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENLVAYSNNSIAI PTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQL KRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKP SKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVL PPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNG IGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHN AQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQ TYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSF PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNG THWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDS FKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNES LIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLK GCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 184 | MoTif 184 SARS-CoV-2 (Spike JN.1) | MFVFLVLLPLVSSQCVMPLFNLITTTQSYTNSFTRGVYYPDKVFRSSV LHLTQDLFLPFFSNVTWFHAISGTNGTKRFDNPVLPFNDGVYFASTE KSNIIRGWIFGTTLDSKTQSLLIVNNATNVFIKVCEFQFCNDPFLDVYH KNNKSWMESESGVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLRE FVFKNIDGYFKIYSKHTPIIGRDFPQGFSALEPLVDLPIGINITRFQTLLA LNRSYLTPGDSSSGWTAGAADYYVGYLQPRTFLLKYNENGTITDAVD CALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNVTNLCPFH EVFNATRFASVYAWNRTRISNCVADYSVLYNFAPFFAFKCYGVSPTKL NDLCFTNVYADSFVIKGNEVRQIAPGQTGNIADYNYKLPDDFTGCVI AWNSNKLDSKHSGNYDYWYRSFRKSKLKPFERDISTEIYQAGNKPC KGKGPNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPK KSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIVDTTDA VRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVSVA IHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGV CASYQTQTKSRRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNF TISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRAL TGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRS FIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLL TDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGV TQNVLYENQKLIANQFNSAIGKIQDSLFSTASALGKLQDVVNHNAQ ALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQT YVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSF PQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSN GTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQLEL DSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNL NESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCC SCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 185 | MoTif 185 HPV 18 (L1) | MCLYTRVLILHYHLLPLYGPLYHPRPLPLHSILVYMVHIIICGHYIILFLRN VNVFPIFLQMALWRPSDNTVYLPPPSVARVVNTDDYVTPTSIFYHAG SSRLLTVGNPYFRVPAGGGNKQDIPKVSAYQYRVFRVQLPDPNKFGLP DTSIYNPETQRLVWACAGVEIGRGQPLGVGLSGHPFYNKLDDTESSHA ATSNVSEDVRDNVSVDYKQTQLCILGCAPAIGEHWAKGTACKSRPLSQ GDCPPLELKNTVLEDGDMVDTGYGAMDFSTLQDTKCEVPLDICQSICK YPDYLQMSADPYGDSMFFCLRREQLFARHFWNRAGTMGDTVPQSLY IKGTGMPASPGSCVYSPSPSGSIVTSDSQLFNKPYWLHKAQGHNNGV CWHNQLFVTVVDTTPSTNLTICASTQSPVPGQYDATKFKQYSRHVEEY DLQFIFQLCTITLTADVMSYIHSMNSSILEDWNFGVPPPPTTSLVDTYRF VQSVAITCQKDAAPAENKDPYDKLKFWNVDLKEKFSLDLDQYPLGRKF LVQAGLRRKPTIGPRKRSAPSATTSSKPAKRVRVRARK | Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 186 | MoTif 186 HPV 06 (E6) | MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYSYAYK QLKVLFRGGYPYAACACCLEFHGKINQYRHFDYAGYATTVEEETKQDIL DVLIRCYLCHKPLCEVEKVKHILTKARFIKLNCTWKGRCLHCWTTCME DMLP | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 187 | MoTif 187 HPV 18 (E6) | MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKD LFVVYRDSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNL LIRCLRCQKPLNPAEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQE RLQRRRETQV | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 188 | MoTif 188 HPV 11 (E6) | MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAYAYKN LKVVWRDNFPFAACACCLELQGKINQYRHFNYAAYAPTVEEETNEDILK VLIRCYLCHKPLCEIEKLKHILGKARFIKLNNQWKGRCLHCWTTCMEDLLP | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E6 (Swiss-Prot ID: P04019) of Human Papillomavirus (HPV). | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 189 | MoTif 189 HPV 16 (E6) | MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVY DFAFRDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNK PLCDLLIRCINCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSR TRRETQL | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 190 | MoTif 190 HPV 16 (E7) | MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAE PDRAHYNIVTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 191 | MoTif 191 HPV18 (E4) | MADPEVPVTTRYPLLSLLNSYSTPPHRIPAPCPWAPQRPTARRRLLHD LDTVDSRRSSIVDLSTHFSVQLHLQATTKDGNSVVVTLRL | Pool of 20 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 192 | MoTif 192 HPV16 (E2) | METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKARE MGFKHINHQVVPTLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDV SLEVYLTAPTGCIKKHGYTVEVQFDGDICNTMHYTNWTHIYICEEASVTV VEGQVDYYGLYYVHEGIRTYFVQFKDDAEKYSKNKVWEVHAGGQVILCP TSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQTTIQRPRSEPDTG NPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDANTL KCLRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQF LSQVKIPKTITVSTGFMSI | Pool of 89 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 193 | MoTif 193 HSV2 (R1) | MANRPAASALAGARSPSERQEPREPEVAPPGGDHVFCRKVSGVMVLSS DPPGPAAYRISDSSFVQCGSNCSMIIDGDVARGHLRDLEGATSTGAFVAI SNVAAGGDGRTAVVALGGTSGPSATTSVGTQTSGEFLHGNPRTPEPQGP QAVPPPPPPPFPWGHECCARRDARGGAEKDVGAAESWSDGPSSDSET EDSDSSDEDTGSETLSRSSSIWAAGATDDDDSDSDSRSDDSVQPDVVV RRRWSDGPAPVAFPKPRRPGDSPGNPGLGAGTGPGSATDPRASADSDS AAHAAAPQADVAPVLDSQPTVGTDPGYPVPLELTPENAEAVARFLGDAV DREPALMLEYFCRCAREESKRVPPRTFGSAPRLTEDDFGLLNYALAEMRR LCLDLPPVPPNAYTPYHLREYATRLVNGFKPLVRRSARLYRILGVLVHLRIR TREASFEEWMRSKEVDLDFGLTERLREHEAQLMILAQALNPYDCLIHSTP NTLVERGLQSALKYEEFYLKRFGGHYMESVFQMYTRIAGFLACRATRGM RHIALGRQGSWWEMFKFFFHRLYDHQIVPSTPAMLNLGTRNYYTSSCY LVNPQATTNQATLRAITGNVSAILARNGGIGLCMQAFNDASPGTASIMP ALKVLDSLVAAHNKQSTRPTGACVYLEPWHSDVRAVLRMKGVLAGEEA QRCDNIFSALWMPDLFFKRLIRHLDGEKNVTWSLFDRDTSMSLADFHG EEFEKLYEHLEAMGFGETIPIQDLAYAIVRSAATTGSPFIMFKDAVNRHYIY DTQGAAIAGSNLCTEIVHPASKRSSGVCNLGSVNLARCVSRQTFDFGRLR DAVQACVLMVNIMIDSTLQPTPQCTRGNDNLRSMGIGMQGLHTACLK MGLDLESAEFRDLNTHIAEVMLLAAMKTSNALCVRGARPFSHFKRSMYR AGRFHWERFSNASPRYEGEWEMLRQSMMKHGLRNSQFIALMPTAASAQ ISDVSEGFAPLFTNLFSKVTRDGETLRPNTLLLKELERTFGGKRLLDAMDGL EAKQWSVAQALPCLDPAHPLRRFKTAFDYDQELLIDLCADRAPYVDHSQS MTLYVTEKADGTLPASTLVRLLVHAYKRGLKTGMYYCKVRKATNSGVFAGD DNIVCTSCAL | Pool of 283 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 194 | MoTif 194 HPV45 (E6) | MARFDDPKQRPYKLPDLCTELNTSLQDVSIACVYCKATLERTEVYQFAFKD LCIVYRDCIAYAACHKCIDFYSRIRELRYYSNSVYGETLEKITNTELYNLLIRCL RCQKPLNPAEKRRHLKDKRRFHSIAGQYRGQCNTCCDQARQERLRRRRE TQV | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 195 | MoTif 195 HPV45 (E7) | MHGPRETLQEIVLHLEPQNELDPVDLLCYEQLSESEEENDEADGVSHAQL PARRAEPQRHKILCVCCKCDGRIELTVESSAEDLRTLQQLFLSTL SFVCPWCATNQ | Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 196 | MoTif 196 HPV 18 (L2) | MVSHRAARRKRASVTDLYKTCKQSGTCPPDVVPKVEGTTLADKILQWSSL GIFLGGLGIGTGSGTGGRTGYIPLGGRSNTVVDVGPTRPPVVIEPVGPTDPS IVTLIEDSSVVTSGAPRPTFTGTSGFDITSAGTTTPAVLDITPSSTSVSISTTNF TNPAFSDPSIIEVPQTGEVAGNVFVGTPTSGTHGYEEIPLQTFASSGTGEEPIS STPLPTVRRVAGPRLYSRAYQQVSVANPEFLTRPSSLITYDNPAFEPVDTTLT FDPRSDVPDSDFMDIIRLHRPALTSRRGTVRFSRLGQRATMFTRSGTQIGAR VHFYHDISPIAPSPEYIELQPLVSATEDNDLFDIYADDMDPAVPVPSRSTTSF AFFKYSPTISSASSYSNVTVPLTSSWDVPVYTGPDITLPSTTSVWPIVSPTAPA STQYIGIHGTHYYLWPLYYFIPKKRKRVPYFFADGFVAA | Pool of 113 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 197 | MoTif 197 HPV 52 (E7) | MRGDKATIKDYILDLQPETTDLHCYEQLGDSSDEEDTDGVDRPDGQAEQ ATSNYYIVTYCHSCDSTLRLCIHSTATDLRTLQQMLLGTLQVVCPGCARL | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 198 | MoTif 198 HPV58 (E6) | MFQDAEEKPRTLHDLCQALETSVHEIELKCVECKKTLQRSEVYDFVFADLRIV YRDGNPFAVCKVCLRLLSKISEYRHYNYSLYGDTLEQTLKKCLNEILIRCIICQR PLCPQEKKRHVDLNKRFHNISGRWTGRCAVCWRPRRRQTQV | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 199 | MoTif 199 HPV35 (E7) | MHGEITTLQDYVLDLEPEATDLYCYEQLCDSSEEEEDTIDGPAGQAKPDTSN YNIVTSCCKCEATLRLCVQSTHIDIRKLEDLLMGTFGIVCPGCSQRA | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 200 | MoTif 200 HPV33 (E6) | MFQDTEEKPRTLHDLCQALETTIHNIELQCVECKKPLQRSEVYDFAFADLTVVY REGNPFGICKLCLRFLSKISEYRHYNYSVYGNTLEQTVKKPLNEILIRCIICQRPLC PQEKKRHVDLNKRFHNISGRWAGRCAACWRSRRRETAL | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 201 | MoTif 201 Collection Papillomavirus | 5 different HPV PepMixes + 2 Controls (15mers, overlap 11) | Collection of 5 peptide pools derived from scans (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Malignant genital cancers |
| 202 | MoTif 202 Marburgvirus (GP/Angola-05) | MKTTCLLISLILIQGVKTLPILEIASNIQPQNVDSVCSGTLQKTEDVHLMGFTLSG QKVADSPLEASKRWAFRAGVPPKNVEYTEGEEAKTCYNISVTDPSGKSLLLDPP TNIRDYPKCKTIHHIQGQNPHAQGIALHLWGAFFLYDRIASTTMYRGKVFTEGN IAAMIVNKTVHKMIFSRQGQGYRHMNLTSTNKYWTSSNGTQTNDTGCFGTLQ EYNSTKNQTCAPSKKPLPLPTAHPEVKLTSTSTDATKLNTTDPNSDDEDLTTSGS GSGEQEPYTTSDAATKQGLSSTMPPTPSPQPSTPQQGGNNTNHSQGVVTEPG KTNTTAQPSMPPHNTTTISTNNTSKHNLSTPSVPIQNATNYNTQSTAPENEQTS APSKTTLLPTENPTTAKSTNSTKSPTTTVPNTTNKYSTSPSPTPNSTAQHLVYFRR KRNILWREGDMFPFLDGLINAPIDFDPVPNTKTIFDESSSSGASAEEDQHASPNI SLTLSYFPKVNENTAHSGENENDCDAELRIWSVQEDDLAAGLSWIPFFGPGIEGL YTAGLIKNQNNLVCRLRRLANQTAKSLELLLRVTTEERTFSLINRHAIDFLLARWG GTCKVLGPDCCIGIEDLSRNISEQIDQIKKDEQKEGTGWGLGGKWWTSDWGVL TNLGILLLLSIAVLIALSCICRIFTKYIG | Pool of 169 peptides derived from a peptide scan (15mers with 11 aa overlap) t | 70%-90% | T-cell immunity | Infection, Marburg Disease, Marburg virus disease |
| 203 | MoTif 203 Human (Melan-A/MART-1) | MPREDAHFIYGYPKKGHGHSYTTAEEAAGIGILTVILGVLLLIGCWYCRRRNGYR ALMDKSLHVGTQCALTRRCPQEGFDHRDSKVSLQEKNCEPVVPNAPPAYEKLS AEQSPPPYSP | Pool of 27 peptides derived from a peptide scan through Melanoma antigen recognized by T-cells 1 (MART-1) (Swiss-Prot ID: Q16655) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 204 | MoTif 204 Human (NY-ESO-1) | MQAEGRGTGGSTGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGA ARASGPGGGAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPMEA ELARRSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSISSCLQQLSLL MWITQCFLPVFLAQPPSGQRR | Pool of 43 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Malignant genital cancers |
| 205 | MoTif 205 Yellow fever (NS4B) | NELGMLEKTKEDLFGKKNLIPSSASPWSWPDLDLKPGAAWTVYVGIVTMLSPM LHHWIKVEYGNLSLSGIAQSASVLSFMDKGIPFMKMNISVIMLLVSGWNSITVM PLLCGIGCAMLHWSLILPGIKAQQSKLAQRRVFHGVAENPVVDGNPTVDIEEAP EMPALYEKKLALYLLLALSLASVAMCRTPFSLAEGIVLASAALGPLIEGNTSLLWNG PMAVSMTGVMRGNHYAFVGVMYNLWKMKTGRR | Pool of 60 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Yellow Fever |
| 206 | MoTif 206 Influenza A (NP (H3N2)) | MASQGTKRSYEQMETDGERQNATEIRASVGKMIDGIGRFYIQMCTELKLSDYEG RLIQNSLTIERMVLSAFDERRNRYLEEHPSAGKDPKKTGGPIYKRVDGRWMRELV LYDKEEIRRIWRQANNGDDATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDP RMCSLMQGSTLPRRSGAAGAAVKGIGTMVMELIRMIKRGINDRNFWRGENGR KTRSAYERMCNILKGKFQTAAQRAMMDQVRESRNPGNAEIEDLIFSARSALILRG SVAHKSCLPACVYGPAVSSGYNFEKEGYSLVGIDPFKLLQNSQVYSLIRPNENPAH KSQLVWMACHSAAFEDLRLLSFIRGTKVSPRGKLSTRGVQIASNENMDNMESST LELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFEKSTVMAAFTGN TEGRTSDMRAEIIRMMEGAKPEEVSFRGRGVFELSDEKATNPIVPSFDMSNEGSY FFGDNAEEYDN | Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 207 | MoTif 207 SARS-CoV-2 (Spike EG.5.1) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTHDLFLPFFS NVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQ SLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNKSWMESEFRVYSSANNCTFEY VSQPFLMDLEGKEGNFKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGFSALEPLV DLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGT ITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFHEVF NATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPTKLNDLCFTNVYAD SFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYNYLY RLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYR VVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQF GRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVP VAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQ TKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTS VDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKT PPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDL ICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAY RFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQAL NTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAE IRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQ EKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNC DVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKE IDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTS CCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Pool of 315 (158 + 157) peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap) - including a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 208 | MoTif 208 Human (HILPDA) | MKHVLNLYLLGVVLTLLSIFVRVMESLEGLLESPSPGTSWTTRSQLANTEPTKGLPDHPSRSM | Pool of 13 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Hypoxia, Metabolism |
| 209 | MoTif 209 SARS-CoV-2 (VME1 B.1.1.529 / BA.1 / Omicron) | MAGSNGTITVEELKKLLEEWNLVIGFLFLTWICLLQFAYANRNRFLYIIKLIFLWLL WPVTLTCFVLAAVYRINWITGGIAIAMACLVGLMWLSYFIASFRLFARTRSMWS FNPETNILLNVPLHGTILTRPLLESELVIGAVILRGHLRIAGHHLGRCDIKDLPKEIT VATSRTLSYYKLGASQRVAGDSGFAAYSRYRIGNYKLNTDHSSSSDNIALLVQ | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 210 | MoTif 210 SARS-CoV-2 (Spike EG.5.1) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTHDLFLPF FSNVTWFHAIHVSGTNGTKRFDNPALPFNDGVYFASTEKSNIIRGWIFGTTLDS KTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNKSWMESEFRVYSSANN CTFEYVSQPFLMDLEGKEGNFKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGF SALEPLVDLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFL LKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNI TNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPTKL NDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNK LDSKPSGNYNYLYRLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSY GFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLTGT GVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTS NQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNN SYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIP TNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAV EQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLA DAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSG WTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLS STASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDILSRLDKVEAEVQID RLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHL MSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHW FVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKN HTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWP WYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGV KLHYT | Pool of 315 (158 + 157) peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap) - including a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 211 | MoTif 211 HSV2 (gD) | MGRLTSGVGTAALLVVAVGLRVVCAKYALADPSLKMADPNRFRGKNLPVLD QLTDPPGVKRVYHIQPSLEDPFQPPSIPITVYYAVLERACRSVLLHAPSEAPQI VRGASDEARKHTYNLTIAWYRMGDNCAIPITVMEYTECPYNKSLGVCPIRTQ PRWSYYDSFSAVSEDNLGFLMHAPAFETAGTYLRLVKINDWTEITQFILEHRA RASCKYALPLRIPPAACLTSKAYQQGVTVDSIGMLPRFIPENQRTVALYSLKIA GWHGPKPPYTSTLLPPELSDTTNATQPELVPEDPEDSALLEDPAGTVSSQIPP NWHIPSIQDVAPHHAPAAPSNPGLIIGALAGSTLAVLVIGGIAFWVRRRAQM APKRLRLPHIRDDDAPPSHQPLFY | Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 212 | MoTif 212 Borrelia (OspA protein) Ultra | see additional product documentation | Pool of 200 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) | 70%-90% | T-cell immunity | Infection, Lyme disease, Sequence diversity |
| 213 | MoTif 213 Influenza A (HA/Hong Kong/1/1968 (H3N2)) | MKTIIALSYIFCLALGQDLPGNDNSTATLCLGHHAVPNGTLVKTITDDQIEVTN ATELVQSSSTGKICNNPHRILDGIDCTLIDALLGDPHCDVFQNETWDLFVERS KAFSNCYPYDVPDYASLRSLVASSGTLEFITEGFTWTGVTQNGGSNACKRGP GSGFFSRLNWLTKSGSTYPVLNVTMPNNDNFDKLYIWGVHHPSTNQEQTS LYVQASGRVTVSTRRSQQTIIPNIGSRPWVRGLSSRISIYWTIVKPGDVLVINS NGNLIAPRGYFKMRTGKSSIMRSDAPIDTCISECITPNGSIPNDKPFQNVNKI TYGACPKYVKQNTLKLATGMRNVPEKQTRGLFGAIAGFIENGWEGMIDGW YGFRHQNSEGTGQAADLKSTQAAIDQINGKLNRVIEKTNEKFHQIEKEFSEV EGRIQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTRRQL RENAEDMGNGCFKIYHKCDNACIESIRNGTYDHDVYRDEALNNRFQIKGVE LKSGYKDWILWISFAISCFLLCVVLLGFIMWACQRGNIRCNICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 214 | MoTif 214 SARS-CoV-2 (S-RBD EG.5.1) | RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAP FFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPD DFTGCVIAWNSNKLDSKPSGNYNYLYRLLRKSKLKPFERDISTEIYQAGNKPCN GVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLV KNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19 |
| 215 | MoTif 215 HPV 16 (E6) | MHQKRTAMFQDPQERPRKLPQLCTELQTTIHDIILECVYCKQQLLRREVYDFAF RDLCIVYRDGNPYAVCDKCLKFYSKISEYRHYCYSLYGTTLEQQYNKPLCDLLIRC INCQKPLCPEEKQRHLDKKQRFHNIRGRWTGRCMSCCRSSRTRRETQL | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 216 | MoTif 216 HPV 18 (E6) | MARFEDPTRRPYKLPDLCTELNTSLQDIEITCVYCKTVLELTEVFEFAFKDLFVVYR DSIPHAACHKCIDFYSRIRELRHYSDSVYGDTLEKLTNTGLYNLLIRCLRCQKPLNP AEKLRHLNEKRRFHNIAGHYRGQCHSCCNRARQERLQRRRETQV | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 217 | MoTif 217 HPV 52 (E7) | MRGDKATIKDYILDLQPETTDLHCYEQLGDSSDEEDTDGVDRPDGQAEQATSN YYIVTYCHSCDSTLRLCIHSTATDLRTLQQMLLGTLQVVCPGCARL | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 218 | MoTif 218 HPV 16 (E7) | MHGDTPTLHEYMLDLQPETTDLYCYEQLNDSSEEEDEIDGPAGQAEPDRAHYNI VTFCCKCDSTLRLCVQSTHVDIRTLEDLLMGTLGIVCPICSQKP | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 219 | MoTif 219 HSV2 (R1) | MANRPAASALAGARSPSERQEPREPEVAPPGGDHVFCRKVSGVMVLSSDPPGPA AYRISDSSFVQCGSNCSMIIDGDVARGHLRDLEGATSTGAFVAISNVAAGGDGRTA VVALGGTSGPSATTSVGTQTSGEFLHGNPRTPEPQGPQAVPPPPPPPFPWGHECC ARRDARGGAEKDVGAAESWSDGPSSDSETEDSDSSDEDTGSETLSRSSSIWAAGA TDDDDSDSDSRSDDSVQPDVVVRRRWSDGPAPVAFPKPRRPGDSPGNPGLGAG TGPGSATDPRASADSDSAAHAAAPQADVAPVLDSQPTVGTDPGYPVPLELTPENA EAVARFLGDAVDREPALMLEYFCRCAREESKRVPPRTFGSAPRLTEDDFGLLNYALA EMRRLCLDLPPVPPNAYTPYHLREYATRLVNGFKPLVRRSARLYRILGVLVHLRIRTRE ASFEEWMRSKEVDLDFGLTERLREHEAQLMILAQALNPYDCLIHSTPNTLVERGLQS ALKYEEFYLKRFGGHYMESVFQMYTRIAGFLACRATRGMRHIALGRQGSWWEMFK FFFHRLYDHQIVPSTPAMLNLGTRNYYTSSCYLVNPQATTNQATLRAITGNVSAILAR NGGIGLCMQAFNDASPGTASIMPALKVLDSLVAAHNKQSTRPTGACVYLEPWHSD VRAVLRMKGVLAGEEAQRCDNIFSALWMPDLFFKRLIRHLDGEKNVTWSLFDRDT SMSLADFHGEEFEKLYEHLEAMGFGETIPIQDLAYAIVRSAATTGSPFIMFKDAVNRH YIYDTQGAAIAGSNLCTEIVHPASKRSSGVCNLGSVNLARCVSRQTFDFGRLRDAVQ ACVLMVNIMIDSTLQPTPQCTRGNDNLRSMGIGMQGLHTACLKMGLDLESAEFRD LNTHIAEVMLLAAMKTSNALCVRGARPFSHFKRSMYRAGRFHWERFSNASPRYEG EWEMLRQSMMKHGLRNSQFIALMPTAASAQISDVSEGFAPLFTNLFSKVTRDGETL RPNTLLLKELERTFGGKRLLDAMDGLEAKQWSVAQALPCLDPAHPLRRFKTAFDYD QELLIDLCADRAPYVDHSQSMTLYVTEKADGTLPASTLVRLLVHAYKRGLKTGMYYC KVRKATNSGVFAGDDNIVCTSCAL | Pool of 283 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 220 | MoTif 220 HPV35 (E7) | MHGEITTLQDYVLDLEPEATDLYCYEQLCDSSEEEEDTIDGPAGQAKPDTSNYNIV TSCCKCEATLRLCVQSTHIDIRKLEDLLMGTFGIVCPGCSQRA | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) through Protein E7 (Swiss-Prot ID: P27230) of Human Papillomavirus (HPV) - type 35. | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 221 | MoTif 221 HPV45 (E6) | MARFDDPKQRPYKLPDLCTELNTSLQDVSIACVYCKATLERTEVYQFAFKDLCIVYRD CIAYAACHKCIDFYSRIRELRYYSNSVYGETLEKITNTELYNLLIRCLRCQKPLNPAEKRR HLKDKRRFHSIAGQYRGQCNTCCDQARQERLRRRRETQV | Pool of 37 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 222 | MoTif 222 HPV45 (E7) | MHGPRETLQEIVLHLEPQNELDPVDLLCYEQLSESEEENDEADGVSHAQLPARRAEP QRHKILCVCCKCDGRIELTVESSAEDLRTLQQLFLSTLSFVCPWCATNQ | Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 223 | MoTif 223 HPV45 (E7) | MHGPRETLQEIVLHLEPQNELDPVDLLCYEQLSESEEENDEADGVSHAQLPARRAEP QRHKILCVCCKCDGRIELTVESSAEDLRTLQQLFLSTLSFVCPWCATNQ | Pool of 24 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 224 | MoTif 224 HPV58 (E6) | MFQDAEEKPRTLHDLCQALETSVHEIELKCVECKKTLQRSEVYDFVFADLRIVYRDGNP FAVCKVCLRLLSKISEYRHYNYSLYGDTLEQTLKKCLNEILIRCIICQRPLCPQEKKRHVDL NKRFHNISGRWTGRCAVCWRPRRRQTQV | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 225 | MoTif 225 HPV16 (E2) | METLCQRLNVCQDKILTHYENDSTDLRDHIDYWKHMRLECAIYYKAREMGFKHINHQ VVPTLAVSKNKALQAIELQLTLETIYNSQYSNEKWTLQDVSLEVYLTAPTGCIKKHGYTVE VQFDGDICNTMHYTNWTHIYICEEASVTVVEGQVDYYGLYYVHEGIRTYFVQFKDDAE KYSKNKVWEVHAGGQVILCPTSVFSSNEVSSPEIIRQHLANHPAATHTKAVALGTEETQ TTIQRPRSEPDTGNPCHTTKLLHRDSVDSAPILTAFNSSHKGRINCNSNTTPIVHLKGDA NTLKCLRYRFKKHCTLYTAVSSTWHWTGHNVKHKSAIVTLTYDSEWQRDQFLSQVKIP KTITVSTGFMSI | Pool of 89 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 226 | MoTif 226 HPV18 (E4) | MADPEVPVTTRYPLLSLLNSYSTPPHRIPAPCPWAPQRPTARRRLLHDLDTVDSRRSSI VDLSTHFSVQLHLQATTKDGNSVVVTLRL | Pool of 20 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 227 | MoTif 227 HPV 06 (E6) | MESANASTSATTIDQLCKTFNLSMHTLQINCVFCKNALTTAEIYSYAYKQLKVLFRGGYPY AACACCLEFHGKINQYRHFDYAGYATTVEEETKQDILDVLIRCYLCHKPLCEVEKVKHILTK ARFIKLNCTWKGRCLHCWTTCMEDMLP | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 228 | MoTif 228 HPV 11 (E6) | MESKDASTSATSIDQLCKTFNLSLHTLQIQCVFCRNALTTAEIYAYAYKNLKVVWRDNFPF AACACCLELQGKINQYRHFNYAAYAPTVEEETNEDILKVLIRCYLCHKPLCEIEKLKHILGKA RFIKLNNQWKGRCLHCWTTCMEDLLP | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 229 | MoTif 229 HPV33 (E6) | MFQDTEEKPRTLHDLCQALETTIHNIELQCVECKKPLQRSEVYDFAFADLTVVYREGNPFG ICKLCLRFLSKISEYRHYNYSVYGNTLEQTVKKPLNEILIRCIICQRPLCPQEKKRHVDLNKRF HNISGRWAGRCAACWRSRRRETAL | Pool of 35 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Genital malignancies, Infection, Malignant genital cancers |
| 230 | MoTif 230 Borrelia (OspA protein) Ultra | see additional product documentation | Pool of 200 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) | 70%-90% | T-cell immunity | Infection, Lyme disease, Sequence diversity |
| 231 | MoTif 231 Human (HMHA1) | MFSRKKRELMKTPSISKKNRAGSPSPQPSGELPRKDGADAVFPGPSLEPPAGSSGVKATG TLKRPTSLSRHASAAGFPLSGAASWTLGRSHRSPLTAASPGELPTEGAGPDVVEDISHLLA DVARFAEGLEKLKECVLRDDLLEARRPRAHECLGEALRVMHQIISKYPLLNTVETLTAAGTL IAKVKAFHYESNNDLEKQEFEKALETIAVAFSSTVSEFLMGEVDSSTLLAVPPGDSSQSMES LYGPGSEGTPPSLEDCDAGCLPAEEVDVLLQRCEGGVDAALLYAKNMAKYMKDLISYLEKR TTLEMEFAKGLQKIAHNCRQSVMQEPHMPLLSIYSLALEQDLEFGHSMVQAVGTLQTQTF MQPLTLRRLEHEKRRKEIKEAWHRAQRKLQEAESNLRKAKQGYVQRCEDHDKARFLVAK AEEEQAGSAPGAGSTATKTLDKRRRLEEEAKNKAEEAMATYRTCVADAKTQKQELEDTKV TALRQIQEVIRQSDQTIKSATISYYQMMHMQTAPLPVHFQMLCESSKLYDPGQQYASHVR QLQRDQEPDVHYDFEPHVSANAWSPVMRARKSSFNVSDVARPEAAGSPPEEGGCTEGT PAKDHRAGRGHQVHKSWPLSISDSDSGLDPGPGAGDFKKFERTSSSGTMSSTEELVDPD GGAGASAFEQADLNGMTPELPVAVPSGPFRHEGLSKAARTHRLRKLRTPAKCRECNSYV YFQGAECEECCLACHKKCLETLAIQCGHKKLQGRLQLFGQDFSHAARSAPDGVPFIVKKC VCEIERRALRTKGIYRVNGVKTRVEKLCQAFENGKELVELSQASPHDISNVLKLYLRQLPEPL ISFRLYHELVGLAKDSLKAEAEAKAASRGRQDGSESEAVAVALAGRLRELLRDLPPENRASL QYLLRHLRRIVEVEQDNKMTPGNLGIVFGPTLLRPRPTEATVSLSSLVDYPHQARVIETLIV HYGLVFEEEPEETPGGQDESSNQRAEVVVQVPYLEAGEAVVYPLQEAAADGCRESRVVS NDSDSDLEEASELLSSSEASALGHLSFLEQQQSEASLEVASGSHSGSEEQLEATAREDGDG DEDGPAQQLSGFNTNQSNNVLQAPLPPMRLRGGRMTLGSCRERQPEFV | Pool of 282 peptides derived from a peptide scan through Minor histocompatibility protein HA-1 (Swiss-Prot ID: Q92619) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer |
| 232 | MoTif 232 EBV (BMRF1) | METTQTLRFKTKALAVLSKCYDHAQTHLKGGVLQVNLLSVNYGGPRLAAVANAGTAGLIS FEVSPDAVAEWQNHQSPEEAPAAVSFRNLAYGRTCVLGKELFGSAVEQASLQFYKRPQG GSRPEFVKLTMEYDDKVSKSHHTCALMPYMPPASDRLRNEQMIGQVLLMPKTASSLQK WARQQGSGGVKVTLNPDLYVTTYTSGEACLTLDYKPLSVGPYEAFTGPVAKAQDVGAVE AHVVCSVAADSLAAALSLCRIPAVSVPILRFYRSGIIAVVAGLLTSAGDLPLDLSVILFNHAS EEAAASTASEPEDKSPRVQPLGTGLQQRPRHTVSPSPSPPPPPRTPTWESPARPETPSPAIP SHSSNTALERPLAVQLARKRTSSEARQKQKHPKKVKQAFNPLI | Pool of 99 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 233 | MoTif 233 EBV (EBNA3a) | MDKDRPGPPALDDNMEEEVPSTSVVQEQVSAGDWENVLIELSDSSSEKEAEDAHLEPAQ KGTKRKRVDHDAGGSAPARPMLPPQPDLPGREAILRRFPLDLRTLLQAIGAAATRIDTRAID QFFGSQISNTEMYIMYAMAIRQAIRDRRRNPASRRDQAKWRLQTLAAGWPMGYQAYSS WMYSYTDHQTTPTFVHLQATLGCTGGRRCHVTFSAGTFKLPRCTPGDRQWLYVQSSVGN IVQSCNPRYSIFFDYMAIHRSLTKIWEEVLTPDQRVSFMEFLGFLQRTDLSYIKSFVSDALGTT SIQTPWIDDNPSTETAQAWNAGFLRGRAYGIDLLRTEGEHVEGATGETREESEDTESDGDD EDLPCIVSRGGPKVKRPPIFIRRLHRLLLMRAGKRTEQGKEVLEKARGSTYGTPRPPVPKPRP EVPQSDETATSHGSAQVPEPPTIHLAAQGMAYPLHEQHGMAPCPVAQAPPTPLPPVSPG DQLPGVFSDGRVACAPVPAPAGPIVRPWEPSLTQAAGQAFAPVRPQHMPVEPVPVPTVA LERPVYPKPVRPAPPKIAMQGPGETSGIRRARERWRPAPWTPNPPRSPSQMSVRDRLARL RAEAQVKQASVEVQPPQLTQVSPQQPMEGPLVPEQQMFPGAPFSQVADVVRAPGVPAM QPQYFDLPLIQPISQGAPVAPLRASMGPVPPVPATQPQYFDIPLTEPINQGASAAHFLPQQP MEGPLVPEQWMFPGAALSQSVRPGVAQSQYFDLPLTQPINHGAPAAHFLHQPPMEGPW VPEQWMFQGAPPSQGTDVVQHQLDALGYTLHGLNHPGVPVSPAVNQYHLSQAAFGLPI DEDESGEGSDTSEPCEALDLSIHGRPCPQAPEWPVQEEGGQDATEVLDLSIHGRPRPRTPE WPVQGEGGQNVTGPETRRVVVSAVVHMCQDDEFPDLQDPPDEA | Pool of 234 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 234 | MoTif 234 EBV (EBNA3b) | MKKAWLSRAQQADAGGASGSEDPPDYGDQGNVQQVGSDPISPAIGPFELSAASEDDPQ SGPVEENLDAAAREEEEPDEQEHNGGDDPLEVHTRQPRFVDVNPTQAPVIQLVHAVYDS MLQSDLRSLGSLFLEQNLNIEEFIWMCMTVRHRCQAIRQKPLPIDKQRRWKLLSPYRTWR MGYRTQTLNVNSFETGGDKVHPLLVTATLGCEEGLRHAITYSAGIVQLPRMSDQNQKIETA FLMARRARSLSAERYTLFFDLVSSGNTLYAIWIGLGTRNRVAFVEFVGWLCKKDHTHIREWF RQCTGRPSPSKPWMRAHPVAVPYDDPLTSEETDLAYARGLAMSIEAARLPDDPIIVEDDDE SEEIEDKCDKDEEESGTEDVTSIPQTLPHSPTVYGRPSVFYRKPDTKSTKKCRAIVTDLSIIKVIE DEHRKKKTARTEQPRAKPDSPAPTVVLRRPPTQKVTGPAGSLSVQAQLEPWQPLSWPHET RVILHGPPTQGDQAHGSMLDLLEKDDQHMEQQVMATLLPPEPHQPRSGRRAPCVYTAD LDIESDEPATSEPVLDQLLPAPGLGPLAIQPLTSPTTSQLRSSAPSHAQTPWPVTHPSQTPGG PTTQSLAPETEAPRQWPMPLRPIPLHPLRMQPISFNPAVRPTPHQPPQVEPTFYQSTWVKP PQQYQPQMGHIPYQPRPTGHSTMLRPQWAPTTMQPPPRAPTPMPPPQGPPTAMQRPQ GAPTPMPPPQGPPTAMQRPRGAPTPMPPPQGPPTAMQLSPRALTGQKGPAKHILRQLLTG GVKSGRPSLKFKAALERQAAAGLRPSPGSGTGAKIVQAPVFYPPVLQPIQVMWQVGSSKAV AASTVTQAPTEYTGERRLGGPMSPTDIPPSKRVKKKAYPERKTPHGGPSHSSTVMWENVSQ GQQQTLECGGTDKQERNMLGMGDIAVSSPSSSETSNDE | Pool of 234 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 235 | MoTif 235 EBV (LMP1) | MEHDLERGPPGPRRPPRGPPLSSSLGLALLLLLLALLFWLYIVMSDWTGGALLVLYSFALMLII IILIIFIFRRDLLCPLGALCILLLMITLLLIALWNLHGQALFLGIVLFIFGCLLVLGIWIYLLEMLWRL GATIWQLLAFFLAFFLDLILLIIALYLQQNWWTLLVDLLWLLLFLAILIWMYYHGQRHSDEHH HDDSLPHPQQATDDSGHESDSNSNEGRHHLLVSGAGDGPPLCSQNLGAPGGGPDNGPQ DPDNTDDNGPQDPDNTDDNGPHDPLPQDPDNTDDNGPQDPDNTDDNGPHDPLPHSP SDSAGNDGGPPQLTEEVENKGGDQGPPLMTDGGGGHSHDSGHGGGDPHLPTLLLGSSGS GGDDDDPHGPVQLSYYD | Pool of 94 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 236 | MoTif 236 EBV (LMP2) | MGSLEMVPMGAGPPSPGGDPDGYDGGNNSQYPSASGSSGNTPTPPNDEERESNEEPPPP YEDPYWGNGDRHSDYQPLGTQDQSLYLGLQHDGNDGLPPPPYSPRDDSSQHIYEEAGRGS MNPVCLPVIVAPYLFWLAAIAASCFTASVSTVVTATGLALSLLLLAAVASSYAAAQRKLLTPVT VLTAVVTFFAICLTWRIEDPPFNSLLFALLAAAGGLQGIYVLVMLVLLILAYRRRWRRLTVCGGI MFLACVLVLIVDAVLQLSPLLGAVTVVSMTLLLLAFVLWLSSPGGLGTLGAALLTLAAALALLA SLILGTLNLTTMFLLMLLWTLVVLLICSSCSSCPLSKILLARLFLYALALLLLASALIAGGSILQTNF KSLSSTEFIPNLFCMLLLIVAGILFILAILTEWGSGNRTYGPVFMCLGGLLTMVAGAVWLTVMS NTLLSAWILTAGFLIFLIGFALFGVIRCCRYCCYYCLTLESEERPPTPYRNTV | Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 237 | MoTif 237 HCMVA (UL32) | MSLQFIGLQRRDVVALVNFLRHLTQKPDVDLEAHPKILKKCGEKRLHRRTVLFNELMLWLGYY RELRFHNPDLSSVLEEFEVRCVAVARRGYTYPFGDRGKARDHLAVLDRTEFDTDVRHDAEIVE RALVSAVILAKMSVRETLVTAIGQTEPIAFVHLKDTEVQRIEENLEGVRRNMFCVKPLDLNLDR HANTALVNAVNKLVYTGRLIMNVRRSWEELERKCLARIQERCKLLVKELRMCLSFDSNYCRNI LKHAVENGDSADTLLELLIEDFDIYVDSFPQSAHTFLGARSPSLEFDDDANLLSLGGGSAFSSV PKKHVPTQPLDGWSWIASPWKGHKPFRFEAHGSLAPAAEAHAARSAAVGYYDEEEKRRERQ KRVDDEVVQREKQQLKAWEERQQNLQQRQQQPPPPARKPSASRRLFGSSADEDDDDDDD EKNIFTPIKKPGTSGKGAASGGGVSSIFSGLLSSGSQKPTSGPLNIPQQQQRHAAFSLVSPQVT KASPGRVRRDSAWDVRPLTETRGDLFSGDEDSDSSDGYPPNRQDPRFTDTLVDITDTETSAK PPVTTAYKFEQPTLTFGAGVNVPAGAGAAILTPTPVNPSTAPAPAPTPTFAGTQTPVNGNSPW APTAPLPGDMNPANWPRERAWALKNPHLAYNPFRMPTTSTASQNTVSTTPRRPSTPRAAV TQTASRDAADEVWALRDQTAESPVEDSEEEDDDSSDTGSVVSLGHTTPSSDYNNDVISPPSQ TPEQSTPSRIRKAKLSSPMTTTSTSQKPVLGKRVATPHASARAQTVTSTPVQGRLEKQVSGTP STVPATLLQPQPASSKTTSSRNVTSGAGTSSASSARQPSASASVLSPTEDDVVSPATSPLSMLS SASPSPAKSAPPSPVKGRGSRVGVPSLKPTLGGKAVVGRPPSVPVSGSAPGRLSGSSRAASTT PTYPAVTTVYPPSSTAKSSVSNAPPVASPSILKPGASAALQSRRSTGTAAVGSPVKSTTGMKTV AFDLSSPQKSGTGPQPGSAGMGGAKTPSDAVQNILQKIEKIKNTEE | Pool of 260 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 238 | MoTif 238 HCMVA (UL40) | MNKFSNTRIGFTCAVMAPRTLILTVGLLCMRIRSLLCSPAETTVTTAAVTSAHGPLCPLVFQGW AYAVYHQGDMALMTLDVYCCRQTSNNTVVAFSHHPADNTLLIEVGNNTRRHVDGISCQDH FRAQHQDCPAQTVHVRGVNESAFGLTHLQSCCLNEHSQLSERVAYHLKLRPATFGLETWAMY TVGILALGSFSSFYSQIARSLGVLPNDHHYALKKA | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 239 | MoTif 239 HCMVA (UL55) | MESRIWCLVVCVNLCIVCLGAAVSSSSTSHATSSTHNGSHTSRTTSAQTRSVYSQHVTSSEAVS HRANETIYNTTLKYGDVVGVNTTKYPYRVCSMAQGTDLIRFERNIICTSMKPINEDLDEGIMVV YKRNIVAHTFKVRVYQKVLTFRRSYAYIYTTYLLGSNTEYVAPPMWEIHHINKFAQCYSSYSRVIG GTVFVAYHRDSYENKTMQLIPDDYSNTHSTRYVTVKDQWHSRGSTWLYRETCNLNCMLTITT ARSKYPYHFFATSTGDVVYISPFYNGTNRNASYFGENADKFFIFPNYTIVSDFGRPNAAPETHRL VAFLERADSVISWDIQDEKNVTCQLTFWEASERTIRSEAEDSYHFSSAKMTATFLSKKQEVNMS DSALDCVRDEAINKLQQIFNTSYNQTYEKYGNVSVFETSGGLVVFWQGIKQKSLVELERLANRS SLNITHRTRRSTSDNNTTHLSSMESVHNLVYAQLQFTYDTLRGYINRALAQIAEAWCVDQRRT LEVFKELSKINPSAILSAIYNKPIAARFMGDVLGLASCVTINQTSVKVLRDMNVKESPGRCYSRP VVIFNFANSSYVQYGQLGEDNEILLGNHRTEECQLPSLKIFIAGNSAYEYVDYLFKRMIDLSSISTV DSMIALDIDPLENTDFRVLELYSQKELRSSNVFDLEEIMREFNSYKQRVKYVEDKVVDPLPPYLK GLDDLMSGLGAAGKAVGVAIGAVGGAVASVVEGVATFLKNPFGAFTIILVAIAVVIITYLIYTRQR RLCTQPLQNLFPYLVSADGTTVTSGSTKDTSLQAPPSYEESVYNSGRKGPGPPSSDASTAAPPY TNEQAYQMLLALARLDAEQRAQQNGTDSLDGQTGTQDKGQKPNLLDRLRHRKNGYRHLKD SDEEENV | Pool of 224 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 240 | MoTif 240 HCV (Capsid Protein) Ultra | see additional product documentation | Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Hepatitis, Infection, Sequence diversity |
| 241 | MoTif 241 Tai Forest Ebolavirus (NP) | MESRAHKAWMTHTASGFETDYHKILTAGLSVQQGIVRQRVIQVHQVTNLEEICQLIIQAFEAGV DFQESADSFLLMLCLHHAYQGDYKQFLESNAVKYLEGHGFRFEVRKKEGVKRLEELLPAASSGK SIRRTLAAMPEEETTEANAGQFLSFASLFLPKLVVGEKACLEKVQRQIQVHSEQGLIQYPTAWQ SVGHMMVIFRLMRTNFLIKFLLIHQGMHMVAGHDANDAVIANSVAQARFSGLLIVKTVLDHI LQKTEHGVRLHPLARTAKVKNEVNSFKAALSSLAQHGEYAPFARLLNLSGVNNLEHGLFPQLS AIALGVATAHGSTLAGVNVGEQYQQLREAATEAEKQLQKYAESRELDHLGLDDQEKKILKDFH QKKNEISFQQTTAMVTLRKERLAKLTEAITSTSLLKTGKQYDDDNDIPFPGPINDNENSEQQDD DPTDSQDTTIPDIIVDPDDGRYNNYGDYPSETANAPEDLVLFDLEDGDEDDHRPSSSSENNNK HSLTGTDSNKTSNWNRNPTNMPKKDSTQNNDNPAQRAQEYARDNIQDTPTPHRALTPISEE TGSNGHNEDDIDSIPPLESDEENNTETTITTTKNTTAPPAPVYRSNSEKEPLPQEKSQKQPNQV SGSENTDNKPHSEQSVEEMYRHILQTQGPFDAILYYYMMTEEPIVFSTSDGKEYVYPDSLEGEH PPWLSEKEALNEDNRFITMDDQQFYWPVMNHRNKFMAILQHHK | Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Ebola, Infection |
| 242 | MoTif 242 HCMVA (UL48)_ 2 subpools | MKVTQASCHQGDIARFGARAGNQCVCNGIMFLHALHLGGTSAVLQTEALDAIMEEGARLD ARLERELQKKLPAGGRLPVYRLGDEVPRRLESRFGRTVHALSRPFNGTTETCDLDGYMCPGIF DFLRYAHAKPRPTYVLVTVNSLARAVVFTEDHMLVFDPHSSAECHNAAVYHCEGLHQVLMV LTGFGVQLSPAFYYEALFLYMLDVATVPEAEIAARLVSTYRDRDIDLTGVVRESADTAATTTTAA PSLPPLPDPIVDPGCPPGVAPSIPVYDPSSSPKKTPEKRRKDLSGSKHGGKKKPPSTTSKTLATA SSSPSAIAAASSSSAVPPSYSCGEGALPALGRYQQLVDEVEQELKALTLPPLPANTSAWTLHAA GTESGANAATATAPSFDEAFLTDRLQQLIIHAVNQRSCLRRPCGPQSAAQQAVRAYLGLSKKL DAFLLNWLHHGLDLQRMHDYLSHKTTKGTYSTLDRALLEKMQVVFDPYGRQHGPALIAWVE EMLRYVESKPTNELSQRLQRFVTKRPMPVSDSFVCLRPVDFQRLTQVIEQRRRVLQRQREEYH GVYEHLAGLITSIDIHDLDASDLNRREILKALQPLDDNAKQELFRLGNAKMLELQMDLDRLSTQ LLTRVHNHILNGFLPVEDLKQMERVVEQVLRLFYDLRDLKLCDGSYEEGFVVIREQLSYLMTGT VRDNVPLLQEILQLRHAYQQATQQNEGRLTQIHDLLHVIETLVRDPGSRGSALTLALVQEQLAQ LEALGGLQLPEVQQRLQNAQLALSRLYEEEEETQRFLDGLSYDDPPNEQTIKRHPQLREMLRRD EQTRLRLINAVLSMFHTLVMRLARDESPRPTFFDAVSLLLQQLPPDSHEREDLRAANATYAQM VKKLEQIEKAGTGASEKRFQALRELVYFFRNHEYFFQHMVGRLGVGPQVTELYERYQHEMEEQ HLERLEREWQEEAGKLTVTSVEDVQRVLARAPSHRVMHQMQQTLTTKMQDFLDKEKRKQEE QQRQLLDGYQKKVQQDLQRVVDAVKGEMLSTIPHQPLEATLELLLGLDQRAQPLLDKFNQDL LSALQQLSKKLDGRINECLHGVLTGDVERRCHPHREAAMQTQASLNHLDQILGPQLLIHETQQ ALQHAVHQAQFIEKCQQGDPTTAITGSEFEGDFARYRSSQQKMEEQLQETRQQMTETSERLDR SLRQDPGSSSVTRVPEKPFKGQELAGRITPPPADFQQPVFKTLLDQQADAARKALSDEADLLN QKVQTQLRQRDEQLSTAQNLWTDLVTRHKMSGGLDVTTPDAKALMEKPLETLRELLGKATQQ LPYLSAERTVRWMLAFLEEALAQITADPTHPHHGSRTHYRNLQQQAVESAVTLAHQIEQNAAC ENFIAQHQEATANGASTPRVDMVQAVEAVWQRLEPGRVAGGAARHQKVQELLQRLGQTLGD LELQETLATEYFALLHGIQTFSYGLDFRSQLEKIRDLRTRFAELAKRRGTRLSNEGVLPNPRKPQAT TSLGAFTRGLNALERHVQLGHQYLLNKLNGSSLVYRLEDIPSVLPATHETDPALIMRDRLRRLCFA RHHDTFLEVVDVFGMRQIVTQAGEPIHLVTDYGNVAFKYLALRDDGRPLAWRRRCSGGGLKN VVTTRYKAITVAVAVCQTLRTFWPQISQYDLRPYLTQHQSHTHPAETHTLHNLKLFCYLVSTAWH QRIDTQQELTAADRVGSGEGGDVGEQRPGRGTVLRLSLQEFCVLIAALYPEYIYTVLKYPVQMSL PSLTAHLHQDVIHAVVNNTHKMPPDHLPEQVKAFCITPTQWPAMQLNKLFWENKLVQQLCQ VGPQKSTPPLGKLWLYAMATLVFPQDMLQCLWLELKPQYAETYASVSELVQTLFQIFTQQCEMV TEGYTQPQLPTGEPVLQMIRVPRQDTTTTDTNTTTEPGLLDVFIQTETALDYALGSWLFGIPVCLG VHVADLLKGQRILVARHLEYTSRDRDFLRIQRSRDLNLSQLLQDTWTETPLEHCWLQAQIRRLR DYLRFPTRLEFIPLVIYNAQDHTVVRVLRPPSTFEQDHSRLVLDEAFPTFPLYDQDDNSSADNIAA SGAAPTPPVPFNRVPVNIQFLRENPPPIARVQQPPRRHRHRAAAAADDDGQIDHVQDDTSRT ADSALVSTAFGGSVFQENRLGETPLCRDELVAVAPGAASTSFASPPITVLTQNVLSALEILRLVRLD LRQLAQSVQDTIQHMRFLYLL | Pool of 562 (281 + 281) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 243 | MoTif 243 Human Adenovirus 5 (Penton Protein) | MRRAAMYEEGPPPSYESVVSAAPVAAALGSPFDAPLDPPFVPPRYLRPTGGRNSIRYSELAP LFDTTRVYLVDNKSTDVASLNYQNDHSNFLTTVIQNNDYSPGEASTQTINLDDRSHWGGD LKTILHTNMPNVNEFMFTNKFKARVMVSRLPTKDNQVELKYEWVEFTLPEGNYSETMTIDL MNNAIVEHYLKVGRQNGVLESDIGVKFDTRNFRLGFDPVTGLVMPGVYTNEAFHPDIILLPG CGVDFTHSRLSNLLGIRKRQPFQEGFRITYDDLEGGNIPALLDVDAYQASLKDDTEQGGGGA GGSNSSGSGAEENSNAAAAAMQPVEDMNDHAIRGDTFATRAEEKRAEAEAAAEAAAPAA QPEVEKPQKKPVIKPLTEDSKKRSYNLISNDSTFTQYRSWYLAYNYGDPQTGIRSWTLLCTPD VTCGSEQVYWSLPDMMQDPVTFRSTRQISNFPVVGAELLPVHSKSFYNDQAVYSQLIRQFT SLTHVFNRFPENQILARPPAPTITTVSENVPALTDHGTLPLRNSIGGVQRVTITDARRRTCPYV YKALGIVSPRVLSSRTF | Pool of 140 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection, Respiratory infection |
| 244 | MoTif 244 HRSVB (Major surface glycoprotein G) | MSKHKNQRTARTLEKTWDTLNHLIVISSCLYRLNLKSIAQIALSVLAMIISTSLIIAAIIFIISANH KVTLTTVTVQTIKNHTEKNITTYLTQVPPERVSSSKQPTTTSPIHTNSATTSPNTKSETHHTTA QTKGRTTTSTQTNKPSTKPRLKNPPKKPKDDYHFEVFNFVPCSICGNNQLCKSICKTIPSNKP KKKPTIKPTNKPTTKTTNKRDPKTPAKTTKKETTTNPTKKPTLTTTERDTSTSQSTVLDTTTLEH TIQQQSLHSTTPENTPNSTQTPTASEPSTSNSTQNTQSHA | Pool of 72 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Bronchiolitis, Infection, Respiratory infection |
| 245 | MoTif 245 Aspergillus fumigatus (Glucanosyltransferase gel1) | MKASAVTAALAVGASTVLAAPSIKARDDVTPITVKGNAFFKGAERFYIRGVDYQPGGSSDL ADPIADADGCKRDIAKFKELGLNTIRVYSVDNSKNHDECMNALADAGIYLVLDVNTPKYSI NRAKPKESYNDVYLQYIFATVDAFAGYKNTLAFFSGNEVINDGPSSSAAPYVKAVTRDLRQ YIRSRKYREIPVGYSAADIDTNRLQMAQYMNCGSDDERSDFFAFNDYSWCDPSSFKTSGW DQKVKNFTGYGLPLFLSEYGCNTNKRQFQEVSSLYSTDMTGVYSGGLVYEYSQEASNYGLV EISGNNVKELPDFDALKTAFEKTSNPSGDGNYNKTGGANPCPAKDAPNWDVDNDALPAIP EPAKKYMTEGAGKGPGFAGPGSQDRGTQSTATAEPGSGSATGSSSSGTSTSSKGAAAGLTVP SLTMAPVVVGAVTLLSTVFGAGLVLL
| Pool of 111 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Allergy, Infection, Respiratory infection |
| 246 | MoTif 246 EBV (GP350/GP340) | MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDL DFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLE SVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLS LPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSP VATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDM PTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSG CENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLNTTGFADP NTTTGLPSSTHVPTNLTAPASTGPTVSTADVTSPTPAGTTSGASPVTPSPSPWDNGTESKAPD MTSSTSPVTTPTPNATSPTPAVTTPTPNATSPTPAVTTPTPNATSPTLGKTSPTSAVTTPTPNAT SPTLGKTSPTSAVTTPTPNATSPTLGKTSPTSAVTTPTPNATGPTVGETSPQANATNHTLGGTS PTPVVTSQPKNATSAVTTGQHNITSSSTSSMSLRPSSNPETLSPSTSDNSTSHMPLLTSAHPTG GENITQVTPASISTHHVSTSSPAPRPGTTSQASGPGNSSTSTKPGEVNVTKGTPPQNATSPQA PSGQKTAVPTVTSTGGKANSTTGGKHTTGHGARTSTEPTTDYGGDSTTPRPRYNATTYLPPST SSKLRPRWTFTSPPVTTAQATVPVPPTSQPRFSNLSMLVLQWASLAVLTLLLLLVMADCAFRR NLSTSHTYTTPPYDDAETYV | Pool of 224 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 247 | MoTif 247 Influenza A (MP1 /California (H1N1)) | MSLLTEVETYVLSIIPSGPLKAEIAQRLESVFAGKNTDLEALMEWLKTRPILSPLTKGILGFVFTLTV PSERGLQRRRFVQNALNGNGDPNNMDRAVKLYKKLKREITFHGAKEVSLSYSTGALASCMGL IYNRMGTVTTEAAFGLVCATCEQIADSQHRSHRQMATTTNPLIRHENRMVLASTTAKAMEQ MAGSSEQAAEAMEVANQTRQMVHAMRTIGTHPSSSAGLKDDLLENLQAYQKRMGVQMQRFK | Pool of 61 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 248 | MoTif 248 Lassa virus (Pre-glycoprotein complex) | MGQIVTFFQEVPHVIEEVMNIVLIALSVLAVLKGLYNFATCGLVGLVTFLLLCGRSCTTSLYKGVYEL QTLELNMETLNMTMPLSCTKNNSHHYIMVGNETGLELTLTNTSIINHKFCNLSDAHKKNLYDHA LMSIISTFHLSIPNFNQYEAMSCDFNGGKISVQYNLSHSYAGDAANHCGTVANGVLQTFMRMA WGGSYIALDSGRGNWDCIMTSYQYLIIQNTTWEDHCQFSRPSPIGYLGLLSQRTRDIYISRRLLGT FTWTLSDSEGKDTPGGYCLTRWMLIEAELKCFGNTAVAKCNEKHDEEFCDMLRLFDFNKQAIQRL KAEAQMSIQLINKAVNALINDQLIMKNHLRDIMGIPYCNYSKYWYLNHTTTGRTSLPKCWLVSN GSYLNETHFSDDIEQQADNMITEMLQKEYMERQGKTPLGLVDLFVFSTSFYLISIFLHLVKIPTHRH IVGKSCPKPHRLNHMGICSCGLYKQPGVPVKWKR | Pool of 120 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Fever, Hemorrhagic fever, Infection, Lassa fever |
| 249 | MoTif 249 Human Adenovirus 26 (Penton Protein) | MRRAVVSSSPPPSYESVMAQATLEVPFVPPRYMAPTEGRNSIRYSELAPQYDTTRVYLVDNKSA DIASLNYQNDHSNFLTTVVQNNDFTPAEASTQTINFDERSRWGGDLKTILHTNMPNVNEYMFT SKFKARVMVSRKHPEGVVETDLSQDKLEYEWFEFTLPEGNFSETMTIDLMNNAILENYLQVGRQ NGVLESDIGVKFDSRNFKLGWDPVTKLVMPGVYTYEAFHPDVVLLPGCGVDFTESRLSNLLGIRK KQPFQEGFRIMYEDLEGGNIPALLDVPKYLESKKKVEDETKNAAAATADTTTRGDTFATPAQETAA DKKVEVLPIEKDESGRSYNLIQGTHDTLYRSWYLSYTYGDPEKGVQSWTLLTTPDVTCGAEQVYW SLPDLMQDPVTFRSTQQVSNYPVVGAELMPFRAKSFYNDLAVYSQLIRSYTSLTHVFNRFPDNQI LCRPPAPTITTVSENVPALTDHGTLPLRSSIRGVQRVTVTDARRRTCPYVYKALGIVAPRVLSSRTF | Pool of 127 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection |
| 250 | MoTif 250 Vaccinia virus (MVA093L) | MAAVKTPVIVVPVIDRPPSETFPNVHEHINDQKFDDVKDNEVMPEKRNVVVVKDDPDHYKDY AFIQWTGGNIRNDDKYTHFFSGFCNTMCTEETKRNIARHLALWDSNFFTELENKKVEYVVIVEN DNVIEDITFLRPVLKAMHDKKIDILQMREIITGNKVKTELVMDKNHAIFTYTGGYDVSLSAYIIRVT TALNIVDEIIKSGGLSSGFYFEIARIENEMKINRQILDNAAKYVEHDPRLVAEYRFENMKPNFWSR IGTAAAKRYPGVMYAFTTPLISFFGLFDINVIGLIVILFIMFMLIFNVKSKLLWFLTGTFVTAFI | Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 251 | MoTif 251 Vaccinia virus (MVA105L) | MPQQLSPINIETKKAISNARLKPLDIHYNESKPTTIQNTGKLVRINFKGGYISGGFLPNEYVLSSLR IYWGKEDDYGSNHLIDVYKYSGEINLVHWNKKKYSSYEEAKKHDDGLIIISIFLQVSDHKNVYFQ KIVNQLDSIRSTNTSAPFDSVFYLDNLLPSKLDYFTYLGTTINHSADAVWIIFPTPINIHSDQLSKF RTLLSSSNHDGKPHYITENYRNPYKLNDDTQVYYSGEIIRAATTSPARENYFMRWLSDLRETCFS YYQKYIEGNKTFAIIAIVFVFILTAILFFMSQRYSREKQN | Pool of 74 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 252 | MoTif 252 Vaccinia virus (MVA189R) | MKPKVNNIGNTPLHNYVSQYDITLIPHPQPIKKWKLKPSISINGYRSTFTMAFPCAQFRPCHC HATKDSLNTVADVRHCLTEYILWVSHRWTHRESAGSLYRLLISFRTDATELFGGELKDSLPWRSL NDSMKTAEELRAIIGLCTQSAIVSGRVFNDKYIDILLMLRKILNENDYLTLLDHIRTAKY | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 253 | MoTif 253 AAV6 (Capsid protein VP1) | MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNGL DKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRAVFQ AKKRVLEPFGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQPAKKRLNFGQTGDSESVPD PQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGVGNASGNWHCDSTWLGDRVITTST RTWALPTYNNHLYKQISSASTGASNDNHYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNW GFRPKRLNFKLFNIQVKEVTTNDGVTTIANNLTSTVQVFSDSEYQLPYVLGSAHQGCLPPFPAD VFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFEDVPFHSSYAHSQSLDR LMNPLIDQYLYYLNRTQNQSGSAQNKDLLFSRGSPAGMSVQPKNWLPGPCYRQQRVSKTKT DNNNSNFTWTGASKYNLNGRESIINPGTAMASHKDDKDKFFPMSGVMIFGKESAGASNTAL DNVMITDEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVHVMGALPGMVWQDRDVYLQG PIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPANPPAEFSATKFASFITQYSTGQVSV EIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDNNGLYTEPRPIGTRYLTRPL | Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Gene therapy, Infection |
| 254 | MoTif 254 SARS-CoV-2 (S-RBD C.37 / Lambda) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGV SPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKV GGNYNYQYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYSPLQSYGFQPTNGVGYQPY RVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 255 | MoTif 255 Human (KRAS) | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEE YSAMRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTV DTKQAQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Leukemia |
| 256 | MoTif 256 SARS-CoV-2 (S-RBD HK.3 + JG.3) | RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGV SPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKP SGNYNYLYRFLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPY RVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 257 | MoTif 257 Pan-SARS-CoV-2 Select | see additional product documentation | Virus-specific pool of 103 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 258 | MoTif 258 Influenza A (HA /Brisbane (H1N1)) | MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKG IAPLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSF ERFEIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLV LWGVHHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPG DTIIFEANGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTIG ECPKYVRSAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGY AADQKSTQNAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYN AELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTY DYPKYSEESKLNREKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 259 | MoTif 259 Influenza A (NP/AnnArbor (H2N2) | MASQGTKRSYEQMETDGERQNANEIRASVGKMIGGIGRFYIQMCTELKLSDYEGRLIQNSL TIERMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYKRVDGKWMRELVLYDKEEIRRIWRQA NNGDDATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGA AVKGVGTMVMELIRMIKRGINDRNFWRGENGRKTRNAYERMCNILKGKFQTAAQRAMMD QVRESRNPGNAEIEDLIFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEKEGYSLVGIDPFK LLQNSQVYSLIRPNENPAHKSQLVWMACNSAAFEDLRVSSFIRGTKVIPRGKLSTRGVQIASN ENMDTMGSSTLELRSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFDKPTIMAAF TGNAEGRTSDMRAEIIRMMEGAKPEEVSFQGRGVFELSDEKATNPIVPSFDMSNEGSYFFGD NAEEYDN | Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 260 | MoTif 260 Vaccinia virus (MVA093L) | MAAVKTPVIVVPVIDRPPSETFPNVHEHINDQKFDDVKDNEVMPEKRNVVVVKDDPDHY KDYAFIQWTGGNIRNDDKYTHFFSGFCNTMCTEETKRNIARHLALWDSNFFTELENKKVEYV VIVENDNVIEDITFLRPVLKAMHDKKIDILQMREIITGNKVKTELVMDKNHAIFTYTGGYDVSL SAYIIRVTTALNIVDEIIKSGGLSSGFYFEIARIENEMKINRQILDNAAKYVEHDPRLVAEYRFEN MKPNFWSRIGTAAAKRYPGVMYAFTTPLISFFGLFDINVIGLIVILFIMFMLIFNVKSKLLWFLT GTFVTAFI | Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 261 | MoTif 261 Vaccinia virus (MVA093L) | MAAVKTPVIVVPVIDRPPSETFPNVHEHINDQKFDDVKDNEVMPEKRNVVVVKDDPDHY KDYAFIQWTGGNIRNDDKYTHFFSGFCNTMCTEETKRNIARHLALWDSNFFTELENKKVEY VVIVENDNVIEDITFLRPVLKAMHDKKIDILQMREIITGNKVKTELVMDKNHAIFTYTGGYDV SLSAYIIRVTTALNIVDEIIKSGGLSSGFYFEIARIENEMKINRQILDNAAKYVEHDPRLVAEYRF ENMKPNFWSRIGTAAAKRYPGVMYAFTTPLISFFGLFDINVIGLIVILFIMFMLIFNVKSKLLW FLTGTFVTAFI | Pool of 79 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 262 | MoTif 262 Vaccinia virus (MVA105L) | MPQQLSPINIETKKAISNARLKPLDIHYNESKPTTIQNTGKLVRINFKGGYISGGFLPNEYVL SSLRIYWGKEDDYGSNHLIDVYKYSGEINLVHWNKKKYSSYEEAKKHDDGLIIISIFLQVSDH KNVYFQKIVNQLDSIRSTNTSAPFDSVFYLDNLLPSKLDYFTYLGTTINHSADAVWIIFPTPIN IHSDQLSKFRTLLSSSNHDGKPHYITENYRNPYKLNDDTQVYYSGEIIRAATTSPARENYFMR WLSDLRETCFSYYQKYIEGNKTFAIIAIVFVFILTAILFFMSQRYSREKQN | Pool of 74 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 263 | MoTif 263 Vaccinia virus (MVA189R) | MKPKVNNIGNTPLHNYVSQYDITLIPHPQPIKKWKLKPSISINGYRSTFTMAFPCAQFRPC HCHATKDSLNTVADVRHCLTEYILWVSHRWTHRESAGSLYRLLISFRTDATELFGGELKDSLP WRSLNDSMKTAEELRAIIGLCTQSAIVSGRVFNDKYIDILLMLRKILNENDYLTLLDHIRTAKY | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Small Pox, Small Pox Vaccine |
| 264 | MoTif 264 AAV6 (Capsid protein VP1) | MAADGYLPDWLEDNLSEGIREWWDLKPGAPKPKANQQKQDDGRGLVLPGYKYLGPFNG LDKGEPVNAADAAALEHDKAYDQQLKAGDNPYLRYNHADAEFQERLQEDTSFGGNLGRA VFQAKKRVLEPFGLVEEGAKTAPGKKRPVEQSPQEPDSSSGIGKTGQQPAKKRLNFGQTGDS ESVPDPQPLGEPPATPAAVGPTTMASGGGAPMADNNEGADGVGNASGNWHCDSTWLG DRVITTSTRTWALPTYNNHLYKQISSASTGASNDNHYFGYSTPWGYFDFNRFHCHFSPRD WQRLINNNWGFRPKRLNFKLFNIQVKEVTTNDGVTTIANNLTSTVQVFSDSEYQLPYVLGS AHQGCLPPFPADVFMIPQYGYLTLNNGSQAVGRSSFYCLEYFPSQMLRTGNNFTFSYTFED VPFHSSYAHSQSLDRLMNPLIDQYLYYLNRTQNQSGSAQNKDLLFSRGSPAGMSVQPKN WLPGPCYRQQRVSKTKTDNNNSNFTWTGASKYNLNGRESIINPGTAMASHKDDKDKFFP MSGVMIFGKESAGASNTALDNVMITDEEEIKATNPVATERFGTVAVNLQSSSTDPATGDVH VMGALPGMVWQDRDVYLQGPIWAKIPHTDGHFHPSPLMGGFGLKHPPPQILIKNTPVPA NPPAEFSATKFASFITQYSTGQVSVEIEWELQKENSKRWNPEVQYTSNYAKSANVDFTVDN NGLYTEPRPIGTRYLTRPL | Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Gene therapy, Infection |
| 265 | MoTif 265 SARS-CoV-2 (S-RBD C.37 / Lambda) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCY GVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNL DSKVGGNYNYQYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYSPLQSYGFQPTNG VGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 266 | MoTif 266 Human (KRAS) | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSA MRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQ AQDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Leukemia |
| 267 | MoTif 267 SARS-CoV-2 (S-RBD HK.3 + JG.3) | RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSP TKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGN YNYLYRFLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVL SFELLHAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 268 | MoTif 268 Pan-SARS-CoV-2 Select | see additional product documentation | Virus-specific pool of 103 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 269 | MoTif 269 Influenza A (HA /Brisbane (H1N1)) | MKVKLLVLLCTFTATYADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLENSHNGKLCLLKGIA PLQLGNCSVAGWILGNPECELLISKESWSYIVEKPNPENGTCYPGHFADYEELREQLSSVSSFERF EIFPKESSWPNHTVTGVSASCSHNGESSFYRNLLWLTGKNGLYPNLSKSYANNKEKEVLVLWGV HHPPNIGDQKALYHTENAYVSVVSSHYSRKFTPEIAKRPKVRDQEGRINYYWTLLEPGDTIIFEA NGNLIAPRYAFALSRGFGSGIINSNAPMDKCDAKCQTPQGAINSSLPFQNVHPVTIGECPKYVR SAKLRMVTGLRNIPSIQSRGLFGAIAGFIEGGWTGMVDGWYGYHHQNEQGSGYAADQKSTQ NAINGITNKVNSVIEKMNTQFTAVGKEFNKLERRMENLNKKVDDGFIDIWTYNAELLVLLENER TLDFHDSNVKNLYEKVKSQLKNNAKEIGNGCFEFYHKCNDECMESVKNGTYDYPKYSEESKLN REKIDGVKLESMGVYQILAIYSTVASSLVLLVSLGAISFWMCSNGSLQCRICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 270 | MoTif 270 Influenza A (NP/AnnArbor (H2N2) | MASQGTKRSYEQMETDGERQNANEIRASVGKMIGGIGRFYIQMCTELKLSDYEGRLIQNSLTIE RMVLSAFDERRNKYLEEHPSAGKDPKKTGGPIYKRVDGKWMRELVLYDKEEIRRIWRQANNGD DATAGLTHMMIWHSNLNDTTYQRTRALVRTGMDPRMCSLMQGSTLPRRSGAAGAAVKGVGT MVMELIRMIKRGINDRNFWRGENGRKTRNAYERMCNILKGKFQTAAQRAMMDQVRESRNPG NAEIEDLIFLARSALILRGSVAHKSCLPACVYGPAVASGYDFEKEGYSLVGIDPFKLLQNSQVYSLIR PNENPAHKSQLVWMACNSAAFEDLRVSSFIRGTKVIPRGKLSTRGVQIASNENMDTMGSSTLEL RSRYWAIRTRSGGNTNQQRASAGQISVQPTFSVQRNLPFDKPTIMAAFTGNAEGRTSDMRAEII RMMEGAKPEEVSFQGRGVFELSDEKATNPIVPSFDMSNEGSYFFGDNAEEYDN | Pool of 122 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 271 | MoTif 271 Zaire Ebola (GP/Mayinga-76) | MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVG LNLEGNGVATDVPSATKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRG FPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHP LREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYTSGKR SNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTVVSNGAKNISGQSPARTSSDPGT NTTTEDHKIMASENSSAMVQVHSQGREAAVSHLTTLATISTSPQSLTTKPGPDNSTHNTPVYKL DISEATQVEQHHRRTDNDSTASDTPSATTAAGPPKAENTNTSKSTDFLDPATTTSPQNHSETAGN NNTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRTRREAIVNAQPKCNPNLHYWTTQDEGA AIGLAWIPYFGPAAEGIYIEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFL LQRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAG IGVTGVIIAVIALFCICKFVF | Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Ebola, Ebola fever, Infection |
| 272 | MoTif 272 Sudan Ebolavirus (GP/Uganda-00) | MGGLSLLQLPRDKFRKSSFFVWVIILFQKAFSMPLGVVTNSTLEVTEIDQLVCKDHLASTDQLKS VGLNLEGSGVSTDIPSATKRWGFRSGVPPKVVSYEAGEWAENCYNLEIKKPDGSECLPPPPDGVR GFPRCRYVHKAQGTGPCPGDYAFHKDGAFFLYDRLASTVIYRGVNFAEGVIAFLILAKPKETFLQSP PIREAVNYTENTSSYYATSYLEYEIENFGAQHSTTLFKIDNNTFVRLDRPHTPQFLFQLNDTIHLHQ QLSNTTGRLIWTLDANINADIGEWAFWENKKNLSEQLRGEELSFEALSLNETEDDDAASSRITKG RISDRATRKYSDLVPKNSPGMVPLHIPEGETTLPSQNSTEGRRVGVNTQETITETAATIIGTNGNH MQISTIGIRPSSSQIPSSSPTTAPSPEAQTPTTHTSGPSVMATEEPTTPPGSSPGPTTEAPTLTTPEN ITTAVKTVLPQESTSNGLITSTVTGILGSLGLRKRSRRQTNTKATGKCNPNLHYWTAQEQHNAAG IAWIPYFGPGAEGIYTEGLMHNQNALVCGLRQLANETTQALQLFLRATTELRTYTILNRKAIDFLLR RWGGTCRILGPDCCIEPHDWTKNITDKINQIIHDFIDNPLPNQDNDDNWWTGWRQWIPAGIG ITGIIIAIIALLCVCKLLC | Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Ebola, Infection |
| 273 | MoTif 273 Human (hSTAR-ECD) | MKTLLLDLALWSLLFQPGWLSFSSQVSQNCHNGSYEISVLMMGNSAFAEPLKNLEDAVNEGLEI VRGRLQNAGLNVTVNATFMYSDGLIHNSGDCRSSTCEGLDLLRKISNAQRMGCVLIGPSCTYST FQMYLDTELSYPMISAGSFGLSCDYKETLTRLMSPARKLMYFLVNFWKTNDLPFKTYSWSTSYVY KNGTETEDCFWYLNALEASVSYFSHELGFKVVLRQDKEFQDILMDHNRKSNVIIMCGGPEFLYKL KGDRAVAEDIVIILVDLFNDQYFEDNVTAPDYMKNVLVLTLSPGNSLLNSSFSRNLSPTKRDFALA YLNGILLFGHMLKIFLENGENITTPKFAHAFRNLTFEGYDGPVTLDDWGDVDSTMVLLYTSVDTK KYKVLLTYDTHVNKTYPVDMSPTFTWKNSKLPNDITGRGP | Pool of 105 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Diarrhea |
| 274 | MoTif 274 Influenza A (MP1/AnnArbor (H2N2) | MSLLTEVETYVLSIIPSGPLKAEIAQRLEDVFAGKNTDLEALMEWLKTRPILSPLTKGILGFVFTLTV PSERGLQRRRFVQNALNGNGDPNNMDRAVKLYRKLKREITFHGAKEIALSYSAGALASCMGLI YNRMGAVTTEVVLGLVCATCEQIADSQHRSHRQMVTTTNPLIRHENRMVLASTTAKAMEQM AGSSEQAAEAMEVASQARQMVQAMRVIGTHPSSSAGLKNDLLENLQAYQKRMGVQMQRFK | Pool of 61 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 275 | MoTif 275 Influenza A (MP2/AnnArbor (H2N2) | MSLLTEVETPIRNEWGCRCNDSSDPLVVAASIIGILHLILWILDHLFFKCIYRFFKHGLKRGPSTEG VPESMREEYRKEQQSAVDADDSHFVSIELE | Pool of 22 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 276 | MoTif276 Human (Kir4.1) | MTSVAKVYYSQTTQTESRPLMGPGIRRRRVLTKDGRSNVRMEHIADKRFLYLKDLWTTFIDMQ WRYKLLLFSATFAGTWFLFGVVWYLVAVAHGDLLELDPPANHTPCVVQVHTLTGAFLFSLESQTT IGYGFRYISEECPLAIVLLIAQLVLTTILEIFITGTFLAKIARPKKRAETIRFSQHAVVASHNGKPCLMIR VANMRKSLLIGCQVTGKLLQTHQTKEGENIRLNQVNVTFQVDTASDSPFLILPLTFYHVVDETSPL KDLPLRSGEGDFELVLILSGTVESTSATCQVRTSYLPEEILWGYEFTPAISLSASGKYIADFSLFDQVV KVASPSGLRDSTVRYGDPEKLKLEESLREQAEKEGSALSVRISNV | Pool of 92 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | SESAME syndrome |
| 277 | MoTif 277 Zaire Ebola (Virion Spike Glycoprotein) | MGVTGILQLPRDRFKRTSFFLWVIILFQRTFSIPLGVIHNSTLQVSDVDKLVCRDKLSSTNQLRSVG LNLEGNGVATDVPSVTKRWGFRSGVPPKVVNYEAGEWAENCYNLEIKKPDGSECLPAAPDGIRG FPRCRYVHKVSGTGPCAGDFAFHKEGAFFLYDRLASTVIYRGTTFAEGVVAFLILPQAKKDFFSSHP LREPVNATEDPSSGYYSTTIRYQATGFGTNETEYLFEVDNLTYVQLESRFTPQFLLQLNETIYASGKR SNTTGKLIWKVNPEIDTTIGEWAFWETKKNLTRKIRSEELSFTAVSNGPKNISGQSPARTSSDPETN TTNEDHKIMASENSSAMVQVHSQGRKAAVSHLTTLATISTSPQPPTTKTGPDNSTHNTPVYKLDI SEATQVGQHHRRADNDSTASDTPPATTAAGPLKAENTNTSKSADSLDLATTTSPQNYSETAGNN NTHHQDTGEESASSGKLGLITNTIAGVAGLITGGRRTRREVIVNAQPKCNPNLHYWTTQDEGAAI GLAWIPYFGPAAEGIYTEGLMHNQDGLICGLRQLANETTQALQLFLRATTELRTFSILNRKAIDFLL QRWGGTCHILGPDCCIEPHDWTKNITDKIDQIIHDFVDKTLPDQGDNDNWWTGWRQWIPAGI GVTGVIIAVIALFCICKFVF | Pool of 167 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Ebola, Ebola fever, Infection |
| 278 | MoTif 278 Human (Prostate-specific antigen PSA) | MWVPVVFLTLSVTWIGAAPLILSRIVGGWECEKHSQPWQVLVASRGRAVCGGVLVHPQWVLT AAHCIRNKSVILLGRHSLFHPEDTGQVFQVSHSFPHPLYDMSLLKNRFLRPGDDSSHDLMLLRL SEPAELTDAVKVMDLPTQEPALGTTCYASGWGSIEPEEFLTPKKLQCVDLHVISNDVCAQVHPQK VTKFMLCAGRWTGGKSTCSGDSGGPLVCNGVLQGITSWGSEPCALPERPSLYTKVVHYRKWIK DTIVANP | Pool of 63 peptides derived from a peptide scan through Prostate-specific antigen (Swiss-Prot ID: P07288) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Prostate cancer |
| 279 | MoTif 279 Nipah Virus (Fusion Glycoprotein F0) | MVVILDKRCYCNLLILILMISECSVGILHYEKLSKIGLVKGVTRKYKIKSNPLTKDIVIKMIPNVSNM SQCTGSVMENYKTRLNGILTPIKGALEIYKNNTHDLVGDVRLAGVIMAGVAIGIATAAQITAGVAL YEAMKNADNINKLKSSIESTNEAVVKLQETAEKTVYVLTALQDYINTNLVPTIDKISCKQTELSLDL ALSKYLSDLLFVFGPNLQDPVSNSMTIQAISQAFGGNYETLLRTLGYATEDFDDLLESDSITGQIIY VDLSSYYIIVRVYFPILTEIQQAYIQELLPVSFNNDNSEWISIVPNFILVRNTLISNIEIGFCLITKRSVI CNQDYATPMTNNMRECLTGSTEKCPRELVVSSHVPRFALSNGVLFANCISVTCQCQTTGRAISQ SGEQTLLMIDNTTCPTAVLGNVIISLGKYLGSVNYNSEGIAIGPPVFTDKVDISSQISSMNQSLQQ SKDYIKEAQRLLDTVNPSLISMLSMIILYVLSIASLCIGLITFISFIIVEKKRNTYSRLEDRRVRPTSSGD LYYIGT | Pool of 134 peptides derived from a peptide scan (15mers with 11aa overlap) | 70%-90% | T-cell immunity | Encephalitis, Fever, Infection |
| 280 | MoTif 280 SARS-CoV-2 (S-RBD EG.5.1) | RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSP TKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGN YNYLYRLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVL SFELLHAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide Scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19 |
| 281 | MoTif 281 Chimpanzee Adenovirus Y25 (Penton Protein) | MMRRAYPEGPPPSYESVMQQAMAAAAAMQPPLEAPYVPPRYLAPTEGRNSIRYSELAPLYDT TRLYLVDNKSADIASLNYQNDHSNFLTTVVQNNDFTPTEASTQTINFDERSRWGGQLKTIMHTN MPNVNEFMYSNKFKARVMVSRKTPNGVTVTDGSQDILEYEWVEFELPEGNFSVTMTIDLMNN AIIDNYLAVGRQNGVLESDIGVKFDTRNFRLGWDPVTELVMPGVYTNEAFHPDIVLLPGCGVDFT ESRLSNLLGIRKRQPFQEGFQIMYEDLEGGNIPALLDVDAYEKSKEESAAAATAAVATASTEVRGDN FASPAAVAAAEAAETESKIVIQPVEKDSKDRSYNVLPDKINTAYRSWYLAYNYGDPEKGVRSWTLL TTSDVTCGVEQVYWSLPDMMQDPVTFRSTRQVSNYPVVGAELLPVYSKSFFNEQAVYSQQLRA FTSLTHVFNRFPENQILVRPPAPTITTVSENVPALTDHGTLPLRSSIRGVQRVTVTDARRRTCPYVYK ALGIVAPRVLSSRTF
| Pool of 131 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection |
| 282 | MoTif 282 Chimpanzee Adenovirus Y25 (Hexon Protein) | MATPSMLPQWAYMHIAGQDASEYLSPGLVQFARATDTYFSLGNKFRNPTVAPTHDVTTDRSQR LTLRFVPVDREDNTYSYKVRYTLAVGDNRVLDMASTYFDIRGVLDRGPSFKPYSGTAYNSLAPKGA PNSSQWEQKKAGNGDTMETHTFGVAPMGGENITIDGLQIGTDATADQDKPIYADKTFQPEPQVG EENWQETESFYGGRALKKDTSMKPCYGSYARPTNVKGGQAKLKVGADGVPTKEFDIDLAFFDTPG GTVNGQDEYKADIVMYTENTYLETPDTHVVYKPGKDDASSEINLVQQSMPNRPNYIGFRDNFIGL MYYNSTGNMGVLAGQASQLNAVVDLQDRNTELSYQLLLDSLGDRTRYFSMWNQAVDSYDPDV RIIENHGVEDELPNYCFPLDGSGTNAAYQGVKVKNGNDGDVESEWENDDTVAARNQLCKGNIFA MEINLQANLWRSFLYSNVALYLPDSYKYTPANITLPTNTNTYDYMNGRVVPPSLVDAYINIGARWS LDPMDNVNPFNHHRNAGLRYRSMLLGNGRYVPFHIQVPQKFFAIKSLLLLPGSYTYEWNFRKDV NMILQSSLGNDLRTDGASISFTSINLYATFFPMAHNTASTLEAMLRNDTNDQSFNDYLSAANMLY PIPANATNVPISIPSRNWAAFRGWSFTRLKTKETPSLGSGFDPYFVYSGSIPYLDGTFYLNHTFKKVS ITFDSSVSWPGNDRLLTPNEFEIKRTVDGEGYNVAQCNMTKDWFLVQMLAHYNIGYQGFYVPEG YKDRMYSFFRNFQPMSRQVVDEVNYKDYQAVTLAYQHNNSGFVGYLAPTMRQGQPYPANYPY PLIGKSAVTSVTQKKFLCDRVMWRIPFSSNFMSMGALTDLGQNMLYANSAHALDMNFEVDPMD ESTLLYVVFEVFDVVRVHQPHRGVIEAVYLRTPFSAGNATT | Pool of 233 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection |
| 283 | MoTif 283 Influenza A (NA/Turkey/1/2005(H5N1)) | MNPNQKIITIGSICMVIGIVSLMLQIGNMISIWVSHSIQTGNQCQAEPISNTKFLTEKAVASVTLAG NSSLCPISGWAVYSKDNSIRIGSRGDVFVIREPFISCSHLECRTFFLTQGALLNDKHSNGTVKDRSP HRTLMSCPVGEAPSPYNSRFESVAWSASACHDGTSWLTIGISGPDNGAVAVLKYNGIITDTIKSW RNNILRTQESECACVNGSCFTVMTDGPSSGQASYKIFKMEKGKVVKSVELDAPNYHYEECSCYPD AGEITCVCRDNWHGSNRPWVSFNQNLEYQIGYICSGVFGDNPRPNDGTGSCGPVFSNGAYGVK GFSFKYGNGVWIGRTKSTNSRSGFEMIWDPNGWTGTDSSFSVKQDIVAITDWSGYSGSFVQHPE LTGLDCIRPCFWVELIRGRPKESTIWTSGSSISFCGVNSDTVSWSWPDGAELPFTIDK | Pool of 110 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 284 | MoTif 284 SARS-CoV-2 (S-RBD HK.3 + JG.3) | RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAPFFAFKCYGVSPT KLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPSGNYN YLYRFLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELL HAPATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 285 | MoTif 285 SARS-CoV-2 (Spike B.1.351 / Beta) | MFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHA IHVSGTNGTKRFANPVLPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQF CNDPFLGVYYHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDG YFKIYSKHTPINLVRGLPQGFSALEPLVDLPIGINITRFQTLHRSYLTPGDSSSGWTAGAAAYYVGYLQ PRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFGEV FNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVR QIAPGQTGNIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQA GSTPCNGVKGFNCYFPLQSYGFQPTYGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNF NFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVA VLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEHVNNSYECDIPIGAGICASYQT QTNSPRRARSVASQSIIAYTMSLGVENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGD STECSNLLLQYGSFCTQLNRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKDFGGFNFSQILPDPSKPSK RSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITS GWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQD VVNQNAQALNTLVKQLSSNFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIR ASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDG KAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELD KYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIA GLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT | Peptide scan through the entire Spike glycoprotein of SARS-CoV-2 Lineage B.1.351, South Africa covering the following mutations: D0080A, D0215G, L0242-, A0243-, L0244-, K0417N, E0484K, N0501Y, D614G, A0701V. | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 286 | MoTif 286 Pan-SARS-CoV-2 Select | see additional product documentation | Virus-specific pool of 103 peptides (defined HLA class I & II-restricted T-cell epitopes) from selected proteins - from SARS-CoV-2- of SARS-CoV-2 (Severe Acute Respiratory Syndrome-Related Coronavirus 2) for T cell assays (e.g. ELISPOT). | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 287 | MoTif 287 Influenza A (HA/Puerto Rico/8/1934 H1N1) | MKANLLVLLCALAAADADTICIGYHANNSTDTVDTVLEKNVTVTHSVNLLEDSHNGKLCRLKGIAPL QLGKCNIAGWLLGNPECDPLLPVRSWSYIVETPNSENGICYPGDFIDYEELREQLSSVSSFERFEIFPKES SWPNHNTNGVTAACSHEGKSSFYRNLLWLTEKEGSYPKLKNSYVNKKGKEVLVLWGIHHPPNSKEQ QNLYQNENAYVSVVTSNYNRRFTPEIAERPKVRDQAGRMNYYWTLLKPGDTIIFEANGNLIAPMYAF ALSRGFGSGIITSNASMHECNTKCQTPLGAINSSLPYQNIHPVTIGECPKYVRSAKLRMVTGLRNIPSIQ SRGLFGAIAGFIEGGWTGMIDGWYGYHHQNEQGSGYAADQKSTQNAINGITNKVNTVIEKMNIQFT AVGKEFNKLEKRMENLNKKVDDGFLDIWTYNAELLVLLENERTLDFHDSNVKNLYEKVKSQLKNNAK EIGNGCFEFYHKCDNECMESVRNGTYDYPKYSEESKLNREKVDGVKLESMGIYQILAIYSTVASSLVLLV SLGAISFWMCSNGSLQCRICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 288 | MoTif 288 Influenza A (NP/Puerto Rico/8/1934 H1N1) | / | Pool of 122 peptides derived from a peptide scan (15mers with 1 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza, Respiratory infection |
| 289 | MoTif 289 SARS-CoV-2 (S-RBD B.1.429 / Epsilon) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKL NDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRYR LFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATV CGPKKSTNLVKNKCVNF | Peptide scan through Spike glycoprotein - Receptor binding domain of SARS-CoV-2 Lineage B.1.429, LA, CAL covering the following mutation: L0452R for T cell assays (e.g. ELISPOT). | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 290 | MoTif 290 Human (HLA classI Ig-like C1 type domain) | PKTHMTHHPISDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVP SGEEQRYTCHVQHEGLPKPLT | Control Pool of 19 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control |
| 291 | MoTif 291 SARS-CoV-2 (S-RBD B.1.617.1 / Kappa) | RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKL NDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYRY RLFRKSNLKPFERDISTEIYQAGSTPCNGVQGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAP ATVCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 292 | MoTif 292 Human (TCRgamma alternate reading frame protein TARP) | MQMFPPSPLFFFLQLLKQSSRRLEHTFVFLRNFSLMLLRYIGKKRRATRFWDPRRGTP | Pool of 12 peptides derived from a peptide scan through TCRgamma alternate reading frame protein (Swiss-Prot ID: A2JGV3) of Human. | 70%-90% | Cancer biomarker research, T-cell immunity | Breast cancer, Cancer, Prostate cancer |
| 293 | MoTif 293 Influenza A (HA/H3N2/Darwin/2021) | MKTIIALSNILCLVFAQKIPGNDNSTATLCLGHHAVPNGTIVKTITNDRIEVTNATELVQNSSIGEICDS PHQILDGGNCTLIDALLGDPQCDGFQNKEWDLFVERSRANSNCYPYDVPDYASLRSLVASSGTLEFK NESFNWTGVKQNGTSSACIRGSSSSFFSRLNWLTSLNNIYPAQNVTMPNKEQFDKLYIWGVHHPNT DKNQISLFAQSSGRITVSTKRSQQAVIPNIGSRPRIRGIPSRISIYWTIVKPGDILLINSTGNLIAPRGYFKI RSGKSSIMRSDAPIGKCKSECITPNGSIPNDKPFQNVNRITYGACPRYVKQSTLKLATGMRNVPEKQT RGIFGAIAGFIENGWEGMVDGWYGFRHQNSEGRGQAADLKSTQAAIDQINGKLNRLIGKTNEKFHQ IEKEFSEVEGRVQDLEKYVEDTKIDLWSYNAELLVALENQHTIDLTDSEMNKLFEKTKKQLRENAEDMG NGCFKIYHKCDNACIGSIRNETYDHNVYRDEALNNRFQIKGVELKSGYKDWILWISFAMSCFLLCIALL GFIMWACQKGNIRCNICI | Pool of 139 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza |
| 294 | MoTif 294 Pan-SARS-CoV-2 Select w/o S | see additional product documentation | Virus-specific pool of 73 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 295 | MoTif 295 SARS-CoV-2 (S-RBD BA.2.75.2) | RVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVLYNFAPFFAFKCYGVSPTKL NDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYR LFRKSKLKPFERDISTEIYQAGNKPCNGVAGSNCYFPLQSYGFRPTYGVGHQPYRVVVLSFELLHAPAT VCGPKKSTNLVKNKCVNF | Pool of 53 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 296 | MoTif 296 West Nile Virus (Capsid Protein) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Defined T-cell epitopes (15mers)) | 70%-90% | T-cell immunity | Encephalitis, Fever, Infection, Meningitis, Sequence diversity, West nile fever |
| 297 | MoTif 297 Yellow Fever Virus (Capsid Protein) Ultra | see additional product documentation | Pool of 138 peptides derived from a peptide scan (Defined T-cell epitopes (15mers)) through Capsid protein of Yellow Fever Virus (YFV). | 70%-90% | T-cell immunity | Fever, Hemorrhagic fever, Infection, Liver failure, Sequence diversity, Yellow Fever |
| 298 | MoTif 298 Influenza B (HA/H0N0/Phuket/2013) | MKAIIVLLMVVTSNADRICTGITSSNSPHVVKTATQGEVNVTGVIPLTTTPTKSYFANLKGTRTRGKLC PDCLNCTDLDVALGRPMCVGTTPSAKASILHEVRPVTSGCFPIMHDRTKIRQLPNLLRGYEKIRLSTQ NVIDAEKAPGGPYRLGTSGSCPNATSKIGFFATMAWAVPKDNYKNATNPLTVEVPYICTEGEDQITVW GFHSDDKTQMKSLYGDSNPQKFTSSANGVTTHYVSQIGDFPDQTEDGGLPQSGRIVVDYMMQKPG KTGTIVYQRGVLLPQKVWCASGRSKVIKGSLPLIGEADCLHEEYGGLNKSKPYYTGKHAKAIGNCPIWV KTPLKLANGTKYRPPAKLLKERGFFGAIAGFLEGGWEGMIAGWHGYTSHGAHGVAVAADLKSTQEAI NKITKNLNSLSELEVKNLQRLSGAMDELHNEILELDEKVDDLRADTISSQIELAVLLSNEGIINSEDEHLL ALERKLKKMLGPSAVDIGNGCFETKHKCNQTCLDRIAAGTFNAGEFSLPTFDSLNITAASLNDDGLDN HTILLYYSTAASSLAVTLMLAIFIVYMVSRDNVSCSICL | Pool of 144 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Flu-like disease, Infection, Influenza |
| 299 | MoTif 299 Crimean-Congo hem. fever virus (Nucleoprotein / IbAr10200) | MENKIEVNNKDEMNRWFEEFKKGNGLVDTFTNSYSFCESVPNLDRFVFQMASATDDAQKDSIYASA LVEATKFCAPIYECAWVSSTGIVKKGLEWFEKNAGTIKSWDESYTELKVDVPKIEQLTGYQQAALKWRK DIGFRVNANTAALSNKVLAEYKVPGEIVMSVKEMLSDMIRRRNLILNRGGDENPRGPVSHEHVDWC REFVKGKYIMAFNPPWGDINKSGRSGIALVATGLAKLAETEGKGIFDEAKKTVEALNGYLDKHKDEVD RASADSMITNLLKHIAKAQELYKNSSALRAQSAQIDTAFSSYYWLYKAGVTPETFPTVSQFLFELGKQP RGTKKMKKALLSTPMKWGKKLYELFADDSFQQNRIYMHPAVLTAGRISEMGVCFGTIPVANPDDAA QGSGHTKSILNLRTNTETNNPCAKTIVKLFEVQKTGFNIQDMDIVASEHLLHQSLVGKQSPFQNAYN VKGNATSANII | Pool of 118 peptides derived from a peptide scan (Peptide scan (15mers with 11 aa overlap)) | 70%-90% | T-cell immunity | Ebola fever, Infection |
| 300 | MoTif 300 St. Louis Encephalitis Virus (Capsid Protein) Ultra | see additional product documentation | Pool of 66 peptides derived from a peptide scan (Defined T-cell epitopes (15mers)) | 70%-90% | T-cell immunity | Encephalitis, Fever, Infection, Sequence diversity |
| 301 | MoTif 301 Collection Melanoma | 7 different TAA PepMixes + 2 Controls (15mers, overlap 11):,Human (MAGEA1),Huma (MAGEA3),Human (MAGEA4),Human (Melan-A/MART-1),Human (Melanocyte protein Pmel 17 gp100),Human (Tyrosinase),Human (Tyrosinase-related protein 2),CEF Pool (extended),Human (Actin) | Collection of 7 peptide pools derived from scans (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Melanoma |
| 302 | MoTif 302 Tick-borne Encephalitis Virus (Capsid Protein) Ultra | see additional product documentation | Pool of 150 peptides derived from a peptide scan (Defined T-cell epitopes (15mers)) | 70%-90% | T-cell immunity | Encephalitis, Infection, Meningitis, Sequence diversity |
| 303 | MoTif 303 Collection SARS-CoV-2 Spike Mutations | 9 different SARS-CoV-2 PepMixes: SARS-CoV-2 (Spike / B.1.1.7 / Alpha) SARS-CoV-2 (Spik / B.1.351 / Beta) SARS-CoV-2 (Spike / P.1 / Gamma) SARS-CoV-2 (Spike / B.1.617.2 / Delta) SARS-CoV-2 (Spike / B.1.429 / Epsilon) SARS-CoV-2 (Spike / B.1.617.1 / Kappa) SARS-CoV- 2 (Spike / C.37 / Lambda) SARS-CoV-2 (Spike / BA.1 / Omicron) SARS-CoV-2 (Spike / BA.2 / Omicron) | Collection of 9 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 304 | MoTif 304 Collection SARS-CoV-2 S-RBD Mutations | 9 different SARS-CoV-2 PepMixes: SARS-CoV-2 (S-RBD / B.1.1.7 / Alpha) SARS-CoV-2 (S-RBD / B.1.351 / Beta) SARS-CoV-2 (S-RBD / P.1 / Gamma) SARS-CoV-2 (S-RBD / B.1.617.2 / Delta) SARS-CoV-2 (S-RBD / B.1.429 / Epsilon) SARS-CoV-2 (S-RBD / B.1.617.1 / Kappa) SARS-CoV-2 (S-RBD / C.37 / Lambda) SARS-CoV-2 (S-RBD / BA.1 / Omicron) SARS-CoV-2 (S-RBD / BA.2 / Omicron) | Collection of 9 peptide pools (overlapping peptides scans, 15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19 |
| 305 | MoTif 305 Human (KRAS) | MTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSA MRDQYMRTGEGFLCVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQA QDLARSYGIPFIETSAKTRQRVEDAFYTLVREIRQYRLKKISKEEKTPGCVKIKKCIIM | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) through GTPase KRas (Swiss-Prot ID: P01116) of Human. | 70%-90% | T-cell immunity | Cancer, Leukemia |
| 306 | MoTif 306 Collection Prostate Cancer | 7 different TAA PepMixes + 2 Controls (15mers, overlap 11):,Human (CEA),Huma(Metalloreductase STEAP1),Human (Myc protein),Human (PAP),Human (Prostate-specific antigen PSA),Human (TCRgamma alternate reading frame protein TARP),Human (WT1/WT33),CEF Pool (extended), Human (Actin) | Collection of 7 peptide pools derived from scans (overlapping peptides scans, 15mers with 11 aa overlap) through 7 tumor associated antigens (prostate cancer markers: CEA, Metalloreductase STEAP1, Myc protein, PAP, PSA, TARP, WT1/WT33) of Homo sapiens plus 2 control pools (CEF Pool (extended) and Actin) | 70%-90% | Cancer biomarker research, T-cell immunity | Cancer, Prostate cancer |
| 307 | MoTif 307 Crimean-Congo hem. fever virus (M Polyprotein / IbAr10200) | MHISLMYAILCLQLCGLGETHGSHNETRHNKTDTMTTPGDNPSSEPPVSTALSITLDPSTVTPTTPASGLE GSGEVYTSPPITTGSLPLSETTPELPVTTGTDTLSAGDVDPSTQTAGGTSAPTVRTSLPNSPSTPSTPQDTH HPVRNLLSVTSPGPDETSTPSGTGKESSATSSPHPVSNRPPTPPATAQGPTENDSHNATEHPESLTQSATP GLMTSPTQIVHPQSATPITVQDTHPSPTNRSKRNLKMEIILTLSQGLKKYYGKILRLLQLTLEEDTEGLLEWC KRNLGLDCDDTFFQKRIEEFFITGEGHFNEVLQFRTPGTLSTTESTPAGLPTAEPFKSYFAKGFLSIDSGYYSA KCYSGTSNSGLQLINITRHSTRIVDTPGPKITNLKTINCINLKASIFKEHREVEINVLLPQVAVNLSNCHVVIK SHVCDYSLDIDGAVRLPHIYHEGVFIPGTYKIVIDKKNKLNDRCTLFTDCVIKGREVRKGQSVLRQYKTEIRI GKASTGSRRLLSEEPSDDCISRTQLLRTETAEIHGDNYGGPGDKITICNGSTIVDQRLGSELGCYTINRVRSF KLCENSATGKNCEIDSVPVKCRQGYCLRITQEGRGHVKLSRGSEVVLDACDTSCEIMIPKGTGDILVDCSG GQQHFLKDNLIDLGCPKIPLLGKMAIYICRMSNHPKTTMAFLFWFSFGYVITCILCKAIFYLLIIVGTLGKRLK QYRELKPQTCTICETTPVNAIDAEMHDLNCSYNICPYCASRLTSDGLARHVIQCPKRKEKVEETELYLNLER IPWVVRKLLQVSESTGVALKRSSWLIVLLVLFTVSLSPVQSAPIGQGKTIEAYRAREGYTSICLFVLGSILFIVS CLMKGLVDSVGNSFFPGLSICKTCSISSINGFEIESHKCYCSLFCCPYCRHCSTDKEIHKLHLSICKKRKKGSN VMLAVCKLMCFRATMEVSNRALFIRSIINTTFVLCILILAVCVVSTSAVEMENLPAGTWEREEDLTNFCHQE CQVTETECLCPYEALVLRKPLFLDSTAKGMKNLLNSTSLETSLSIEAPWGAINVQSTYKPTVSTANIALSWS SVEHRGNKILVSGRSESIMKLEERTGISWDLGVEDASESKLLTVSVMDLSQMYSPVFEYLSGDRQVGEWP KATCTGDCPERCGCTSSTCLHKEWPHSRNWRCNPTWCWGVGTGCTCCGLDVKDLFTDYMFVKWKVE YIKTEAIVCVELTSQERQCSLIEAGTRFNLGPVTITLSEPRNIQQKLPPEIITLHPRIEEGFFDLMHVQKVLSAS TVCKLQSCTHGVPGDLQVYHIGNLLKGDKVNGHLIHKIEPHFNTSWMSWDGCDLDYYCNMGDWPSC TYTGVTQHNHASFVNLLNIETDYTKNFHFHSKRVTAHGDTPQLDLKARPTYGAGEITVLVEVADMELHT KKIEISGLKFASLACTGCYACSSGISCKVRIHVDEPDELTVHVKSDDPDVVAASSSLMARKLEFGTDSTFKA FSAMPKTSLCFYIVEREHCKSCSEEDTKKCVNTKLEQPQSILIEHKGTIIGKQNSTCTAKASCWLESVKSFFY GLKNMLSGIFGNVFMGIFLFLAPFILLILFFMFGWRILFCFKCCRRTRGLFKYRHLKDDEETGYRRIIEKLNN KKGKNKLLDGERLADRRIAELFSTKTHIG | Pool of 419 (vial 1: Pep 1-210, vial 2: 211-419) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Diarrhea, Hemorrhagic fever, Infection, Liver failure |
| 308 | MoTif 308 eGFP | MVSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQ CFSRYPDHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGH KLEYNYNSHNVYIMADKQKNGIKVNFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSAL SKDPNEKRDHMVLLEFVTAAGITLGMDELYK | Pool of 57 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Control |
| 309 | MoTif 309 Rabies virus (Glycoprotein) | MVPQVLLFAPLLVFPLCFGKFPIYTIPDKLGPWSPIDLHHLSCPNNLVVEDEGCTNLSGFSYMELKVGYIS AIKVNGFTCTGVVTEAETYTNFVGYVTTTFKRKHFRPTPDACRAAYNWKMAGDPRYEESLHNPYPDYH WLRTVKTTKESLVIISPSVTDLDPYDKSLHSRVFPGGNCSGITVSSTYCSTNHDYTIWMPENLRLGTSCDI FTHSRGKRASKGDKTCGFVDERGLYKSLKGACKLKLCGVLGLRLMDGTWVAMQTSDETKWCPPGQLVN LHDFRSDEIEHLVEEELVKKREECLDALESIMTTKSVSFRRLSHLRKLVPGFGKAYTIFNKTLMEADAHYKSV QTWNEIIPSKGCLRVGERCHPHVNGVFFNGIILGSDGHVLIPEMQSSLLQQHMELLESSVIPLMHPLADP STVFKDGDEVEDFVEVHLPDVHKQVSGVDLGLPKWGKYVLMIAGALIALMLIIFLMTCCRRVNRPESTQS NLGGTGRNVSVPSQSGKVISSWESYKSGGETRL | Pool of 129 peptides derived from a peptide scan (15mers with 11aa overlap) | 70%-90% | T-cell immunity | Encephalitis, Infection |
| 310 | MoTif 310 Pan-CMV Select | see additional product documentation | Virus-specific pool of 99 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | T-cell immunity | Control, Cytomegalovirus disease, Infection, Infectious mononucleosis, Opportunistic infections |
| 311 | MoTif 311 Pan-EBV Select | see additional product documentation | Virus-specific pool of 135 peptides (defined HLA class I & II-restricted T-cell epitopes) | 70%-90% | T-cell immunity | Autoimmune disease, Burkitt's lymphoma, Hodgkin's lymphoma, Infection, Infectious mononucleosis, Nasopharyngeal carcinoma |
| 312 | MoTif 312 Human (N-glycanase 1) | MAAAALGSSSGSASPAVAELCQNTPETFLEASKLLLTYADNILRNPNDEKYRSIRIGNTAFSTRLLPVRGAV ECLFEMGFEEGETHLIFPKKASVEQLQKIRDLIAIERSSRLDGSNKSHKVKSSQQPAASTQLPTTPSSNPSGL NQHTRNRQGQSSDPPSASTVAADSAILEVLQSNIQHVLVYENPALQEKALACIPVQELKRKSQEKLSRAR KLDKGINISDEDFLLLELLHWFKEEFFHWVNNVLCSKCGGQTRSRDRSLLPSDDELKWGAKEVEDHYCDA CQFSNRFPRYNNPEKLLETRCGRCGEWANCFTLCCRAVGFEARYVWDYTDHVWTEVYSPSQQRWLHCD ACEDVCDKPLLYEIGWGKKLSYVIAFSKDEVVDVTWRYSCKHEEVIARRTKVKEALLRDTINGLNKQRQLFL SENRRKELLQRIIVELVEFISPKTPKPGELGGRISGSVAWRVARGEMGLQRKETLFIPCENEKISKQLHLCYNIV KDRYVRVSNNNQTISGWENGVWKMESIFRKVETDWHMVYLARKEGSSFAYISWKFECGSVGLKVDSISIR TSSQTFQTGTVEWKLRSDTAQVELTGDNSLHSYADFSGATEVILEAELSRGDGDVAWQHTQLFRQSLNDH EENCLEIIIKFSDL | Pool of 161 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Microcephaly |
| 313 | MoTif 313 SARS-CoV-2 (NCAP B1.1.529 / BA.1 / Omicron) | MSDNGPQNQRNALRITFGGPSDSTGSNQNGGARSKQRRPQGLPNNTASWFTALTQHGKEDLKFPRGQ GVPINTNSSPDDQIGYYRRATRRIRGGDGKMKDLSPRWYFYYLGTGPEAGLPYGANKDGIIWVATEGALN TPKDHIGTRNPANNAAIVLQLPQGTTLPKGFYAEGSRGGSQASSRSSSRSRNSSRNSTPGSSKRTSPARMA GNGGDAALALLLLDRLNQLESKMSGKGQQQQGQTVTKKSAAEASKKPRQKRTATKAYNVTQAFGRRGP EQTQGNFGDQELIRQGTDYKHWPQIAQFAPSASAFFGMSRIGMEVTPSGTWLTYTGAIKLDDKDPNFKD QVILLNKHIDAYKTFPPTEPKKDKKKKADETQALPQRQKKQQTVTLLPAADLDDFSKQLQQSMSSADSTQA | Pool of 102 peptides derived from a peptide scan (15mers with 11 aa overlap - (incl. 5x 14mers)) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection |
| 314 | MoTif 314 Human (CFTR) | MQRSPLEKASVVSKLFFSWTRPILRKGYRQRLELSDIYQIPSVDSADNLSEKLEREWDRELASKKNPKLINA LRRCFFWRFMFYGIFLYLGEVTKAVQPLLLGRIIASYDPDNKEERSIAIYLGIGLCLLFIVRTLLLHPAIFGLHHIG MQMRIAMFSLIYKKTLKLSSRVLDKISIGQLVSLLSNNLNKFDEGLALAHFVWIAPLQVALLMGLIWELLQA SAFCGLGFLIVLALFQAGLGRMMMKYRDQRAGKISERLVITSEMIENIQSVKAYCWEEAMEKMIENLRQTE LKLTRKAAYVRYFNSSAFFFSGFFVVFLSVLPYALIKGIILRKIFTTISFCIVLRMAVTRQFPWAVQTWYDSLGA INKIQDFLQKQEYKTLEYNLTTTEVVMENVTAFWEEGFGELFEKAKQNNNNRKTSNGDDSLFFSNFSLLGT PVLKDINFKIERGQLLAVAGSTGAGKTSLLMVIMGELEPSEGKIKHSGRISFCSQFSWIMPGTIKENIIFGVSY DEYRYRSVIKACQLEEDISKFAEKDNIVLGEGGITLSGGQRARISLARAVYKDADLYLLDSPFGYLDVLTEKEIF ESCVCKLMANKTRILVTSKMEHLKKADKILILHEGSSYFYGTFSELQNLQPDFSSKLMGCDSFDQFSAERRN SILTETLHRFSLEGDAPVSWTETKKQSFKQTGEFGEKRKNSILNPINSIRKFSIVQKTPLQMNGIEEDSDEPLER RLSLVPDSEQGEAILPRISVISTGPTLQARRRQSVLNLMTHSVNQGQNIHRKTTASTRKVSLAPQANLTELDI YSRRLSQETGLEISEEINEEDLKECFFDDMESIPAVTTWNTYLRYITVHKSLIFVLIWCLVIFLAEVAASLVVLWL LGNTPLQDKGNSTHSRNNSYAVIITSTSSYYVFYIYVGVADTLLAMGFFRGLPLVHTLITVSKILHHKMLHSVL QAPMSTLNTLKAGGILNRFSKDIAILDDLLPLTIFDFIQLLLIVIGAIAVVAVLQPYIFVATVPVIVAFIMLRAYFLQ TSQQLKQLESEGRSPIFTHLVTSLKGLWTLRAFGRQPYFETLFHKALNLHTANWFLYLSTLRWFQMRIEMIFV IFFIAVTFISILTTGEGEGRVGIILTLAMNIMSTLQWAVNSSIDVDSLMRSVSRVFKFIDMPTEGKPTKSTKPYK NGQLSKVMIIENSHVKKDDIWPSGGQMTVKDLTAKYTEGGNAILENISFSISPGQRVGLLGRTGSGKSTLLS AFLRLLNTEGEIQIDGVSWDSITLQQWRKAFGVIPQKVFIFSGTFRKNLDPYEQWSDQEIWKVADEVGLRSV IEQFPGKLDFVLVDGGCVLSHGHKQLMCLARSVLSKAKILLLDEPSAHLDPVTYQIIRRTLKQAFADCTVILCE HRIEAMLECQQFLVIEENKVRQYDSIQKLLNERSLFRQAISPSDRVKLFPHRNSSKCKSKPQIAALKEETEEEV QDTRL | Pool of 368 (vial 1: Pep 1-184, vial 2: 185-368) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cystic Fibrosis, Epithelium, Respiratory infection |
| 315 | MoTif 315 HSV2 (gB) | MRGGGLICALVVGALVAAVASAAPAAPAAPRASGGVAATVAANGGPASRPPPVPSPATTKARKRKTKKPP KRPEATPPPDANATVAAGHATLRAHLREIKVENADAQFYVCPPPTGATVVQFEQPRRCPTRPEGQNYTEGI AVVFKENIAPYKFKATMYYKDVTVSQVWFGHRYSQFMGIFEDRAPVPFEEVIDKINAKGVCRSTAKYVRNN METTAFHRDDHETDMELKPAKVATRTSRGWHTTDLKYNPSRVEAFHRYGTTVNCIVEEVDARSVYPYDEF VLATGDFVYMSPFYGYREGSHTEHTSYAADRFKQVDGFYARDLTTKARATSPTTRNLLTTPKFTVAWDWVP KRPAVCTMTKWQEVDEMLRAEYGGSFRFSSDAISTTFTTNLTQYSLSRVDLGDCIGRDAREAIDRMFARKYN ATHIKVGQPQYYLATGGFLIAYQPLLSNTLAELYVREYMREQDRKPRNATPAPLREAPSANASVERIKTTSSIEF ARLQFTYNHIQRHVNDMLGRIAVAWCELQNHELTLWNEARKLNPNAIASATVGRRVSARMLGDVMAVST CVPVAPDNVIVQNSMRVSSRPGTCYSRPLVSFRYEDQGPLIEGQLGENNELRLTRDALEPCTVGHRRYFIFGG GYVYFEEYAYSHQLSRADVTTVSTFIDLNITMLEDHEFVPLEVYTRHEIKDSGLLDYTEVQRRNQLHDLRFADI DTVIRADANAAMFAGLCAFFEGMGDLGRAVGKVVMGVVGGVVSAVSGVSSFMSNPFGALAVGLLVLAGL VAAFFAFRYVLQLQRNPMKALYPLTTKELKTSDPGGVGGEGEEGAEGGGFDEAKLAEAREMIRYMALVSAM ERTEHKARKKGTSALLSSKVTNMVLRKRNKARYSPLHNEDEAGDEDEL | Pool of 224 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 316 | MoTif 316 HSV2 (gC) | MALGRVGLAVGLWGLLWVGVVVVLANASPGRTITVGPRGNASNAAPSASPRNASAPRTTPTPPQPRKAT KSKASTAKPAPPPKTGPPKTSSEPVRCNRHDPLARYGSRVQIRCRFPNSTRTESRLQIWRYATATDAEIGTAPS LEEVMVNVSAPPGGQLVYDSAPNRTDPHVIWAEGAGPGASPRLYSVVGPLGRQRLIIEELTLETQGMYYWV WGRTDRPSAYGTWVRVRVFRPPSLTIHPHAVLEGQPFKATCTAATYYPGNRAEFVWFEDGRRVFDPAQIHT QTQENPDGFSTVSTVTSAAVGGQGPPRTFTCQLTWHRDSVSFSRRNASGTASVLPRPTITMEFTGDHAVCT AGCVPEGVTFAWFLGDDSSPAEKVAVASQTSCGRPGTATIRSTLPVSYEQTEYICRLAGYPDGIPVLEHHGSH QPPPRDPTERQVIRAVEGAGIGVAVLVAVVLAGTAVVYLTHASSVRYRRLR | Pool of 118 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Encephalitis, Genital herpes, Infection, Oral Herpes |
| 317 | MoTif 317 BKV (large T antigen) | MDKVLNREESMELMDLLGLERAAWGNLPLMRKAYLKKCKEFHPDKGGDEDKMKRMNTLYKKMEQDVK VAHQPDFGTWNSSEVPTYGTEEWESWWSSFNEKWDEDLFCHEDMFASDEEATADSQHSTPPKKKRKVED PKDFPSDLHQFLSQAVFSNRTLACFAVYTTKEKAQILYKKLMEKYSVTFISRHMCAGHNIIFFLTPHRHRVSAI NNFCQKLCTFSFLICKGVNKEYLLYSALTRDPYHIIEESIQGGLKEHDFNPEEPEETKQVSWKLITEYAVETKCED VFLLLGMYLEFQYNVEECKKCQKKDQPYHFKYHEKHFANAIIFAESKNQKSICQQAVDTVLAKKRVDTLHMT REEMLTERFNHILDKMDLIFGAHGNAVLEQYMAGVAWLHCLLPKMDSVIFDFLHCVVFNVPKRRYWLFKG PIDSGKTTLAAGLLDLCGGKALNVNLPMERLTFELGVAIDQYMVVFEDVKGTGAESKDLPSGHGINNLDSLR DYLDGSVKVNLEKKHLNKRTQIFPPGLVTMNEYPVPKTLQARFVRQIDFRPKIYLRKSLQNSEFLLEKRILQSG MTLLLLLIWFRPVADFSKDIQSRIVEWKERLDSEISMYTFSRMKYNICMGKCILDITREEDSETEDSGHGSSTE SQSQCSSQVSDTSAPDSENPHSQELHLCKGFQCFKRPKTPPPK | Pool of 170 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Merkel cell carcinoma, Nephritis, interstitial |
| 318 | MoTif 318 BKV (capsid protein VP1) | MAPTKRKGECPGAAPKKPKEPVQVPKLLIKGGVEVLEVKTGVDAITEVECFLNPEMGDPDDNLRGYSQHLS AENAFESDSPDRKMLPCYSTARIPLPNLNEDLTCGNLLMWEAVTVKTEVIGITSMLNLHAGSQKVHENGGG KPVQGSNFHFFAVGGDPLEMQGVLMNYRTKYPQGTITPKNPTAQSQVMNTDHKAYLDKNNAYPVECWIP DPSRNENTRYFGTYTGGENVPPVLHVTNTATTVLLDEQGVGPLCKADSLYVSAADICGLFTNSSGTQQWRG LARYFKIRLRKRSVKNPYPISFLLSDLINRRTQKVDGQPMYGMESQVEEVRVFDGTEQLPGDPDMIRYIDRQ GQLQTKMV | Pool of 88 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Merkel cell carcinoma, Nephritis, interstitial |
| 319 | MoTif 319 SARS-CoV-2 (Spike HV.1) | MFVFLVLLPLVSSQCVNLITRTQSYTNSFTRGVYYPDKVFRSSVLHSTHDLFLPFFSNVTWFHAIHVSGTNGT KRFDNPALPFNDGVYFASTEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDVYQKNNK SWMESELRVYSSANNCTFEYVSQPFLMDLEGKEGNFKNLREFVFKNIDGYFKIYSKHTPINLERDLPQGFSAL EPLVDLPIGINITRFQTLLALHRSYLTPVDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSE TKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFHEVFNATTFASVYAWNRKRISNCVADYSVIYNFAP FFAFKCYGVSPTKLNDLCFTNVYADSFVIRGNEVSQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKPS GNYNYRYRLLRKSKLKPFERDISTEIYQAGNKPCNGVAGPNCYSPLQSYGFRPTYGVGHQPYRVVVLSFELLH APATVCGPKKSTNLVKNKCVNFNFNGLTGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFG GVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIP IGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTM YICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKR SFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFNGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGA GAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNT LVKQLSSKFGAISSVLNDILSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQ SKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQR NFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQK EIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKF DEDDSEPVLKGVKLHYT | Pool of 315 (158+157) peptides derived from a peptide scan (15mers with 11 aa overlap - incl. a few 13 - 17mers) | 70%-90% | T-cell immunity | Covid-19, Infection, Respiratory infection, Severe acute respiratory syndrome (SARS) |
| 320 | MoTif 320 Influenza A (NA/H3N2/Darwin/2021) | MNPNQKIITIGSVSLTISTICFFMQIAILITTVTLHFKQYEFNSPPNNQVMLCEPTIIERNITEIVYLTNTTIEKEICP KPAEYRNWSKPQCGITGFAPFSKDNSIRLSAGGDIWVTREPYVSCDLDKCYQFALGQGTTLNNVHSNNTVRD RTPYRTLLMNELGVPFHLGTKQVCIAWSSSSCHDGKAWLHVCITGDDKNATASFIYNGRLVDSVVSWSNDILR TQESECVCINGTCTVVMTDGNATGKADTKILFIEEGKIVHTSKLSGSAQHVEECSCYPRYPGVRCVCRDNWKG SNRPIIDINIKDHSIVSRYVCSGLVGDTPRKSDSSSSSHCLNPNNEKGDHGVKGWAFDDGNDVWMGRTINET SRLGYETFKVVEGWSNPKSKLQINRQVIVDRGDRSGYSGIFSVEGKSCINRCFYVELIRGRKEETEVLWTSNSIVV FCGTSGTYGTGSWPDGANLSLMHI | Pool of 115 peptides derived from a peptide scan (15mers with 11aa overlap) | 70%-90% | T-cell immunity | Fever, Flu-like disease, Infection, Influenza |
| 321 | MoTif 321 BKV (capsid protein VP2, isoform VP3) | MALELFNPDEYYDILFPGVNTFVNNIQYLDPRHWGPSLFATISQALWHVIRDDIPSITSQELQRRTERFFRDSL ARFLEETTWTIVNAPINFYNYIQQYYSDLSPIRPSMVRQVAEREGTRVHFGHTYSIDDADSIEEVTQRMDLRNQ QSVHSGEFIEKTIAPGGANQRTAPQWMLPLLLGLYGTVTPALEAYEDGPNQKKRRVSRGSSQKAKGTRASAKT TNKRRSRSSRS | Pool of 56 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Merkel cell carcinoma, Nephritis, interstitial |
| 322 | MoTif 322 AAV9 (Capsid Protein VP1) | MAADGYLPDWLEDNLSEGIREWWALKPGAPQPKANQQHQDNARGLVLPGYKYLGPGNGLDKGEPVNAA DAAALEHDKAYDQQLKAGDNPYLKYNHADAEFQERLKEDTSFGGNLGRAVFQAKKRLLEPLGLVEEAAKTAPGKKRPVEQSPQEPDSSAGIGKSGAQPAKKRLNFGQTGDTESVPDPQPIGEPPAAPSGVGSLTMASGGGAPVADNNEGADGVGSSSGNWHCDSQWLGDRVITTSTRTWALPTYNNHLYKQISNSTSGGSSNDNAYFGYSTPWGYFDFNRFHCHFSPRDWQRLINNNWGFRPKRLNFKLFNIQVKEVTDNNGVKTIANNLTSTVQVFTDSDYQLPYVLGSAHEGCLPPFPADVFMIPQYGYLTLNDGSQAVGRSSFYCLEYFPSQMLRTGNNFQFSYEFENVPFHSSYAHSQSLDRLMNPLIDQYLYYLSKTINGSGQNQQTLKFSVAGPSNMAVQGRNYIPGPSYRQQRVSTTVTQNNNSEFAWPGASSWALNGRNSLMNPGPAMASHKEGEDRFFPLSGSLIFGKQGTGRDNVDADKVMITNEEEIKTTNPVATESYGQVATNHQSAQAQAQTGWVQNQGILPGMVWQDRDVYLQGPIWAKIPHTDGNFHPSPLMGGFGMKHPPPQILIKNTPVPADPPTAFNKDKLNSFITQYSTGQVSVEIEWELQKENSKRWNPEIQYTSNYYKSNNVEFAVNTEGVYSEPRPIGTRYLTRNL | Pool of 182 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cancer, Gene therapy, Infection |
| 323 | MoTif 323 MERS-CoV (Spike Glycoprotein) | MIHSVFLLMFLLTPTESYVDVGPDSVKSACIEVDIQQTFFDKTWPRPIDVSKADGIIYPQGRTYSNITITYQGLFP YQGDHGDMYVYSAGHATGTTPQKLFVANYSQDVKQFANGFVVRIGAAANSTGTVIISPSTSATIRKIYPAFMLGSSVGNFSDGKMGRFFNHTLVLLPDGCGTLLRAFYCILEPRSGNHCPAGNSYTSFATYHTPATDCSDGNYNRNASLNSFKEYFNLRNCTFMYTYNITEDEILEWFGITQTAQGVHLFSSRYVDLYGGNMFQFATLPVYDTIKYYSIIPHSIRSIQSDRKAWAAFYVYKLQPLTFLLDFSVDGYIRRAIDCGFNDLSQLHCSYESFDVESGVYSVSSFEAKPSGSVVEQAEGVECDFSPLLSGTPPQVYNFKRLVFTNCNYNLTKLLSLFSVNDFTCSQISPAAIASNCYSSLILDYFSYPLSMKSDLSVSSAGPISQFNYKQSFSNPTCLILATVPHNLTTITKPLKYSYINKCSRFLSDDRTEVPQLVNANQYSPCVSIVPSTVWEDGDYYRKQLSPLEGGGWLVASGSTVAMTEQLQMGFGITVQYGTDTNSVCPKLEFANDTKIASQLGNCVEYSLYGVSGRGVFQNCTAVGVRQQRFVYDAYQNLVGYYSDDGNYYCLRACVSVPVSVIYDKETKTHATLFGSVACEHISSTMSQYSRSTRSMLKRRDSTYGPLQTPVGCVLGLVNSSLFVEDCKLPLGQSLCALPDTPSTLTPRSVRSVPGEMRLASIAFNHPIQVDQLNSSYFKLSIPTNFSFGVTQEYIQTTIQKVTVDCKQYVCNGFQKCEQLLREYGQFCSKINQALHGANLRQDDSVRNLFASVKSSQSSPIIPGFGGDFNLTLLEPVSISTGSRSARSAIEDLLFDKVTIADPGYMQGYDDCMQQGPASARDLICAQYVAGYKVLPPLMDVNMEAAYTSSLLGSIAGVGWTAGLSSFAAIPFAQSIFYRLNGVGITQQVLSENQKLIANKFNQALGAMQTGFTTTNEAFHKVQDAVNNNAQALSKLASELSNTFGAISASIGDIIQRLDVLEQDAQIDRLINGRLTTLNAFVAQQLVRSESAALSAQLAKDKVNECVKAQSKRSGFCGQGTHIVSFVVNAPNGLYFMHVGYYPSNHIEVVSAYGLCDAANPTNCIAPVNGYFIKTNNTRIVDEWSYTGSSFYAPEPITSLNTKYVAPQVTYQNISTNLPPPLLGNSTGIDFQDELDEFFKNVSTSIPNFGSLTQINTTLLDLTYEMLSLQQVVKALNESYIDLKELGNYTYYNKWPWYIWLGFIAGLVALALCVFFILCCTGCGTNCMGKLKCNRCCDRYEEYDLEPHKVHVH | Pool of 336 (168+168) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Covid-19, Infection, Middle Eastern Respiratory Syndrome (MERS), Respiratory infection |
| 324 | MoTif 324 M. tuberculosis (RpfA) | MSGRHRKPTTSNVSVAKIAFTGAVLGGGGIAMAAQATAATDGEWDQVARCESGGNWSINTGNGYLGGLQF TQSTWAAHGGGEFAPSAQLASREQQIAVGERVLATQGRGAWPVCGRGLSNATPREVLPASAAMDAPLDAAAVNGEPAPLAPPPADPAPPVELAANDLPAPLGEPLPAAPADPAPPADLAPPAPADVAPPVELAVNDLPAPLGEPLPAAPADPAPPADLAPPAPADLAPPAPADLAPPAPADLAPPVELAVNDLPAPLGEPLPAAPAELAPPADLAPASADLAPPAPADLAPPAPAELAPPAPADLAPPAAVNEQTAPGDQPATAPGGPVGLATDLELPEPDPQPADAPPPGDVTEAPAETPQVSNIAYTKKLWQAIRAQDVCGNDALDSLAQPYVIG | Pool of 99 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 325 | MoTif 325 F. tularensis (Omp) | MFYKLNKQGRKIMKKTILGAMIAGGLMVSATTAMAGGVGFANVQDIFETSPLGKAKVTADEKKLKPQMDQL KQNITALQEKVNAYTQEKDDVQTDDSKGDTKDAQSADKVENQDKQQAQADLEKAMKDYQNLMNQVQKM ASDDADAFKDALTKASAQVAKEKQLDAILPAEMSLYNVDSIDVTKDVIAKMQ | Pool of 45 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Rabbit fever, Respiratory infection, Tularemia |
| 326 | MoTif 326 L.monocytogenes (LLO) | MKKIMLVFITLILVSLPIAQQTEAKDASAFNKENSISSMAPPASPPASPKTPIEKKHADEIDKYIQGLDYNKNNVL VYHGDAVTNVPPRKGYKDGNEYIVVEKKKKSINQNNADIQVVNAISSLTYPGALVKANSELVENQPDVLPVKR DSLTLSIDLPGMTNQDNKIVVKNATKSNVNNAVNTLVERWNEKYAQAYPNVSAKIDYDDEMAYSESQLIAKFGTAFKAVNNSLNVNFGAISEGKMQEEVISFKQIYYNVNVNEPTRPSRFFGKAVTKEQLQALGVNAENPPAYISSVAYGRQVYLKLSTNSHSTKVKAAFDAAVSGKSVSGDVELTNIIKNSSFKAVIYGGSAKDEVQIIDGNLGDLRDILKKGATFNRETPGVPIAYTTNFLKDNELAVIKNNSEYIETTSKAYTDGKINIDHSGGYVAQFNISWDEVNYDPEGNEIVQHKNWSENNKSKLAHFTSSIYLPGNARNINVYAKECTGLAWEWWRTVIDDRNLPLVKNRNISIWGTTLYPKYSNKVDNPIE | Pool of 130 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Listeriosis |
| 327 | MoTif 327 M. tuberculosis (ACR) | MATTLPVQRHPRSLFPEFSELFAAFPSFAGLRPTFDTRLMRLEDEMKEGRYEVRAELPGVDPDKDVDIMVRD GQLTIKAERTEQKDFDGRSEFAYGSFVRTVSLPVGADEDDIKATYDKGILTVSVAVSEGKPTEKHIQIRSTN | Pool of 34 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 328 | MoTif 328 M. tuberculosis (HBHA) | MAENSNIDDIKAPLLAALGAADLALATVNELITNLRERAEETRTDTRSRVEESRARLTKLQEDLPEQLTELREKF TAEELRKAAEGYLEAATSRYNELVERGEAALERLRSQQSFEEVSARAEGYVDQAVELTQEALGTVASQTRAVGE RAAKLVGIELPKKAAPAKKAAPAKKAAPAKKAAAKKAPAKKAAAKKVTQK | Pool of 47 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 329 | MoTif 329 S. pyogenes (CAS9)_2 subpools | MDKKYSIGLDIGTNSVGWAVITDEYKVPSKKFKVLGNTDRHSIKKNLIGALLFDSGETAEATRLKRTARRRYTR RKNRICYLQEIFSNEMAKVDDSFFHRLEESFLVEEDKKHERHPIFGNIVDEVAYHEKYPTIYHLRKKLVDSTDKA DLRLIYLALAHMIKFRGHFLIEGDLNPDNSDVDKLFIQLVQTYNQLFEENPINASGVDAKAILSARLSKSRRLEN LIAQLPGEKKNGLFGNLIALSLGLTPNFKSNFDLAEDAKLQLSKDTYDDDLDNLLAQIGDQYADLFLAAKNLSD AILLSDILRVNTEITKAPLSASMIKRYDEHHQDLTLLKALVRQQLPEKYKEIFFDQSKNGYAGYIDGGASQEEFYK FIKPILEKMDGTEELLVKLNREDLLRKQRTFDNGSIPHQIHLGELHAILRRQEDFYPFLKDNREKIEKILTFRIPYYV GPLARGNSRFAWMTRKSEETITPWNFEEVVDKGASAQSFIERMTNFDKNLPNEKVLPKHSLLYEYFTVYNELT KVKYVTEGMRKPAFLSGEQKKAIVDLLFKTNRKVTVKQLKEDYFKKIECFDSVEISGVEDRFNASLGTYHDLLKI IKDKDFLDNEENEDILEDIVLTLTLFEDREMIEERLKTYAHLFDDKVMKQLKRRRYTGWGRLSRKLINGIRDKQS GKTILDFLKSDGFANRNFMQLIHDDSLTFKEDIQKAQVSGQGDSLHEHIANLAGSPAIKKGILQTVKVVDELVK VMGRHKPENIVIEMARENQTTQKGQKNSRERMKRIEEGIKELGSQILKEHPVENTQLQNEKLYLYYLQNGRD MYVDQELDINRLSDYDVDHIVPQSFLKDDSIDNKVLTRSDKNRGKSDNVPSEEVVKKMKNYWRQLLNAKLI TQRKFDNLTKAERGGLSELDKAGFIKRQLVETRQITKHVAQILDSRMNTKYDENDKLIREVKVITLKSKLVSDFR KDFQFYKVREINNYHHAHDAYLNAVVGTALIKKYPKLESEFVYGDYKVYDVRKMIAKSEQEIGKATAKYFFYSN IMNFFKTEITLANGEIRKRPLIETNGETGEIVWDKGRDFATVRKVLSMPQVNIVKKTEVQTGGFSKESILPKRNS DKLIARKKDWDPKKYGGFDSPTVAYSVLVVAKVEKGKSKKLKSVKELLGITIMERSSFEKNPIDFLEAKGYKEVKK DLIIKLPKYSLFELENGRKRMLASAGELQKGNELALPSKYVNFLYLASHYEKLKGSPEDNEQKQLFVEQHKHYLD EIIEQISEFSKRVILADANLDKVLSAYNKHRDKPIREQAENIIHLFTLTNLGAPAAFKYFDTTIDRKRYTSTKEVLDA TLIHQSITGLYETRIDLSQLGGD | Pool of 340 (170 + 170) peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Cellulitis, Gene editing, Infection |
| 330 | MoTif 330 M. tuberculosis (CFP-10) | MAEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVVRFQEAANKQKQEL DEISTNIRQAGVQYSRADEEQQQALSSQMGF | Pool of 23 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 331 | MoTif 331 M. tuberculosis (MPT64) | MRIKIFMLVTAVVLLCCSGVATAAPKTYCEELKGTDTGQACQIQMSDPAYNINISLPSYYPDQKSLENYIAQTR DKFLSAATSSTPREAPYELNITSATYQSAIPPRGTQAVVLKVYQNAGGTHPTTTYKAFDWDQAYRKPITYDTL WQADTDPLPVVFPIVQGELSKQTGQQVSIAPNAGLDPVNYQNFAVTNDGVIFFFNPGELLPEAAGPTQVLVP RSAIDSMLA | Pool of 55 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 332 | MoTif 332 M. tuberculosis (PPE68) | MLWHAMPPELNTARLMAGAGPAPMLAAAAGWQTLSAALDAQAVELTARLNSLGEAWTGGGSDKALAAA TPMVVWLQTASTQAKTRAMQATAQAAAYTQAMATTPSLPEIAANHITQAVLTATNFFGINTIPIALTEMDYFIR MWNQAALAMEVYQAETAVNTLFEKLEPMASILDPGASQSTTNPIFGMPSPGSSTPVGQLPPAATQTLGQLGE MSGPMQQLTQPLQQVTSLFSQVGGTGGGNPADEEAAQMGLLGTSPLSNHPLAGGSGPSAGAGLLRAESLPGAGGSLTRTPLMSQLIEKPVAPSVMPAAAAGSSATGGAAPVGAGAMGQGAQSGGSTRPGLVAPAPLAQEREEDDEDDWDEEDDW | Pool of 90 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 333 | MoTif 333 M. tuberculosis (Ag85A) | MQLVDRVRGAVTGMSRRLVVGAVGAALVSGLVGAVGGTATAGAFSRPGLPVEYLQVPSPSMGRDIKVQFQS GGANSPALYLLDGLRAQDDFSGWDINTPAFEWYDQSGLSVVMPVGGQSSFYSDWYQPACGKAGCQTYKWE TFLTSELPGWLQANRHVKPTGSAVVGLSMAASSALTLAIYHPQQFVYAGAMSGLLDPSQAMGPTLIGLAMGD AGGYKASDMWGPKEDPAWQRNDPLLNVGKLIANNTRVWVYCGNGKPSDLGGNNLPAKFLEGFVRTSNIKF QDAYNAGGGHNGVFDFPDSGTHSWEYWGAQLNAMKPDLQRALGATPNTGPAPQGA | Pool of 82 peptides derived from a peptide scan (15mers with 11 aa overlap) t | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 334 | MoTif 334 P. vivax (CSP) Ultra | see additional product documentation | Pool of 157 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) | 70%-90% | T-cell immunity | Infection, Malaria, Sequence diversity |
| 335 | MoTif 335 M. tuberculosis (EspA) | MSRAFIIDPT ISAIDGLYDL LGIGIPNQGG ILYSSLEYFE KALEELAAAF PGDGWLGSAA DKYAGKNRNH VNFFQELADL DRQLISLIHD QANAVQTTRD ILEGAKKGLE FVRPVAVDLT YIPVVGHALS AAFQAPFCAG AMAVVGGALA YLVVKTLINA TQLLKLLAKL AELVAAAIAD IISDVADIIK GTLGEVWEFI TNALNGLKEL WDKLTGWVTG LFSRGWSNLE SFFAGVPGLT GATSGLSQVT GLFGAAGLSA SSGLAHADSL ASSASLPALA GIGGGSGFGG LPSLAQVHAA STRQALRPRA DGPVGAAAEQ VGGQSQLVSA QGSQGMGGPV GMGGMHPSSG ASKGTTTKKY SEGAAAGTED AERAPVEADA GGGQKVLVRN VV | Pool of 96 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 336 | MoTif 336 M. tuberculosis (EsxN) | MTINYQFGDVDAHGAMIRAQAASLEAEHQAIVRDVLAAGDFWGGAGSVACQEFITQLGRNFQVIYEQANAHGQKVQAAGNNMAQTDSAVGSSWA | Pool of 21 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 337 | MoTif 337 M. tuberculosis (RpfD) | MTPGLLTTAGAGRPRDRCARIVCTVFIETAVVATMFVALLGLSTISSKADDIDWDAIAQCESGGNWAANTGNGLYGGLQISQATWDSNGGVGSPAAASPQQQIEVADNIMKTQGPGAWPKCSSCSQGDAPLGSLTHILTFLAAETGGCSGSRDD | Pool of 36 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 338 | MoTif 338 M. tuberculosis (HRP1) | MTTARDIMNAGVTCVGEHETLTAAAQYMREHDIGALPICGDDDRLHGMLTDRDIVIKGLAAGLDPNTATAGELARDSIYYVDANASIQEMLNVMEEHQVRRVPVISEHRLVGIVTEADIARHLPEHAIVQFVKAICSPMALAS | Pool of 33 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 339 | MoTif 339 M. tuberculosis (Rv1733c) | MIATTRDREGATMITFRLRLPCRTILRVFSRNPLVRGTDRLEAVVMLLAVTVSLLTIPFAAAAGTAVQDSRSHVYA HQAQTRHPATATVIDHEGVIDSNTTATSAPPRTKITVPARWVVNGIERSGEVNAKPGTKSGDRVGIWVDSAGQLVDEPAPPARAIADAALAALGLWLSVAAVAGALLALTRAILIRVRNASWQHDIDSLFCTQR | Pool of 50 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | Cancer biomarker research, T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 340 | MoTif 340 M. tuberculosis (TB8.4) | MRLSLTALSAGVGAVAMSLTVGAGVASADPVDAVINTTCNYGQVVAALNATDPGAAAQFNASPVAQSYLRN FLAAPPPQRAAMAAQLQAVPGAAQYIGLVESVAGSCNNY | Pool of 25 peptides derived from a peptide scan (15mers with 11 aa overlap) | 70%-90% | T-cell immunity | Infection, Opportunistic infections, Respiratory infection, Tuberculosis |
| 341 | MoTif 341 P. falciparum (CSP) Ultra | see additional product documentation | Pool of 198 peptides derived from a peptide scan (Selected immunogenic peptides (15mers)) | 70%-90% | T-cell immunity | Infection, Influenza, Malaria, Sequence diversity |